| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abstracts Index
|
|
|
2005
|
8 |
6 |
p. A228-A236
nvt p.
|
artikel
|
| 2 |
A Comparison of Self-Selectivity Corrections in Economic Evaluations and Outcomes Research
|
Jeong, Jinook
|
|
2005
|
8 |
6 |
p. 656-666
11 p.
|
artikel
|
| 3 |
An Economic Evaluation of Triptan Products for Migraine
|
Perfetto, Eleanor M.
|
|
2005
|
8 |
6 |
p. 647-655
9 p.
|
artikel
|
| 4 |
CN1 COST-EFFECTIVENESS ANALYSIS OF OXALIPLATIN/5-FU/LV IN ADJUVANT TREATMENT OF STAGE III COLON CANCER IN THE UK AND GERMANY
|
Aballea, S
|
|
2005
|
8 |
6 |
p. A21-
1 p.
|
artikel
|
| 5 |
CN2 COST-EFFECTIVENESS OFTEMOZOLOMIDE FORTHE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN THE UK
|
Uyl-de Groot, CA
|
|
2005
|
8 |
6 |
p. A21-
1 p.
|
artikel
|
| 6 |
CN4 COST MINIMISATION ANALYSIS OF FIRST LINE POLYCHEMOTHERAPY REGIMENS IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER
|
Launois, R
|
|
2005
|
8 |
6 |
p. A22-
1 p.
|
artikel
|
| 7 |
CN3 HEALTH ECONOMIC EVALUATION BASED ON THE 5-YEAR COMPLETED TREATMENT ANALYSIS OF THE ATAC TRIAL COMPARING ANASTROZOLE VERSUS TAMOXIFEN IN ADJUVANT TREATMENT OF POSTMENOPAUSAL HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
|
Moeremans, K
|
|
2005
|
8 |
6 |
p. A21-A22
nvt p.
|
artikel
|
| 8 |
CO4 A COMPARISON OF LOGISTIC REGRESSION AND COX PROPORTIONAL HAZARDS MODELS FOR IDENTIFICATION OF RISK FACTORS FOR RENAL IMPAIRMENT IN HORMONE REFRACTORY PROSTATE CANCER (HRPC) PATIENTS WITH BONE METASTASES (BM) TREATED WITH ZOLEDRONIC ACID (ZA)
|
Oh, WK
|
|
2005
|
8 |
6 |
p. A16-A17
nvt p.
|
artikel
|
| 9 |
CO2 EARLY GLYCEMIC CONTROL IMPROVES HEALTH AND ECONOMIC BENEFITS IN TYPE 2 DIABETES: A MODEL BASED ANALYSIS
|
Eddy, D
|
|
2005
|
8 |
6 |
p. A16-
1 p.
|
artikel
|
| 10 |
CO3 META-REGRESSION ASSESSMENT OF ATOMOXETINE EFFICACY USING RANDOMIZED CONTROLLED ADHD TRIALS
|
Bae, JP
|
|
2005
|
8 |
6 |
p. A16-
1 p.
|
artikel
|
| 11 |
Cost-Effectiveness of Rosuvastatin Compared with Other Statins from a Managed Care Perspective
|
Benner, Joshua S.
|
|
2005
|
8 |
6 |
p. 618-628
11 p.
|
artikel
|
| 12 |
CO1 VALIDATION OF DIAGNOSTIC PROCEDURES IN SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA CONCORDANCE BETWEEN INITIAL AND FINAL DIAGNOSIS IN DAILY CLINICAL PRACTICE
|
Carballido, J
|
|
2005
|
8 |
6 |
p. A15-A16
nvt p.
|
artikel
|
| 13 |
CV3 A COST-EFFECTIVENESS ANALYSIS OF CANDESARTAN IN THE TREATMENT OF CHRONIC HEART FAILURE
|
Lamotte, M
|
|
2005
|
8 |
6 |
p. A3-
1 p.
|
artikel
|
| 14 |
CV1 ATRIAL BASED PACING DECREASES ATRIAL FIBRILLATION RELATED HOSPITALIZATIONS AND COSTS IN BRADY-TACHY SYNDROME
|
Ruciñski, P
|
|
2005
|
8 |
6 |
p. A2-
1 p.
|
artikel
|
| 15 |
CV2 COSTS OF CARDIOVASCULAR DISEASE: A CASE-CONTROL STUDY
|
De Portu, S
|
|
2005
|
8 |
6 |
p. A2-A3
nvt p.
|
artikel
|
| 16 |
CV4 DISCRETE EVENT SIMULATION OF THE ECONOMIC CONSEQUENCES OF ADDING MANAGED VENTRICULAR PACING MODE (DDDR-MVP) TO A STANDARD DUAL CHAMBER PACEMAKER (DDDR) IN FRANCE
|
Deniz, HB
|
|
2005
|
8 |
6 |
p. A3-
1 p.
|
artikel
|
| 17 |
DISCLOSURE INFORMATION
|
|
|
2005
|
8 |
6 |
p. A221-A227
nvt p.
|
artikel
|
| 18 |
DN3 COST-EFFECTIVENESS OF NON-INVASIVE IMAGING IN THE DIAGNOSIS OF PARKINSONISM
|
Brüggenjürgen, B
|
|
2005
|
8 |
6 |
p. A15-
1 p.
|
artikel
|
| 19 |
DN2 COST-UTILITY ANALYSIS IN A UK SETTING OF SELF MONITORING OF BLOOD GLUCOSE IN PATIENTS WITH TYPE-2 DIABETES
|
Palmer, AJ
|
|
2005
|
8 |
6 |
p. A14-A15
nvt p.
|
artikel
|
| 20 |
DN1 ECONOMIC EVALUATIONOF SPECT-DATSCAN IN THE DIAGNOSIS OF PATIENTS WITH CLINICALLY UNCERTAIN PARKINSONISM IN ITALY
|
Busca, R
|
|
2005
|
8 |
6 |
p. A14-
1 p.
|
artikel
|
| 21 |
DN4 PHARMACOECONONOMIC EVALUATION OF SEDATION WITH REMIFENTANIL/PROPOFOLVERSUS MIDAZOLAM/FENTANYL IN THE INTENSIVE CARE UNIT
|
Muellejans, B
|
|
2005
|
8 |
6 |
p. A15-
1 p.
|
artikel
|
| 22 |
Economic Burden of Patients with Anemia in Selected Diseases
|
Ershler, William B.
|
|
2005
|
8 |
6 |
p. 629-638
10 p.
|
artikel
|
| 23 |
Erratum
|
|
|
2005
|
8 |
6 |
p. A237-
1 p.
|
artikel
|
| 24 |
HP7 ADHERENCE TO IMMUNOSUPPRESSIVE THERAPY IN PRIVATE PAYER TRANSPLANT RECIPIENTS
|
Lalla, A
|
|
2005
|
8 |
6 |
p. A12-
1 p.
|
artikel
|
| 25 |
HP6 EFFECT OF CO-PAYMENT ON COMPLIANCE TO STATINS AFTER CORONARY HEART DISEASE HOSPITALIZATION
|
Ye, X
|
|
2005
|
8 |
6 |
p. A12-
1 p.
|
artikel
|
| 26 |
HP1 IDENTIFYING PREDICTORS OF OFF-LABEL UTILIZATION PATTERNS OF TWO BIOTECHNOLOGY DRUGS, RECOMBINANT ERYTHROPOIETIN ALFA AND DARBEPOETIN ALFA A MULTI-HOSPITAL STUDY
|
Patkar, AD
|
|
2005
|
8 |
6 |
p. A6-
1 p.
|
artikel
|
| 27 |
HP8 PATIENT CHARACTERICS, GLYCEMIC CONTROL, AND THE USE OF ANTIDIABETIC AGENTS AMONG INDIVIDUALS DIAGNOSED WITH TYPE-2 DIABETES: EVIDENCE FROM THE UK
|
Secnik, K
|
|
2005
|
8 |
6 |
p. A12-A13
nvt p.
|
artikel
|
| 28 |
HP2 PHARMACIST RESPONSE TO COMPUTER-GENERATED DRUG THERAPY ALERTS IN A LONG TERM CARE SETTING
|
Wegner, S
|
|
2005
|
8 |
6 |
p. A6-A7
nvt p.
|
artikel
|
| 29 |
HP3 PHYSICIAN PRESCRIBING OF SLEEP DISORDER MEDICATIONS IN UNITED STATES OUTPATIENT SETTINGS: FACTORS AFFECTING PRESCRIPTION OF HIGH ABUSE POTENTIAL AND COSTLY MEDICATIONS
|
Rasu, R
|
|
2005
|
8 |
6 |
p. A7-
1 p.
|
artikel
|
| 30 |
HP4 PRIMARY CARE AND GATEKEEPER MODELS IN GERMANY — WHAT DO THE PATIENTS WANT?
|
Kielhorn, H
|
|
2005
|
8 |
6 |
p. A7-
1 p.
|
artikel
|
| 31 |
HP5 TREATMENT PATTERNS AMONG POSTMENOPAUSAL OSTEOPOROTIC WOMEN STARTING ON DAILY OR WEEKLY BISPHOSPHONATE THERAPY
|
Huybrechts, KF
|
|
2005
|
8 |
6 |
p. A11-A12
nvt p.
|
artikel
|
| 32 |
IC4 ECONOMIC ANALYSIS OF THE STRATEGY STUDY: TIROFIBAN AND DRUG ELUTING STENTS VERSUS ABCIXIMAB AND BARE METAL STENTS
|
Mittmann, N
|
|
2005
|
8 |
6 |
p. A11-
1 p.
|
artikel
|
| 33 |
IC3 HEALTH ECONOMIC EVALUATION OF BIVALIRUDIN IN THE MANAGEMENT OF PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN BELGIUM
|
Ethgen, O
|
|
2005
|
8 |
6 |
p. A11-
1 p.
|
artikel
|
| 34 |
IC2 PREDICTING THE COST-EFFECTIVENESS OFTHEABT-578 COATED DRIVER CORONARY STENT (ENDEAVOR) IN DE NOVO NATIVE CORONARY ARTERY LESIONS
|
Remák, E
|
|
2005
|
8 |
6 |
p. A10-A11
nvt p.
|
artikel
|
| 35 |
IC1 THE COST-EFFECTIVENESS OF DRUG-ELUTING STENTS BASED ON THE A SYNTHESIS OF THE RESULTS OF I 5 RANDOMISED CONTROLLED TRIALS
|
Hawkins, N
|
|
2005
|
8 |
6 |
p. A10-
1 p.
|
artikel
|
| 36 |
Impact of Computer-Generated Personalized Goals on Cholesterol Lowering
|
Levetan, Claresa S.
|
|
2005
|
8 |
6 |
p. 639-646
8 p.
|
artikel
|
| 37 |
IN2 ASSESSEMENT OF THE ADDITIONAL COST OF DROTRECOGIN ALFA (ACTIVATED) RELATIVE TO STANDARD CARE IN THE TREATMENT OF SEVERE SEPSIS IN A MULTICENTIC OBSERVATIONAL STUDY IN FRANCE
|
Payet, S
|
|
2005
|
8 |
6 |
p. A20-
1 p.
|
artikel
|
| 38 |
IN3 COST-EFFECTIVENESS OF VORICONAZOLE VERSUS LIPOSOMALAMPHOTERICIN B FOR INVASIVE ASPERGILLOSIS INFECTION IN THE UK
|
Mesrobian, X
|
|
2005
|
8 |
6 |
p. A20-
1 p.
|
artikel
|
| 39 |
IN1 COSTS ASSOCIATED WITH SHORTER DURATION OF ANTIBIOTIC THERAPY IN HOSPITALIZED PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA
|
Opmeer, BC
|
|
2005
|
8 |
6 |
p. A19-
1 p.
|
artikel
|
| 40 |
IN4 LOWERING THE AGE THRESHOLD FOR ROUTINE INFLUENZA VACCINATION: AN ECONOMIC EVALUATION FOR FOUR EUROPEAN COUNTRIES
|
Aballea, S
|
|
2005
|
8 |
6 |
p. A20-
1 p.
|
artikel
|
| 41 |
In Memoriam: Alan Williams (1928–2005)
|
Kind, Paul
|
|
2005
|
8 |
6 |
p. 615-617
3 p.
|
artikel
|
| 42 |
MC2 IMPACT OF THE PROPENSITY SCORE ESTIMATION METHOD WHEN MATCHING PATIENTS TO REDUCE RECRUITMENT BIAS IN OBSERVATIONAL STUDIES
|
Riou França, L
|
|
2005
|
8 |
6 |
p. A1-
1 p.
|
artikel
|
| 43 |
MC3 METAMODELLING FORTHE CALCULATION OF THE EXPECTED VALUE OF PERFECT INFORMATION ON INDIVIDUAL MODEL PARAMETERS
|
Oostenbrink, JB
|
|
2005
|
8 |
6 |
p. A1-A2
nvt p.
|
artikel
|
| 44 |
MC5 ON EVALUATING COST ASSOCIATED WITH EVENT-CENSORED DATA APPLICATION TO ALL-CAUSE GRAFT FAILURE FOLLOWING KIDNEYTRANSPLANTATION
|
Irish, WD
|
|
2005
|
8 |
6 |
p. A17-
1 p.
|
artikel
|
| 45 |
MC6 PERFORMANCE OF THE DMM SIMULATION MODEL IN PREDICTING REAL WORLD CHANGES IN GLYCEMIC CONTROL FOLLOWING DIAGNOSIS OF DIABETES
|
James, PW
|
|
2005
|
8 |
6 |
p. A17-
1 p.
|
artikel
|
| 46 |
MC8 THE APPLICATION OF BAYESIAN METHODS TO EVALUATE THE IMPACT OF TIME-DELAY ON THE COST-EFFECTIVENESS OF PRIMARY ANGIOPLASTY FOR ACUTE MYOCARDIAL INFARCTION
|
Palmer, SJ
|
|
2005
|
8 |
6 |
p. A18-
1 p.
|
artikel
|
| 47 |
MC7 THE PHARMACOGENOMICS BIAS IN DECISION MODELS
|
Siebert, U
|
|
2005
|
8 |
6 |
p. A17-
1 p.
|
artikel
|
| 48 |
MC4 UNCONDITIONAL POWER FOR SECONDARY OBJECTIVES IN A CLINICAL TRIAL
|
Wang, J
|
|
2005
|
8 |
6 |
p. A2-
1 p.
|
artikel
|
| 49 |
MC1 USE OF A MODIFIED RECURSIVE PARTITIONING AND AMALGAMATION (RECPAM)TECHNIQUE IN OUTCOMES RESEARCH
|
Katz, LM
|
|
2005
|
8 |
6 |
p. A1-
1 p.
|
artikel
|
| 50 |
PAL2 ATTRIBUTES FOR PREFERENCE OF NEW FAST DISSOLVING TABLET (FDT) FORMULATION OF EBASTINE IN PATIENTS WITH ALLERGY
|
Roger, A
|
|
2005
|
8 |
6 |
p. A23-
1 p.
|
artikel
|
| 51 |
PAL1 DETERMINING THE MINIMAL CLINICALLY IMPORTANT DIFFERENCE FORTHE ESPRINT-15 QUESTIONNAIRE FOR PATIENTS WITH ALLERGIC RINHITIS
|
Baro, E
|
|
2005
|
8 |
6 |
p. A23-
1 p.
|
artikel
|
| 52 |
PAL3 DEVELOPMENT, PILOT TESTING, SCORING AND VALIDATION OF A MANAGEMENT TOOL FOR PATIENTS UNDERGOING SPECIFIC IMMUNO-THERAPY
|
Arnould, B
|
|
2005
|
8 |
6 |
p. A23-A24
nvt p.
|
artikel
|
| 53 |
PAR9 A MODEL TO ESTIMATE HEALTH UTILITIES INDEX MARK 3 UTILITY SCORES FROM WOMAC INDEX SCORES IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE
|
Marshall, DA
|
|
2005
|
8 |
6 |
p. A26-A27
nvt p.
|
artikel
|
| 54 |
PAR10 ARE THEY RELEVANT? A CRITICAL EVALUATION OF THE INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH CORE SETS FOR OSTEOARTHRITIS FROM THE PERSPECTIVE OF PATIENTS WITH KNEE OSTEOARTHRITIS IN SINGAPORE
|
Xie, F
|
|
2005
|
8 |
6 |
p. A27-
1 p.
|
artikel
|
| 55 |
PAR17 BURDEN OF ILLNESS, COSTS AND OUTCOMES OF RHEUMATOID ARTHRITIS IN HUNGARY
|
Péntek, M
|
|
2005
|
8 |
6 |
p. A29-
1 p.
|
artikel
|
| 56 |
PAR8 COST COMPARISON OF THE COMBINATION TRAMADOL PLUS PARACETAMOL VERSUS NSAIDS PLUS PROTON PUMP INHIBITORS IN THE TREATMENT OF OSTEOARTHRITIS IN THE NETHERLANDS
|
Liedgens, H
|
|
2005
|
8 |
6 |
p. A26-
1 p.
|
artikel
|
| 57 |
PAR1 COSTS AND EFFECTS OF CELECOXIB IN THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS IN THE NETHERLANDS
|
Al, M
|
|
2005
|
8 |
6 |
p. A24-
1 p.
|
artikel
|
| 58 |
PAR19 CRITERIA-BASED INTERPRETATION OF SF-36 IMPROVEMENTS FROM ADALIMUMAB PLUS METHOTREXATE (MTX) COMBINATION THERAPY VS. MTX ALONE IN EARLY RHEUMATOID ARTHRITIS (RA)
|
Cifaldi, M
|
|
2005
|
8 |
6 |
p. A29-A30
nvt p.
|
artikel
|
| 59 |
PAR20 EFFECTS OF LONG-TERM ADALIMUMAB THERAPY ON HEALTH UTILITY AND FATIGUE IN PATIENTS WITH LONGSTANDING, SEVERE RHEUMATOID ARTHRITIS (RA)—RESULTS FROM A 3-YEAR FOLLOW-UP STUDY
|
Mittendorf, T
|
|
2005
|
8 |
6 |
p. A30-
1 p.
|
artikel
|
| 60 |
PAR14 EVALUATION OF ACCESS TO HIGH-COST MEDICINES IN AUSTRALIA USING NATIONAL CLAIMS DATA
|
Lu, CY
|
|
2005
|
8 |
6 |
p. A28-
1 p.
|
artikel
|
| 61 |
PAR6 GASTROINTESTINAL (Gl) EVENTS, MEDICATION USE AND HEALTH CARE COSTS FOR NEW USERS OF CYCLOOXYGENASE (COX)-2 INHIBITORSAND NONSELECTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
|
Gilmore, A
|
|
2005
|
8 |
6 |
p. A25-A26
nvt p.
|
artikel
|
| 62 |
PAR7 HEALTH CARE UTILIZATION AND EXPENDITURE OF TWO PROGRAMS FOR OSTEOARTHRITIS OF THE KNEE AND HIP: ASSESSMENT AND IMPACT IN REAL-LIFE CONDITIONS
|
De Jong, R
|
|
2005
|
8 |
6 |
p. A26-
1 p.
|
artikel
|
| 63 |
PAR12 IMPROVEMENT IN HEALTH UTILITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH ADALIMUMAB (HUMIRA®)
|
Anis, AH
|
|
2005
|
8 |
6 |
p. A27-
1 p.
|
artikel
|
| 64 |
PAR2 METAL ON METAL (MOM) HIP RESURFACING (BIRMINGHAM HIP RESURFACING (BHR)) IN YOUNG PATIENTS WITH SEVERE HIP DAMAGE—A COST UTILITY ANALYSIS
|
Richardson, JB
|
|
2005
|
8 |
6 |
p. A24-
1 p.
|
artikel
|
| 65 |
PAR4 OSTEOARTHRITIS:CHONDROITIN SULFATE LONG TERM UTILIZATION IS COST-SAVING
|
Taieb, C
|
|
2005
|
8 |
6 |
p. A25-
1 p.
|
artikel
|
| 66 |
PAR5 OSTEOARTHRITIS:CHONDROITIN SULFATE LONG TERM UTILIZATION REDUCES CONSUMPTION OF COXIBS, NSAIDS & ANALGESICS
|
Taieb, C
|
|
2005
|
8 |
6 |
p. A25-
1 p.
|
artikel
|
| 67 |
PAR18 PATIENT COMPLIANCE IN THE TREATMENT OF RHEUMATOID ARTHRITIS WITH BIOLOGIC DMARDS AND PREDICTING FACTORS: A LITERATURE REVIEW
|
Schmidt, E
|
|
2005
|
8 |
6 |
p. A29-
1 p.
|
artikel
|
| 68 |
PAR16 POTENTIAL PROBLEMS IN USING RCT DATA TO ESTIMATE COST-EFFECTIVENESS: RESULTS FROM AN ANALYSIS OF ETANERCEPT USE IN RHEUMATOID ARTHRITIS
|
Farahani, P
|
|
2005
|
8 |
6 |
p. A28-A29
nvt p.
|
artikel
|
| 69 |
PAR3 PRODUCTIVITY BENEFITS FROM CONTROLLED-RELEASE VS SHORT ACTING OPIOIDS FOR TREATMENT OF PERSISTENT MODERATE TO SEVERE OSTEOARTHRITIS (OA) PAIN OF THE HIP/KNEE
|
Marshall, DA
|
|
2005
|
8 |
6 |
p. A24-A25
nvt p.
|
artikel
|
| 70 |
PAR15 TARGETED ACCESS TO HIGH-COST MEDICINES IN AUSTRALIA: EARLY ANALYSIS FROM A QUALITATIVE STUDY
|
Lu, CY
|
|
2005
|
8 |
6 |
p. A28-
1 p.
|
artikel
|
| 71 |
PAR13 THE DIRECT MEDICAL COST OF RHEUMATOID ARTHRITIS IN HONG KONG
|
Lee, VWY
|
|
2005
|
8 |
6 |
p. A27-A28
nvt p.
|
artikel
|
| 72 |
PAR11 VALIDITY STUDIES AND SATISFACTION THRESHOLD OF THE ARTHRITIS TREATMENT SATISFACTION QUESTIONNAIRE (ARTS)
|
Ruíz, M
|
|
2005
|
8 |
6 |
p. A27-
1 p.
|
artikel
|
| 73 |
PAS3 ASTHMA CONTROL IN SPAIN. DOES TREATMENT PROFILE AND SEASON MATTER?
|
Fueyo, A
|
|
2005
|
8 |
6 |
p. A31-
1 p.
|
artikel
|
| 74 |
PAS8 ASTHMA RELATED QUALITY OF LIFE IS CORRELATED WITH ASTHMA CONTROL AMONG RESPIRE STUDY PARTICIPANTS
|
Moisan, J
|
|
2005
|
8 |
6 |
p. A32-
1 p.
|
artikel
|
| 75 |
PAS6 CLINICAL OUTCOME OF CHRONIC ASTHMA
|
Reissell, E
|
|
2005
|
8 |
6 |
p. A32-
1 p.
|
artikel
|
| 76 |
PAS1 COMPARISON OF TREATMENT WITH BUDESONIDE/FORMOTEROL (BUD/FM) PLUS BUD/FM PRN AS SINGLE INHALERTREATMENT VERSUS REGULAR BUD AND FM PLUS FM PRN AS MONOPRODUCTS IN PATIENTS WITH ASTHMA IN GREECE
|
Papageorgiou, M
|
|
2005
|
8 |
6 |
p. A30-
1 p.
|
artikel
|
| 77 |
PAS2 FLUTICASONE PROPIONATE/SALMETEROL COMBINATION IMPROVES HEALTH OUTCOMES AND QUALITY OF LIFE IN CHILDREN WITH POORLY CONTROLLED ASTHMA IN IRELAND
|
Hill, P
|
|
2005
|
8 |
6 |
p. A30-A31
nvt p.
|
artikel
|
| 78 |
PAS5 IMPACT OF MONTELUKASTTHERAPY ON ASTHMA-RELATED HEALTH CARE RESOURCES USE IN MILD TO MODERATE ASTHMATIC PATIENTS WITH SEASONAL ALLERGIC RHINITIS IN SPAIN
|
Pinto Blázquez, JA
|
|
2005
|
8 |
6 |
p. A31-
1 p.
|
artikel
|
| 79 |
PAS4 THE COST OF ASTHMA EXACERBATIONS OF DIFFERENT SEVERITY LEVELS
|
Dewilde, S
|
|
2005
|
8 |
6 |
p. A31-
1 p.
|
artikel
|
| 80 |
PAS7 THE HUMAN IMPACT OF SEVERE PERSISTENT ALLERGIC ASTHMA: RESULTS FROM A MULTINATIONAL STUDY
|
Turk, F
|
|
2005
|
8 |
6 |
p. A32-
1 p.
|
artikel
|
| 81 |
PAS9 THE SPANISH VERSION OF THE MINI-ASTHMA QUALITY OF LIFE QUESTIONNAIRE: EXAMINATION OF RESPONSIVENESS TO CHANGE
|
Caloto, MT
|
|
2005
|
8 |
6 |
p. A32-A33
nvt p.
|
artikel
|
| 82 |
PCN36 A COST UTILITY ANALYSIS OF FIRST-LINE CHEMOTHERAPY REGIMENS IN THE TREATMENT OF METASTATIC BREAST CANCERAFTERANTHRACYCLINE FAILURE
|
Le Lay, K
|
|
2005
|
8 |
6 |
p. A44-
1 p.
|
artikel
|
| 83 |
PCN35 A COST UTILITY ANALYSIS OF FULVESTRANT VERSUS EXEMESTANE IN THE SECOND LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER IN GREECE (PRELIMINARY RESULTS)
|
Pangali, M
|
|
2005
|
8 |
6 |
p. A44-
1 p.
|
artikel
|
| 84 |
PCN16 ADDING RITUXIMABTO STANDARD CHEMOTHERAPY APPEARS DOMINANT VS. CHEMOTHERAPY ALONE IN ADVANCED STAGE NHL—INTERIM RESULTS FROM A RANDOMIZED CLINICAL TRIAL (RCT)
|
Hieke, K
|
|
2005
|
8 |
6 |
p. A38-
1 p.
|
artikel
|
| 85 |
PCN41 A NEW MEASURE FOR ASSESSING HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH ADVANCED COLORECTAL CANCER (ACC): “CCRA-QOL”
|
Perulero, N
|
|
2005
|
8 |
6 |
p. A46-
1 p.
|
artikel
|
| 86 |
PCN50 A PILOT STUDY ASSESSING THE QUALITY OF LIFE IMPACT OF ADVERSE EVENTS EXPERIENCED BY ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS RECEIVING SECOND-LINE CHEMOTHERAPY
|
Tilden, D
|
|
2005
|
8 |
6 |
p. A48-A49
nvt p.
|
artikel
|
| 87 |
PCN39 APPLICATION OF AN ALGORITHM FOR DEFINING RETROSPECTIVE COHORTS OF COLORECTAL CANCER (CRC) PATIENTS TREATED WITH DIFFERENT FIRST-LINE CHEMOTHERAPY REGIMENS +/− BEVACIZUMABTO ADMINISTRATIVE CLAIMS DATA
|
Cisternas, MG
|
|
2005
|
8 |
6 |
p. A45-
1 p.
|
artikel
|
| 88 |
PCN52 ASSESSING QOL IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) TREATED WITH CHEMOTHERAPY
|
Miller, KL
|
|
2005
|
8 |
6 |
p. A49-
1 p.
|
artikel
|
| 89 |
PCN38 ASSESSING THE IMPACT ON STAFF RESOURCE AND PATIENT WAITING TIME OF A SWITCH FROM IV TO ORAL CHEMOTHERAPY: TIME AND MOTION MODEL FOR HTAS
|
Taylor, H
|
|
2005
|
8 |
6 |
p. A45-
1 p.
|
artikel
|
| 90 |
PCN19 AUSTRALIAN COST-EFFECTIVENESS ANALYSIS OF ANASTROZOLEVSTAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER BASED ON THE 5-YEAR COMPLETED TREATMENT ANALYSIS OF THE ATAC TRIAL
|
Benedict, A
|
|
2005
|
8 |
6 |
p. A39-
1 p.
|
artikel
|
| 91 |
PCN30 COMPARATIVE ANALYSIS OF DRUG COST OF BREAST, CERVICAL AND COLORECTAL CANCER IN HUNGARY
|
Boncz, I
|
|
2005
|
8 |
6 |
p. A42-
1 p.
|
artikel
|
| 92 |
PCN7 COST ANALYSIS OF 3-YEARS FOLLOW-UP OF A TRASTUZUMAB TREATED COHORT
|
Le Lay, K
|
|
2005
|
8 |
6 |
p. A35-
1 p.
|
artikel
|
| 93 |
PCN9 COST COMPARISON ANALYSIS OF INTRAVENOUS VERSUS COMBINED INTRAVENOUS-ORAL CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER
|
Skowron, A
|
|
2005
|
8 |
6 |
p. A35-
1 p.
|
artikel
|
| 94 |
PCN14 COST-EFFECTIVENESS ANALYSIS OF ARANESP® (DARBEPOETIN ALFA) ADMINISTERED ONCE EVERY THREE WEEKS COMPARED TO ONCE EVERY WEEK
|
Demarteau, N
|
|
2005
|
8 |
6 |
p. A37-
1 p.
|
artikel
|
| 95 |
PCN32 COST-EFFECTIVENESS ANALYSIS OF LETROZOLE VERSUS TAMOXIFEN AS INITIAL ADJUVANT THERAPY IN HORMONE-RECEPTOR POSITIVE POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER IN THE UK
|
Karnon, J
|
|
2005
|
8 |
6 |
p. A43-
1 p.
|
artikel
|
| 96 |
PCN31 COST EFFECTIVENESS MODEL OF IV BISPHOSPHONATES IN THE PREVENTION OF BONE COMPLICATIONS IN BREAST CANCER PATIENTS WITH BONE METASTASES: A GERMAN INPATIENT PERSPECTIVE
|
Botteman, M
|
|
2005
|
8 |
6 |
p. A42-A43
nvt p.
|
artikel
|
| 97 |
PCN34 COST-EFFECTIVENESS OF ANASTROZOLE OVERTAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER FROM A UK NATIONAL HEALTH SERVICE PERSPECTIVE: THE 5-YEAR COMPLETED TREATMENT ANALYSIS OF THE ATAC TRIAL
|
Brown, R
|
|
2005
|
8 |
6 |
p. A43-A44
nvt p.
|
artikel
|
| 98 |
PCN13 COST-EFFECTIVENESS OF HEPATIC ARTERY INFUSION FOR METASTATIC COLORECTAL CANCER (CALGB 9481)
|
Weeks, JC
|
|
2005
|
8 |
6 |
p. A37-
1 p.
|
artikel
|
| 99 |
PCN4 COST OF CARE AND ECONOMIC IMPACT OF CETUXIMAB IN THE TREATMENT OF METASTATIC COLORECTAL CANCER IN SPAIN
|
Rubio, M
|
|
2005
|
8 |
6 |
p. A34-
1 p.
|
artikel
|
| 100 |
PCN22 COSTS OF COMMON TREATMENT OPTIONS FOR INDOLENT FOLLICULAR NON-HODGKIN'S LYMPHOMA
|
Van Agthoven, M
|
|
2005
|
8 |
6 |
p. A40-
1 p.
|
artikel
|
| 101 |
PCN33 COST-UTILITY ANALYSIS OF CHEMOTHERAPY IN ADVANCED OR RECURRENT GASTRIC CANCER: ORAL FLUOROPYRIMIDINETS-I VERSUS CONVENTIONAL INTRAVENOUS CHEMOTHERAPY
|
Sakamaki, H
|
|
2005
|
8 |
6 |
p. A43-
1 p.
|
artikel
|
| 102 |
PCN43 CRITICAL APPRAISAL OF SCIENTIFIC POSTERS COMPARING ANEMIA TREATMENTS IN CANCER PATIENTS: APPLYING ISPORTASK FORCE GUIDELINES ON METHODOLOGICAL QUALITY OF RETROSPECTIVE STUDIES
|
Demarteau, N
|
|
2005
|
8 |
6 |
p. A46-
1 p.
|
artikel
|
| 103 |
PCN26 CUTANEOUS CANCER TREATMENT AND COSTS IN GERMANY
|
Nijhuis, T
|
|
2005
|
8 |
6 |
p. A41-
1 p.
|
artikel
|
| 104 |
PCN40 DEVELOPMENT OF AN ALGORITHM FOR THE IDENTIFICATION AND CLASSIFICATION OF COLORECTAL CANCER (CRC) PATIENTS ACCORDING TO FIRST-LINE CHEMOTHERAPY +/− BEVACIZUMAB, AND INITIATION OF SECOND-LINE THERAPY USING ADMINISTRATIVE CLAIMS RECORDS
|
Cisternas, MG
|
|
2005
|
8 |
6 |
p. A45-
1 p.
|
artikel
|
| 105 |
PCN51 DEVELOPMENT OF A NEW SCALE TO ASSESS PATIENT PERCEPTIONS OF CANCER-RELATED FATIGUE: THE PERFORM PROJECT
|
Baro, E
|
|
2005
|
8 |
6 |
p. A49-
1 p.
|
artikel
|
| 106 |
PCN28 DOCUMENTATION OF PHARMACY COST IN THE PREPARATION OF CHEMOTHERAPY INFUSIONS IN ACADEMIC AND COMMUNITY-BASED ONCOLOGY PRACTICES
|
Brixner, D
|
|
2005
|
8 |
6 |
p. A41-A42
nvt p.
|
artikel
|
| 107 |
PCN27 ECONOMIC ANALYSIS OF BISPHOSPHONATES FROM THE PAYERS PERSPECTIVE IN BRAZIL
|
Calabró, AA
|
|
2005
|
8 |
6 |
p. A41-
1 p.
|
artikel
|
| 108 |
PCN23 ECONOMIC ASPECTS AND DRIVERS OF FEBRILE NEUTROPENIA IN CANCER—A MULTICENTRE RETROSPECTIVE ANALYSIS IN BELGIUM
|
Moeremans, K
|
|
2005
|
8 |
6 |
p. A40-
1 p.
|
artikel
|
| 109 |
PCN11 ECONOMIC EVALUATION OF BORTEZOMIB IN THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS IN CANADA
|
Yoong, K
|
|
2005
|
8 |
6 |
p. A36-
1 p.
|
artikel
|
| 110 |
PCN1 ECONOMIC IMPACT OF ADOPTING PEMETREXED PLUS CISPLATIN FOR MALIGNANT PLEURAL MESOTHELIOMA INTO SCOTTISH CLINICAL PRACTICE
|
Chetty, M
|
|
2005
|
8 |
6 |
p. A33-
1 p.
|
artikel
|
| 111 |
PCN24 ESTIMATING THE COST OF INFORMAL CAREGIVING IN LUNG CANCER PATIENTS.THE HABIT STUDY
|
Mangone, M
|
|
2005
|
8 |
6 |
p. A40-
1 p.
|
artikel
|
| 112 |
PCN44 HEALTH RELATED QUALITY OF LIFE EVALUATIONS IN PROSTATE CANCER: WHO'S BEING STUDIED?
|
Ramsey, SD
|
|
2005
|
8 |
6 |
p. A46-A47
nvt p.
|
artikel
|
| 113 |
PCN49 HEALTH STATE DESCRIPTIONS FOR METASTATIC BREAST CANCER: A QUALITATIVE STUDY
|
Narewska, J
|
|
2005
|
8 |
6 |
p. A48-
1 p.
|
artikel
|
| 114 |
PCN12 IMPACT OF ADJUVANT CHEMOTHERAPY WITH DOCETAXEL FOR EARLY BREAST CANCER: COST-EFFECTIVENESS ANALYSIS (CEA) OF A DOCETAXEL, DOXORUBICIN AND CYCLOPHOSPHAMIDE REGIMEN (TAC) VERSUS 5-FLUOROURACIL, DOXORUBICIN AND CYCLOPHOSPHAMIDE (FAC) IN FRANCE
|
Miadi-Fargier, H
|
|
2005
|
8 |
6 |
p. A36-A37
nvt p.
|
artikel
|
| 115 |
PCN37 IMPACT OF HEALTH CARE REFORMSAND CHANGING PAYMENT MECHANISMS ON HEALTH ECONOMIC EVALUATIONS IN GERMANY
|
Hieke, K
|
|
2005
|
8 |
6 |
p. A44-
1 p.
|
artikel
|
| 116 |
PCN25 INFLUENCE OF THE PORTION OF MEDICAL EXPENSE PAID INDIVIDUALLY ON PHYSICIANS'ATTITUDE TOWARDS CANCER TREATEMENT IN JAPAN
|
Saito, S
|
|
2005
|
8 |
6 |
p. A40-A41
nvt p.
|
artikel
|
| 117 |
PCN8 INITIATION OF TRANSDERMAL OPIOID THERAPY IN CANCER PATIENTS WITH MODERATE OR SEVERE MALIGNANT PAIN—TREATMENT PATTERNS AND COSTS IN A GERMAN UNIVERSITY HOSPITAL
|
Paessens, B
|
|
2005
|
8 |
6 |
p. A35-
1 p.
|
artikel
|
| 118 |
PCN2 LEAD TIME IN THE EVALUATION OF HISTORICAL SURVIVAL IMPROVEMENTS IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
|
Martins, R
|
|
2005
|
8 |
6 |
p. A33-
1 p.
|
artikel
|
| 119 |
PCN18 LETROZOLE (FEMARA) IS A COST-EFFECTIVE TREATMENT IN THE EXTENDED ADJUVANT SETTING IN WOMEN WITH EARLY BREAST CANCER: AN APPLICATION TO CANADA
|
El Ouagari, K
|
|
2005
|
8 |
6 |
p. A38-
1 p.
|
artikel
|
| 120 |
PCN42 MODELLING THE EFFECT OF A NOVEL THERAPEUTIC AGENT ON THE EVOLUTION OF UTILITY IN REFRACTORY MULTIPLE MYELOMA PATIENTS
|
Mujica-Mota, R
|
|
2005
|
8 |
6 |
p. A46-
1 p.
|
artikel
|
| 121 |
PCN53 MONITORING AND SECURING QUALITY IN ONCOLOGICAL CARE—THE 2004 LONGITUDINAL PASQOC® RESULTS
|
Behrens, M
|
|
2005
|
8 |
6 |
p. A49-A50
nvt p.
|
artikel
|
| 122 |
PCN45 MULTILINGUAL VALIDATION OF THE FACT-LEUKEMIA IN 7 LANGUAGES
|
Eremenco, SL
|
|
2005
|
8 |
6 |
p. A47-
1 p.
|
artikel
|
| 123 |
PCN20 ORAL AND INTRAVENOUS CHEMOTHERAPY FOR FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE UK NHS SYSTEM
|
Le Lay, K
|
|
2005
|
8 |
6 |
p. A39-
1 p.
|
artikel
|
| 124 |
PCN29 PER-PATIENT COST OF HOSPITAL CARE FOR ADVANCED BREAST CANCER IN THE UK BASED ON A PATIENT-LEVEL RESOURCE UTILISATION DATASET
|
Wolowacz, S
|
|
2005
|
8 |
6 |
p. A42-
1 p.
|
artikel
|
| 125 |
PCN15 PHARMACOECONOMIC ANALYSIS OF EXEMESTANE VERSUS TAMOXIFEN AS ADJUVANT THERAPY FOR PATIENTS WITH EARLY-STAGE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER
|
Gil, JM
|
|
2005
|
8 |
6 |
p. A37-A38
nvt p.
|
artikel
|
| 126 |
PCN3 POPULATION-BASED BUDGET IMPACT MODEL OF APREPITANT (EMEND) IN HIGHLY EMETOGENIC CISPLATINE-BASED CHEMOTHERAPY
|
Le Lay, K
|
|
2005
|
8 |
6 |
p. A33-A34
nvt p.
|
artikel
|
| 127 |
PCN6 POPULATION-BASED BUDGET IMPACT MODEL OF APREPITANT (EMEND) IN MODERATELY EMETOGENIC CHEMOTHERAPY (MEC)
|
Francesconi, C
|
|
2005
|
8 |
6 |
p. A34-A35
nvt p.
|
artikel
|
| 128 |
PCN48 QUALITY OF LIFE AND RESOURCE UTILIZATION OF PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER: A CANADIAN PERSPECTIVE
|
Mittmann, N
|
|
2005
|
8 |
6 |
p. A48-
1 p.
|
artikel
|
| 129 |
PCN17 THE COST-EFFECTIVENESS OF CETUXIMAB IN COMBINATION WITH IRINOTECAN FORTHE TREATMENT OF PATIENTS WITH EGFR-EXPRESSING METASTATIC COLORECTAL CANCER AFTER FAILURE OF IRINOTECAN-INCLUDING CYTOTOXIC THERAPY IN SCOTLAND
|
Tilden, D
|
|
2005
|
8 |
6 |
p. A38-
1 p.
|
artikel
|
| 130 |
PCN10 THE COST-EFFECTIVENESS OF POST-OPERATIVE RADIOTHERAPY AFTER BREAST CONSERVATION SURGERY IN STAGEI-II BREAST CANCER IN SWEDEN
|
Persson, U
|
|
2005
|
8 |
6 |
p. A36-
1 p.
|
artikel
|
| 131 |
PCN5 THE COST OF SECOND-LINE TREATMENT OF OVARIAN CANCER IN POLISH SETTINGS
|
Macioch, T
|
|
2005
|
8 |
6 |
p. A34-
1 p.
|
artikel
|
| 132 |
PCN21 TREATMENT COST OF COLORECTAL CANCER CHEMOTHERAPIES IN GERMANY
|
Hieke, K
|
|
2005
|
8 |
6 |
p. A39-A40
nvt p.
|
artikel
|
| 133 |
PCN47 VALIDATION OF THE SPANISH VERSION OF THE UCLA PROSTATE CANCER INDEX: RELIABILITY AND VALIDITY OF A HEALTH-RELATED QUALITY OF LIFE MEASURE.
|
Ibarz, R
|
|
2005
|
8 |
6 |
p. A47-A48
nvt p.
|
artikel
|
| 134 |
PCN46 WHAT ARE THE PSYCHOSOCIAL CONSEQUENCES OF AN ABNORMAL SCREENING-MAMMOGRAPHY?
|
Brodersen, J
|
|
2005
|
8 |
6 |
p. A47-
1 p.
|
artikel
|
| 135 |
PCV74 A BUDGET IMPACT MODEL FOR EPLERENONE IN THE TREATMENT OF HEART FAILURE POST MYOCARDIAL INFARCTION
|
Tabberer, M
|
|
2005
|
8 |
6 |
p. A111-
1 p.
|
artikel
|
| 136 |
PCV33 A COST-EFFECTIVENESS ANALYSIS OF LOW-DOSE ASPIRIN IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN FOUR EUROPEAN COUNTRIES
|
Lamotte, M
|
|
2005
|
8 |
6 |
p. A98-A99
nvt p.
|
artikel
|
| 137 |
PCV19 A LITERATURE REVIEW OF PATIENT-REPORTED OUTCOMES (PRO) USED IN ATRIAL FIBRILLATION
|
Staniek, V
|
|
2005
|
8 |
6 |
p. A94-
1 p.
|
artikel
|
| 138 |
PCV50 A MULTILEVEL ANALYSIS ON PRESCRIBED STATINES IN A BOLOGNA HEALTH AUTHORITY FROM 2000 TO 2003
|
Roli, G
|
|
2005
|
8 |
6 |
p. A103-A104
nvt p.
|
artikel
|
| 139 |
PCV11 ANTICOAGULATION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: AN EVALUATION OF STABILITY AND EARLY FACTORS THAT PREDICT LONGER-TERM STABILITY ON WARFARIN IN A LARGE UK POPULATION
|
Currie, CJ
|
|
2005
|
8 |
6 |
p. A91-A92
nvt p.
|
artikel
|
| 140 |
PCV3 A PHARMACO-ECONOMIC EVALUATION OF AGGRESSIVE CHOLESTEROL LOWERING AFTER ACUTE CORONARY SYNDROME IN BELGIUM: A SHORT-TERM AND LONG-TERM ASSESSMENT
|
Annemans, L
|
|
2005
|
8 |
6 |
p. A89-
1 p.
|
artikel
|
| 141 |
PCV48 ASSESSMENT OF MAXIMUM LDL-C REDUCTION AND GOAL ATTAINMENT BY SWITCHING PATIENTS TO DUAL INHIBITION THERAPY (EZETIMIBE/SIMVASTATIN) IN SPAIN
|
Davies, G
|
|
2005
|
8 |
6 |
p. A103-
1 p.
|
artikel
|
| 142 |
PCV49 BELGIAN EVALUATION OF SCREENING AND TREATMENT OF HIGH RISK PATIENTS BASED ON WAIST AND AGE (BEST)
|
De Backer, G
|
|
2005
|
8 |
6 |
p. A103-
1 p.
|
artikel
|
| 143 |
PCV63 CARDIOVASCULAR DRUG USE IN NIS REGION
|
Kodela, BC
|
|
2005
|
8 |
6 |
p. A107-A108
nvt p.
|
artikel
|
| 144 |
PCV54 CARDIOVASCULAR RISK CONTROL IN HYPERTENSION AND/OR DYSLIPIDEMIA IN PRIMARY CARE
|
Sicras Mainar, A
|
|
2005
|
8 |
6 |
p. A105-
1 p.
|
artikel
|
| 145 |
PCV22 CASE-BASED-COSTING VS. MARKOV-MODELLING—A COMPARISON OF COST-EFFECTIVENESS-ANALYSES FOR CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE
|
Voelkl, M
|
|
2005
|
8 |
6 |
p. A95-
1 p.
|
artikel
|
| 146 |
PCV85 CLINICAL OUTCOME AND COST-EFFECTIVENESS OF DIFFERENT BYPASS MATERIALS IN VASCULAR SURGERY
|
Eidt, D
|
|
2005
|
8 |
6 |
p. A114-
1 p.
|
artikel
|
| 147 |
PCV30 CLOPIDOGREL LOADING DOSE AND CARDIOVASCULAR OUTCOMES IN ACUTE CORONARY SYNDROME PATIENTS WHO UNDERGO PERCUTANEOUS CORONARY INTERVENTION
|
Wang, C
|
|
2005
|
8 |
6 |
p. A97-A98
nvt p.
|
artikel
|
| 148 |
PCV46 COST-ANALYSIS OF HYPERCHOLESTEROLEMIATREATMENTS WITHIN THE SLOVAK PHARMACEUTICAL MARKET
|
Tesar, T
|
|
2005
|
8 |
6 |
p. A102-A103
nvt p.
|
artikel
|
| 149 |
PCV77 COST AND OUTCOMES AFTER FIRST ACUTE MYOCARDIAL INFARCTION HOSPITAL ADMISSION: A LONGITUDINAL STUDY USING ADMINISTRATIVE DATABASES
|
Morsanutto, A
|
|
2005
|
8 |
6 |
p. A112-
1 p.
|
artikel
|
| 150 |
PCV24 COST-EFFECTIVENESS ANALYSIS OF ALDOSTERONE BLOCKADE WITH EPLERENONE IN PATIENTS WITH HEART FAILURE AFTER ACUTE MYOCARDIAL INFARCTION (EPHESUS) IN THE FRENCH CONTEXT
|
De Pouvourville, GA
|
|
2005
|
8 |
6 |
p. A95-A96
nvt p.
|
artikel
|
| 151 |
PCV21 COST EFFECTIVENESS ANALYSIS OF BISOPROLOL TREATMENT FOR HEART FAILURE
|
Menditto, E
|
|
2005
|
8 |
6 |
p. A94-A95
nvt p.
|
artikel
|
| 152 |
PCV1 COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION IN HUNGARY
|
Borsos, K
|
|
2005
|
8 |
6 |
p. A88-
1 p.
|
artikel
|
| 153 |
PCV76 COST-EFFECTIVENESS ANALYSIS OF THE USE OF ACETYLSALICYLIC ACID COMPARED TO CLOPIDOGREL IN THE SECONDARY PREVENTION OF PATIENTS WITH PREVIOUS MYOCARDIAL INFRACTION
|
Piñol, C
|
|
2005
|
8 |
6 |
p. A112-
1 p.
|
artikel
|
| 154 |
PCV69 COST-EFFECTIVENESS OF ADD-ON THERAPY WITH PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) IN STATIN-TREATED PATIENTS WITH DYSLIPIDEMIA AND PERSISTENTLY LOW HDL-C IN THE UK AND GERMANY
|
Roze, S
|
|
2005
|
8 |
6 |
p. A109-A110
nvt p.
|
artikel
|
| 155 |
PCV89 COST-EFFECTIVENESS OF AN EXTENDED FOUR-WEEK FONDAPARINUX PROPHYLAXIS REGIMEN FOR THE PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS UNDERGOING MAJOR ORTHOPEDIC SURGERY
|
Bischof, M
|
|
2005
|
8 |
6 |
p. A115-A116
nvt p.
|
artikel
|
| 156 |
PCV2 COST-EFFECTIVENESS OF AN INTENSIVE TREATMENT WITH 80MGATORVASTATINVS 40 MG PRAVASTATIN IN ACUTE CORONARY SYNDROME: AN ECONOMIC EVALUATION BASED ON THE PROVE-IT (PRAVASTATIN ORATORVASTATIN EVALUATION AND INFECTION THERAPY)
|
F Bobadilla, J
|
|
2005
|
8 |
6 |
p. A89-
1 p.
|
artikel
|
| 157 |
PCV26 COST-EFFECTIVENESS OF CANDESARTAN IN GERMANY FOR PATIENTS WITH CHRONIC HEART FAILURE
|
Voelkl, M
|
|
2005
|
8 |
6 |
p. A96-
1 p.
|
artikel
|
| 158 |
PCV31 COST-EFFECTIVENESS OF CONTRAST ECHOCARDIOGRAPHY IN THE DIAGNOSIS OF CORONARY ARTERY DISEASE
|
Richardson, R
|
|
2005
|
8 |
6 |
p. A98-
1 p.
|
artikel
|
| 159 |
PCV5 COST-EFFECTIVENESS OF DRUG ELUTING STENTS FOR STABLE ANGINA
|
Kristiansen, IS
|
|
2005
|
8 |
6 |
p. A90-
1 p.
|
artikel
|
| 160 |
PCV83 COST-EFFECTIVENESS OF ENDOVASCULARVERSUS CONVENTIONAL ABDOMINAL AORTIC ANEURYSM REPAIR AT ONE YEAR; RESULTS OF A RANDOMIZED TRIAL
|
Buskens, E
|
|
2005
|
8 |
6 |
p. A114-
1 p.
|
artikel
|
| 161 |
PCV75 COST-EFFECTIVENESS OF EPTIFIBATIDE IN NSTEMI PATIENTS IN POLAND
|
Dewilde, S
|
|
2005
|
8 |
6 |
p. A111-A112
nvt p.
|
artikel
|
| 162 |
PCV91 COST EFFECTIVENESS OF EXTENDED PROPHYLAXIS WITH FONDAPARINUX TO PREVENT VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING HIP FRACTURE SURGERY USING UK AND DUTCH ESTIMATES OF COSTS
|
Van Hout, B
|
|
2005
|
8 |
6 |
p. A116-
1 p.
|
artikel
|
| 163 |
PCV90 COST EFFECTIVENESS OF FONDAPARINUX COMPARED WITH ENOXAPARIN FOR EXTENDED PROPHYLAXIS AGAINST VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING HIP FRACTURE SURGERY USING DUTCH ESTIMATES OF COSTS
|
Van Hout, B
|
|
2005
|
8 |
6 |
p. A116-
1 p.
|
artikel
|
| 164 |
PCV58 COST-EFFECTIVENESS OF INDAPAMIDE IN PATIENTS WITH MILD-TO-MODERATE HYPERTENSION
|
Stafylas, PC
|
|
2005
|
8 |
6 |
p. A106-
1 p.
|
artikel
|
| 165 |
PCV57 COST-EFFECTIVENESS OF NEBIVOLOL VERSUS ATENOLOL AND ACE INHIBITOR MONOTHERAPY IN PATIENTS WITH MODERATE HYPERTENSION
|
Lippert, B
|
|
2005
|
8 |
6 |
p. A106-
1 p.
|
artikel
|
| 166 |
PCV68 COST-EFFECTIVENESS OF RAISING HDL-CWITH PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) IN STATIN-TREATED PATIENTS WITH PERSISTENT DYSLIPIDEMIA IN AUSTRIAN, SWEDISH AND NORWEGIAN SETTINGS
|
Roze, S
|
|
2005
|
8 |
6 |
p. A109-
1 p.
|
artikel
|
| 167 |
PCV71 COST-EFFECTIVENESS OF ROSUVASTATIN COMPARED WITH GENERIC SIMVASTATIN IN THE UK NHS
|
Miller, PS
|
|
2005
|
8 |
6 |
p. A110-
1 p.
|
artikel
|
| 168 |
PCV44 COST-EFFECTIVENESS OF ROSUVASTATIN IN THE PREVENTION OF ISCHEMIC HEART DISEASE IN PORTUGAL
|
Gouveia-Pinto, C
|
|
2005
|
8 |
6 |
p. A102-
1 p.
|
artikel
|
| 169 |
PCV80 COST ESTIMATION IN PATIENTS WITH AN ATHEROTROMBOTIC EVENT
|
Guzmán, JA
|
|
2005
|
8 |
6 |
p. A113-
1 p.
|
artikel
|
| 170 |
PCV60 COST-MINIMIZATION ANALYSIS OF TREATMENT OF MILD-TO-MODERATE HYPERTENSION IN UNITED STATES
|
Stafylas, PC
|
|
2005
|
8 |
6 |
p. A107-
1 p.
|
artikel
|
| 171 |
PCV8 COST OF HOSPITALIZATION FOR PATIENTS WITH ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY IN POLAND
|
Kowalik, E
|
|
2005
|
8 |
6 |
p. A90-A91
nvt p.
|
artikel
|
| 172 |
PCV27 COSTS AND OUTCOMES AFTER FIRST HEART FAILURE HOSPITAL ADMISSION: A LONGITUDINAL STUDY USING ADMINISTRATIVE DATABASES
|
Morsanutto, A
|
|
2005
|
8 |
6 |
p. A96-A97
nvt p.
|
artikel
|
| 173 |
PCV7 COSTS OF DIAGNOSIS OF ARRHYTHMOGENIC RIGTH VENTRICULAR CARDIOMYOPATHY IN INDIVIDUALS WITH A FAMILY HISTORY OF THE DISEASE IN POLAND
|
Glinka, M
|
|
2005
|
8 |
6 |
p. A90-
1 p.
|
artikel
|
| 174 |
PCV82 COST-UTILITY OF CILOSTAZOL FOR THE TREATMENT OF INTERMITTENT CLAUDICATION IN SCOTLAND
|
Ratcliffe, A
|
|
2005
|
8 |
6 |
p. A113-A114
nvt p.
|
artikel
|
| 175 |
PCV81 DISCRETE EVENT SIMULATION OF LONG-TERM HEALTH BENEFITS AND COST-EFFECTIVENESS OF IMPLANTING DUAL CHAMBERVS. SINGLE CHAMBER VENTRICULAR PACEMAKERS IN ITALY
|
Ward, AJ
|
|
2005
|
8 |
6 |
p. A113-
1 p.
|
artikel
|
| 176 |
PCV10 DRIVERS OF UNDERUSE OF VITAMIN K ANTAGONISTS IN PATIENTS WITH CHRONIC NONVALVULAR ATRIAL FIBRILLATION IN FRANCE: THE ENSEFAL STUDY
|
Guenoun, M
|
|
2005
|
8 |
6 |
p. A91-
1 p.
|
artikel
|
| 177 |
PCV23 ECONOMIC EVALUATION OFVALSARTAN IN PATIENTS WITH CHRONIC HEART FAILURE IN THE HUNGARIAN HEALTH CARE SETTING
|
Kosa, J
|
|
2005
|
8 |
6 |
p. A95-
1 p.
|
artikel
|
| 178 |
PCV13 EPIDEMIOLOGY AND COSTS OF ATRIAL TACHYARRHYTMIAS
|
Diotallevi, P
|
|
2005
|
8 |
6 |
p. A92-
1 p.
|
artikel
|
| 179 |
PCV56 EVALUATION OF COSTS RELATED TO HYPERTENSION IN PATIENTS WITH CONCOMITANT DISEASES IN POLAND
|
Hermanowski, T
|
|
2005
|
8 |
6 |
p. A105-A106
nvt p.
|
artikel
|
| 180 |
PCV55 EVALUATION OF COSTS RELATED TO HYPERTENSION IN PATIENTS WITH UNCONTROLLED HYPERTENSION IN POLAND
|
Hermanowski, T
|
|
2005
|
8 |
6 |
p. A105-
1 p.
|
artikel
|
| 181 |
PCV67 FACTORS DETERMINING COMPLIANCE IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN DAILY CLINICAL PRACTICE
|
Sicras Mainar, A
|
|
2005
|
8 |
6 |
p. A109-
1 p.
|
artikel
|
| 182 |
PCV64 HEALTH CARE UTILIZATION OF ANTIHYPERTENSIVE MEDICATION WITHIN THE SLOVAK REPUBLIC
|
Tesar, T
|
|
2005
|
8 |
6 |
p. A108-
1 p.
|
artikel
|
| 183 |
PCV40 HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH CORONARY HEART DISEASE: A STUDY USING EQ-5D QUESTIONNAIRE
|
De Portu, S
|
|
2005
|
8 |
6 |
p. A100-A101
nvt p.
|
artikel
|
| 184 |
PCV92 HEALTH RELATED QUALITY OF LIFE (QOL) IN PATIENTS RECEIVING VITAMIN K ANTAGONISTS (VKA): A STUDY USING EQ-5D QUESTIONNAIRE
|
Monzini, M
|
|
2005
|
8 |
6 |
p. A116-A117
nvt p.
|
artikel
|
| 185 |
PCV35 HOSPITALIZATIONS FOR CARDIOVASCULAR EVENTS: FRENCH DRG ANALYSIS
|
Erard, C
|
|
2005
|
8 |
6 |
p. A99-
1 p.
|
artikel
|
| 186 |
PCV4 HOW MUCH IS THE ACUTE CORONARY SYNDROMES IN-HOSPITAL THERAPY: A PILOT STUDY ON THERAPY
|
Adameová, A
|
|
2005
|
8 |
6 |
p. A89-
1 p.
|
artikel
|
| 187 |
PCV52 IMPACT OF COMPLIANCE AND PERSISTENCE OF TREATMENT WITH VALSARTAN ON HYPERTENSION CLINICAL OUTCOMES
|
Halpern, MT
|
|
2005
|
8 |
6 |
p. A104-
1 p.
|
artikel
|
| 188 |
PCV28 IMPACT OF MODIFIED SYSTEM OF OBJECTIFIED JUDGMENT ANALYSIS (SOJA) METHODOLOGY ON PRESCRIBING COSTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACEIS)
|
Alabbadi, I
|
|
2005
|
8 |
6 |
p. A97-
1 p.
|
artikel
|
| 189 |
PCV43 IMPACT OF NEW EUROPEAN (ESC 2003) GUIDELINES ON TREATMENT OF HYPERCHOLESTEROLEMIA IN DAILY PRACTICE
|
Goettsch, WG
|
|
2005
|
8 |
6 |
p. A101-A102
nvt p.
|
artikel
|
| 190 |
PCV6 IMPACT OF STATIN THERAPY INTENSITY ON ALL-CAUSE MORTALITY FOLLOWING CARDIOVASCULAR HOSPITALIZATION IN A MANAGED CARE POPULATION
|
Fintel, DJ
|
|
2005
|
8 |
6 |
p. A90-
1 p.
|
artikel
|
| 191 |
PCV16 KNOWLEDGE AND USE OF TREATMENT GUIDELINES FOR STROKE PREVENTION OF PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION (AFIB) IN GERMANY
|
Burkowitz, J
|
|
2005
|
8 |
6 |
p. A93-
1 p.
|
artikel
|
| 192 |
PCV62 LIPID PROFILE IN HYPERTENSIVES WITH AND WITHOUT CARDIOVASCULAR DISEASE: HAS THE HDL COLESTEROL BEEN FORGOTTEN?
|
Sicras Mainar, A
|
|
2005
|
8 |
6 |
p. A107-
1 p.
|
artikel
|
| 193 |
PCV32 LONG-TERM COST-EFFECTIVENESS OF CLOPIDOGREL IN ACUTE CORONARY SYNDROMES BASED ON CURE AND PCI-CURE IN POLAND
|
Pietrasik, AL
|
|
2005
|
8 |
6 |
p. A98-
1 p.
|
artikel
|
| 194 |
PCV12 MANAGEMENT PATTERNS AND COSTS OF ATRIAL FIBRILLATION IN A LARGE COMMERCIALLY INSURED U.S. POPULATION
|
Fidan, D
|
|
2005
|
8 |
6 |
p. A92-
1 p.
|
artikel
|
| 195 |
PCV53 PATIENT PROFILE AND STATINS EFFECTIVENESS IN USUAL CARE
|
Sicras Mainar, A
|
|
2005
|
8 |
6 |
p. A104-A105
nvt p.
|
artikel
|
| 196 |
PCV66 PATIENTS ON ARBS (AND VALSARTAN AS A REPRESENTATIVE) EXPERIENCE HIGHER PERSISTENCE AND COMPLIANCE (ADHERENCE) WITH THERAPY COMPARED TO OTHER ANTIHYPERTENSIVE CLASSES IN A GERMAN SICKNESS FUND POPULATION
|
Höer, A
|
|
2005
|
8 |
6 |
p. A108-A109
nvt p.
|
artikel
|
| 197 |
PCV65 PHARMACOECONOMIC ANALYSIS OF 160MG VALSARTAN VERSUS LOSARTAN AND TELMISARTAN IN THE TREATMENT OF SYSTEMIC ARTERIAL HYPERTENSION IN THE MEXICAN HEALTH SECTOR
|
Guzman, JA
|
|
2005
|
8 |
6 |
p. A108-
1 p.
|
artikel
|
| 198 |
PCV59 PHARMACO-ECONOMIC ANALYSIS OF VALSARTAN/HYDROCHLOROTHIAZIDE (HCTZ)VERSUS CANDESARTAN/HCTZ AND VERSUS TELMISARTAN/HCTZ IN THE TREATMENT OF SYSTEMIC ARTERIAL HYPERTENSION IN MEXICO
|
Carlos, FDJ
|
|
2005
|
8 |
6 |
p. A106-A107
nvt p.
|
artikel
|
| 199 |
PCV20 PHARMACOTHERAPY AND OUTCOMES AMONG VETERANS WITH CHRONIC HEART FAILURE (2000-2002)
|
Johnson, ML
|
|
2005
|
8 |
6 |
p. A94-
1 p.
|
artikel
|
| 200 |
PCV41 PORTUGUESE ACTIVE POPULATION HEALTH RELATED QUALITY OF LIFE RESULTS USING THE SF-6D
|
Ferreira, LN
|
|
2005
|
8 |
6 |
p. A101-
1 p.
|
artikel
|
| 201 |
PCV79 POSTMYOCARDIAL INFARCTION CARDIAC REHABILITATION IN LOW RISK PATIENTS. RESULTS WITH A COORDINATED PROGRAM OF CARDIOLOGICAL AND PRIMARY CARE
|
Lafuente de Otto, V
|
|
2005
|
8 |
6 |
p. A112-A113
nvt p.
|
artikel
|
| 202 |
PCV51 PROJECTED LDL-C REDUCTION AND GOAL ATTAINMENT BY SWITCHING PATIENTS TO DUAL INHIBITION THERAPY (EZETIMIBE/SIMVASTATIN 10/20MG) IN SPAIN
|
Nocea, G
|
|
2005
|
8 |
6 |
p. A104-
1 p.
|
artikel
|
| 203 |
PCV42 RECENT TREND IN MANAGEMENT OF HYPERCHOLESTEROLEMIA AND GOAL ATTAINMENT
|
Goettsch, WG
|
|
2005
|
8 |
6 |
p. A101-
1 p.
|
artikel
|
| 204 |
PCV47 ROSUVASTATIN 40MG VERSUS ATORVASTATIN 80MG IN HIGH-RISK PATIENTS WITH HYPERCHOLESTEROLAEMIA: ECONOMIC ANALYSIS OF THE POLARIS STUDY
|
Miller, PS
|
|
2005
|
8 |
6 |
p. A103-
1 p.
|
artikel
|
| 205 |
PCV84 SURGICAL TREATMENT OF ABDOMINAL AORTIC ANEURISM: ANALYSIS OF OPERATING COSTS. ENDOVASCULAR TREATMENT VERSUS TRADITIONAL SURGERY
|
Palmieri, B
|
|
2005
|
8 |
6 |
p. A114-
1 p.
|
artikel
|
| 206 |
PCV15 SURVEY OF CURRENT ANTICOAGULANT MONITORING SERVICES IN THE UK—A GENERAL PRACTICE PERSPECTIVE
|
Emmas, C
|
|
2005
|
8 |
6 |
p. A93-
1 p.
|
artikel
|
| 207 |
PCV25 THE ADD-ON TREATMENT WITH METOPROLOL SUCCINATE IN PATIENTS WITH CHRONIC HEART FAILURE (CHF) LEADS TO COST SAVINGS IN THE GERMAN HEALTH CARE SYSTEM—A MODEL APPROACH
|
Hass, B
|
|
2005
|
8 |
6 |
p. A96-
1 p.
|
artikel
|
| 208 |
PCV14 THE COST OF ANTICOAGULATION MONITORING SERVICES IN THE UK NATIONAL HEALTH SERVICE
|
Arya, R
|
|
2005
|
8 |
6 |
p. A92-
1 p.
|
artikel
|
| 209 |
PCV70 THE COSTS OF METABOLIC SYNDROME
|
Mangone, M
|
|
2005
|
8 |
6 |
p. A110-
1 p.
|
artikel
|
| 210 |
PCV78 THE DIRECT COSTS OF SELECTED CARDIOVASCULAR DISEASES IN AUSTRIA
|
Fritz, C
|
|
2005
|
8 |
6 |
p. A112-
1 p.
|
artikel
|
| 211 |
PCV45 THE ECONOMIC ASSESSMENT OF SWITCHING TO DUAL INHIBITION CHOLESTEROL LOWERING THEARPY IN FINLAND
|
Sintonen, H
|
|
2005
|
8 |
6 |
p. A102-
1 p.
|
artikel
|
| 212 |
PCV86 THE ECONOMIC BURDEN OF EXPERIENCING MAJOR COMPLICATIONS DURING PERCUTANEOUS CORONARY INTERVENTION
|
Long, KH
|
|
2005
|
8 |
6 |
p. A114-A115
nvt p.
|
artikel
|
| 213 |
PCV9 THE EFFECT OF ANTICOAGULATION FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION-COMPARING EFFICACY AND EFFECTIVENESS
|
Dewilde, S
|
|
2005
|
8 |
6 |
p. A91-
1 p.
|
artikel
|
| 214 |
PCV39 THE EFFECT OF GENDER ON HEALTH-RELATED QUALITY OF LIFE AFTER CORONARY STENT IMPLANTATION
|
Brüggenjürgen, B
|
|
2005
|
8 |
6 |
p. A100-
1 p.
|
artikel
|
| 215 |
PCV61 THE FRENCH CV@GOAL EDUCATIONAL PROGRAM FOR IMPROVING HBP MANAGEMENT BY PATIENTSAND PHYSICIANS: ASSESSMENT OF ITS IMPACT ON PATIENT'S KNOWLEDGE AND PATIENT-PHYSICIAN RELATIONSHIP
|
Mosqueda, Jasso
|
|
2005
|
8 |
6 |
p. A107-
1 p.
|
artikel
|
| 216 |
PCV38 THIENOPYRIDINE THERAPY IN ACUTE CORONARY SYNDROME PATIENTS RESIDING IN GERMANY
|
Lage, MJ
|
|
2005
|
8 |
6 |
p. A100-
1 p.
|
artikel
|
| 217 |
PCV88 TREATMENT PATTERN, RESOURCE UTILIZATION AND COSTS OF INPATIENTTHROMBOPROPHYLAXIS IN POLAND
|
Orlewska, E
|
|
2005
|
8 |
6 |
p. A115-
1 p.
|
artikel
|
| 218 |
PCV36 USE OF ABCIXIMAB IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) IN FRANCE
|
Fillon, F
|
|
2005
|
8 |
6 |
p. A99-
1 p.
|
artikel
|
| 219 |
PCV29 USE OF CONTRAST ECHOCARDIOGRAPHY: A REVIEW OF CLINICAL DATA USING A SYSTEMATIC APPROACH
|
Cottrell, S
|
|
2005
|
8 |
6 |
p. A97-
1 p.
|
artikel
|
| 220 |
PCV73 USE OF PROPENSITY SCORE METHODOLOGY IN CARDIOVASCULAR DEVICE TRIALS: U.S. FOOD AND DRUG ADMINISTRATION PERSPECTIVES
|
Muni, N
|
|
2005
|
8 |
6 |
p. A111-
1 p.
|
artikel
|
| 221 |
PCV37 USE OF TIME-STAMPED HOSPITAL DATA TO EXAMINE CARE PATTERNS OF ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
|
Wang, C
|
|
2005
|
8 |
6 |
p. A100-
1 p.
|
artikel
|
| 222 |
PCV72 UTILIZATION PATTERNS OF ASPIRIN AMONG NSAID TREATED SUBJECTS WITH VARYING CARDIOVASCULAR RISK PROFILES IN A HEALTH BENEFITS POPULATION
|
Vanderpoel, PR
|
|
2005
|
8 |
6 |
p. A110-A111
nvt p.
|
artikel
|
| 223 |
PCV87 VITAE THROMBOSIS STUDY: THE PREVALENCE AND BURDEN OF VENOUS THROMBOEMBOLIC DISEASE (VTE) IN EUROPE
|
Cohen, AT
|
|
2005
|
8 |
6 |
p. A115-
1 p.
|
artikel
|
| 224 |
PCV17 VKA TREATMENT RELATED COSTS IN FRANCE IN PATIENTS WITH CHRONIC NONVALVULAR ATRIAL FIBRILLATION: COST DATA FROM THE INTERNATIONAL STUDY OF ANTICOAGULATION MANAGEMENT (ISAM)
|
Drouet, L
|
|
2005
|
8 |
6 |
p. A93-
1 p.
|
artikel
|
| 225 |
PCV18 WHEN SHOULD PATIENTS BE SWITCHED FROMVKATO NEW TREATMENT: DEVELOPMENT AND PILOT TESTING OF A SELF-REPORTED QUESTIONNAIRE TO TARGET PATIENTS WHO WOULD BENEFIT MOST
|
Arnould, B
|
|
2005
|
8 |
6 |
p. A94-
1 p.
|
artikel
|
| 226 |
PDB31 A LIFETIME MODELLED ECONOMIC EVALUATION COMPARING PIOGLITAZONE AND ROSIGLITAZONE FORTHE TREATMENT OF TYPE-2 DIABETES MELLITUS IN THE UK
|
Tilden, D
|
|
2005
|
8 |
6 |
p. A164-
1 p.
|
artikel
|
| 227 |
PDB15 A MODEL BASED ANALYSIS OF COSTS AND EFFECTIVENESS OF CHIROPODIST CARE IN DIABETEC PATIENTS
|
Habacher, W
|
|
2005
|
8 |
6 |
p. A158-A159
nvt p.
|
artikel
|
| 228 |
PDB38 ANALYSIS OF THE COST OF DIABETES TREATMENT IN BULGARIA
|
Ivanova, DA
|
|
2005
|
8 |
6 |
p. A166-
1 p.
|
artikel
|
| 229 |
PDB56 AN ASSESSMENT OF THE LONG-TERM OUTCOME FOR LIRAGLUTIDE+METFORMIN VERSUS METFORMIN AND VERSUS METFORMIN+GLIMEPIRIDE INTYPE-2 PATIENTS WITH INADE-QUATE GLYCAEMIC CONTROL
|
Hammer, M
|
|
2005
|
8 |
6 |
p. A172-
1 p.
|
artikel
|
| 230 |
PDB22 ASSESSING THE EFFICIENCY OF USING CONTINUOUS SUBCUTANEOUS INSULIN-INFUSION (CSII) VERSUS MULTIPLE DAILY INJECTIONS (MDI) IN SPANISH DIABETES MELLITUSTYPE-I (DM I) PATIENTS. COST—EFFECTIVENESS ANALYSIS
|
Castell, C
|
|
2005
|
8 |
6 |
p. A161-
1 p.
|
artikel
|
| 231 |
PDB24 ASSESSMENT OF THE LONG-TERM COST-EFFECTIVENESS OF INSULIN ASPART + METFORMIN VERSUS HUMAN INSULIN + METFORMIN REGIMENS IN TYPE-2 DIABETES IN GERMANY BASED ON THE CLINICAL FINDINGS OF THE PHAZIT STUDY
|
Roze, S
|
|
2005
|
8 |
6 |
p. A161-A162
nvt p.
|
artikel
|
| 232 |
PDB20 BIPHASIC INSULIN ASPART 30 VERSUS ORAL HYPOGLYCEMIC AGENTS IN THE TREATMENT OF TYPE-2 DIABETES: LONG-TERM PROJECTION OF CLINICAL AND COST OUTCOMES IN SWEDEN
|
Palmer, AJ
|
|
2005
|
8 |
6 |
p. A160-
1 p.
|
artikel
|
| 233 |
PDB12 BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF ROSIGLITAZONE IN THE TREATMENT OFTYPE-2 DIABETES. THE ITALIAN NHS PERSPECTIVE
|
Novelli, M
|
|
2005
|
8 |
6 |
p. A158-
1 p.
|
artikel
|
| 234 |
PDB8 CLINICAL BENEFITS OF PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) AND EZETIMIBE IN STATIN-TREATED TYPE-2 DIABETES PATIENTS FAILING TO REACH TARGET CHOLESTEROL LEVELS
|
Liens, D
|
|
2005
|
8 |
6 |
p. A156-A157
nvt p.
|
artikel
|
| 235 |
PDB26 COMPARATIVE EVALUATION OF THE LONG-TERM COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 AND INSULIN GLARGINE IN A SUB-POPULATION OF POORLY CONTROLLED PATIENTS WITH TYPE-2 DIABETES RECEIVING ORAL ANTIDIABETIC AGENTS
|
Cobden, D
|
|
2005
|
8 |
6 |
p. A162-
1 p.
|
artikel
|
| 236 |
PDB33 COST-CONSEQUENCE ANALYSIS OF SCREENING AND OPTIMIZED TREATMENT OF NEPHROPATHY IN HYPERTENSIVE PATIENTS WITH TYPE-2 DIABETES INA FRENCH SETTING
|
Palmer, AJ
|
|
2005
|
8 |
6 |
p. A165-
1 p.
|
artikel
|
| 237 |
PDB28 COST-EFFECTIVENESS ANALYSES OF BASAL-BOLUS THERAPY OF TYPE-1 DIABETES USING INSULIN DETEMIR + HUMAN SOLUBLE INSULIN VERSUS NEUTRAL PROTAMINE HAGEDORM + HUMAN SOLUBLE INSULIN REGIMENS IN GERMANY
|
Valentine, WJ
|
|
2005
|
8 |
6 |
p. A163-
1 p.
|
artikel
|
| 238 |
PDB21 COST-EFFECTIVENESS ANALYSIS OF BASAL/BOLUS THERAPY IN TYPE-1 DIABETES USING INSULIN DETEMIR + INSULIN ASPART OR HUMAN SOLUBLE INSULIN-BASED BASAL/BOLUS REGIMENS IN GERMANY
|
Valentine, WJ
|
|
2005
|
8 |
6 |
p. A160-A161
nvt p.
|
artikel
|
| 239 |
PDB27 COST-EFFECTIVENESS OFACARBOSE IN ADDITION TO EXISTING TREATMENTS IN TYPE-2 DIABETES IN GERMANY
|
Roze, S
|
|
2005
|
8 |
6 |
p. A163-
1 p.
|
artikel
|
| 240 |
PDB18 COST-EFFECTIVENESS OF ADD-ON PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) THERAPY IN DIABETIC VERSUS NON-DIABETIC PATIENTS WITH DYSLIPIDEMIA: A UK PERSPECTIVE
|
Paschen, B
|
|
2005
|
8 |
6 |
p. A159-A160
nvt p.
|
artikel
|
| 241 |
PDB30 COST-EFFECTIVENESS OF PREVENTIVE INTERVENTIONS IN DIABETES MELLITUS AND ITS (MACROVASCULAR)COMPLICATIONS: A SYSTEMATIC LITERATURE REVIEW
|
Vijgen, SMC
|
|
2005
|
8 |
6 |
p. A164-
1 p.
|
artikel
|
| 242 |
PDB14 COST OF DIABETES MELLITUS TYPE-2 AND SELF MEASUREMENT OF BLOOD GLUCOSE IN GERMANY: A HEALTH INSURANCE PERSPECTIVE
|
Weber, C
|
|
2005
|
8 |
6 |
p. A158-
1 p.
|
artikel
|
| 243 |
PDB36 COST OF TYPE-2 DIABETES MELLITUS IN HONG KONG CHINESE
|
Chan, BS
|
|
2005
|
8 |
6 |
p. A165-A166
nvt p.
|
artikel
|
| 244 |
PDB16 COSTS ASSOCIATED WITH GLUCOSE CONTROL IN THE NON-DIABETIC CRITICALLY ILL PATIENT
|
Conner, TM
|
|
2005
|
8 |
6 |
p. A159-
1 p.
|
artikel
|
| 245 |
PDB37 COSTS OF STAYS OF CARDIOVASCULAR EVENTS OF DIABETIC PATIENTS IN THE FRENCH HOSPITALS
|
Colin, X
|
|
2005
|
8 |
6 |
p. A166-
1 p.
|
artikel
|
| 246 |
PDB40 COST-UTILITY ANALYSIS IN A USA SETTING OF SCREENING AND OPTIMIZED TREATMENT OF NEPHROPATHY IN HYPERTENSIVE PATIENTS WITH TYPE-2 DIABETES
|
Palmer, AJ
|
|
2005
|
8 |
6 |
p. A167-
1 p.
|
artikel
|
| 247 |
PDB60 DEVELOPMENT AND EVALUATION OF THE ASK ADHERENCE BARRIER SURVEY IN PATIENTS WITH CHRONIC CONDITIONS
|
Yu-Isenberg, KS
|
|
2005
|
8 |
6 |
p. A173-
1 p.
|
artikel
|
| 248 |
PDB59 DEVELOPMENT OF A SCALE FOR DIABETIC PATIENT PROFILING BASED ON PATIENT ATTITUDE TOWARDS INSULIN
|
Arnould, B
|
|
2005
|
8 |
6 |
p. A173-
1 p.
|
artikel
|
| 249 |
PDB34 DIABETES PREVALENCE AND DIRECT MEDICAL COST ANALYSIS PER YEAR FROM 1997 TO 2001 IN TAIWAN
|
Tarn, TH
|
|
2005
|
8 |
6 |
p. A165-
1 p.
|
artikel
|
| 250 |
PDB41 DIABETIC PERIPHERAL NEUROPATHY: EVALUATION OF THE ASSOCIATION BETWEEN NEUROPATHIC SYMPTOMS (NTSS-6-SA)AND HEALTH CARE RESOURCE USE AND PRODUCTIVE LOSSES
|
Currie, CJ
|
|
2005
|
8 |
6 |
p. A167-
1 p.
|
artikel
|
| 251 |
PDB58 DIABETIC PERIPHERAL NEUROPATHY: EVALUATION OF THE ASSOCIATION BETWEEN NEUROPATHIC SYMPTOMS (NTSS-6-SA) AND HEALTH-RELATED UTILITY (EQ5D)
|
Currie, CJ
|
|
2005
|
8 |
6 |
p. A172-A173
nvt p.
|
artikel
|
| 252 |
PDB1 DIABETIC PERIPHERAL NEUROPATHY: EVALUATION OF THE INTER-ASSOCIATION BETWEEN THE RANGES OF NEUROPATHIC SYMPTOMS
|
Currie, CJ
|
|
2005
|
8 |
6 |
p. A154-
1 p.
|
artikel
|
| 253 |
PDB17 ECONOMIC ASSESSMENT OF ADD-ON THERAPY WITH PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) IN STATIN-TREATED PATIENTS WITH DYSLIPIDEMIA AND TYPE-2 DIABETES IN GERMANY AND SWEDEN
|
Berger, W
|
|
2005
|
8 |
6 |
p. A159-
1 p.
|
artikel
|
| 254 |
PDB23 ECONOMIC EVALUATION OF DETEMIR-BASED BASAL/BOLUS THERAPY VERSUS NPH-BASED BASAL/BOLUS THERAPY FOR TYPE-1 DIABETES IN GERMANY
|
Palmer, AJ
|
|
2005
|
8 |
6 |
p. A161-
1 p.
|
artikel
|
| 255 |
PDB19 ECONOMIC EVALUATION OF SWITCHING TYPE-1 DIABETES PATIENTS FROM LONG-ACTING INSULIN GLARGINE INA BASAL/BOLUS REGIMEN TO LONG-ACTING INSULIN DETEMIR IN AN AUSTRIAN SETTING
|
Palmer, AJ
|
|
2005
|
8 |
6 |
p. A160-
1 p.
|
artikel
|
| 256 |
PDB32 ECONOMIC EVALUATION OF THE LAPTOP-STUDY RESULTS
|
Högy, B
|
|
2005
|
8 |
6 |
p. A164-
1 p.
|
artikel
|
| 257 |
PDB51 EVALUATING INTERVENTIONS ALONG THE COURSE OF DISEASE: MODELING DIABETES AND ITS MACROVASCULAR COMPLICATIONS
|
Feenstra, TL
|
|
2005
|
8 |
6 |
p. A170-A171
nvt p.
|
artikel
|
| 258 |
PDB39 EVALUATION OF THE COST-UTILITY OF INSULIN DETEMIR COMPARED TO INSULIN GLARGINE, BOTH IN COMBINATION WITH INSULIN ASPART INTYPE-I DIABETES IN GERMANY AND AUSTRIA
|
Roze, S
|
|
2005
|
8 |
6 |
p. A166-A167
nvt p.
|
artikel
|
| 259 |
PDB25 FIXED COMBINATION METFORMIN PLUS GLIBENCLAMIDE (GLUCOVANCE®) IS COST AND LIFE SAVING COMPARED TO METFORMIN PLUS ROSIGLITAZONE IN TYPE-2 DIABETES PATIENTS IN FRANCE
|
Cugnardey, N
|
|
2005
|
8 |
6 |
p. A162-
1 p.
|
artikel
|
| 260 |
PDB4 HEALTH CARE UTILIZATION AND EXPENDITURES ASSOCIATED WITH USE OF INSULIN GLARGINE
|
Miller, PR
|
|
2005
|
8 |
6 |
p. A155-
1 p.
|
artikel
|
| 261 |
PDB29 HEALTH ECONOMIC EVALUATION OF INSULIN GLARGINE FOR THE TREATMENT OF TYPE-1 AND TYPE-2 DIABETES
|
Thompson, M
|
|
2005
|
8 |
6 |
p. A163-
1 p.
|
artikel
|
| 262 |
PDB5 IMPROVED TREATMENT SATISFACTION IN PATIENTS WITH TYPE-2 DIABETES TREATED WITH EXENATIDE OR INSULIN GLARGINE
|
Secnik, K
|
|
2005
|
8 |
6 |
p. A155-A156
nvt p.
|
artikel
|
| 263 |
PDB42 IMPROVING DIABETES CARE MANAGEMENT ACROSS A SET OF COMPREHENSIVE MEASURES IN A MEDICAID MANAGED CARE ORGANIZATION
|
Alison, L
|
|
2005
|
8 |
6 |
p. A167-A168
nvt p.
|
artikel
|
| 264 |
PDB53 INTERNAL VALIDATION OF THE ECONOMIC ASSESSMENT OF GLYCEMIC CONTROL AND LONG-TERM EFFECTS (EAGLE) DIABETES MODEL
|
Walzer, S
|
|
2005
|
8 |
6 |
p. A171-
1 p.
|
artikel
|
| 265 |
PDB48 KNOWLEDGE ABOUT INSULIN AND WILLINGNESS TO USE IT INFLUENCE GLYCEMIC CONTROL IN PATIENTS WITH TYPE-2 DIABETES MELLITUS ONLY TREATED WITH ORAL ANTIDIABETIC DRUGS—A GERMAN SURVEY
|
Stridde, E
|
|
2005
|
8 |
6 |
p. A169-A170
nvt p.
|
artikel
|
| 266 |
PDB55 MEASURING QUALITY OF LIFE WITH EQ-5D IN AN AUSTRIAN OUTPATIENT CLINIC FOR PATIENTS WITH DIABETES MELLITUS
|
Seereiner, S
|
|
2005
|
8 |
6 |
p. A172-
1 p.
|
artikel
|
| 267 |
PDB50 MODELLING THE CLINICAL CONSEQUENCES OF RIMONABANT IN ADDITION TO DIET AND EXERCISE IN ABDOMINALLY OBESE PATIENTS WITH TYPE-2 DIABETES
|
Annemans, L
|
|
2005
|
8 |
6 |
p. A170-
1 p.
|
artikel
|
| 268 |
PDB49 PATTERNS OF BLOOD GLUCOSE MONITORING IN RELATION TO GLYCAEMIC CONTROL AMONG PATIENTS WITH TYPE-2 DIABETES IN THE UK
|
Secnik, K
|
|
2005
|
8 |
6 |
p. A170-
1 p.
|
artikel
|
| 269 |
PDB61 PERCEIVED HEALTH CARE INFORMATION ON DIABETES: MEASUREMENT OF PATIENT SATISFACTION
|
Carmosino, G
|
|
2005
|
8 |
6 |
p. A173-A174
nvt p.
|
artikel
|
| 270 |
PDB45 PREDICTORS OF DIABETES MEDICATION UTILIZATION AND HEALTH CARE COSTS IN U.S. PATIENTS WITH TYPE-2 DIABETES: RESULTS FROM A NATIONAL SURVEY STUDY
|
Shenolikar, R
|
|
2005
|
8 |
6 |
p. A168-A169
nvt p.
|
artikel
|
| 271 |
PDB9 PROJECTED IMPACT ON CORONARY HEART DISEASE AT 5, 10 AND 35 YEARS OF ADDING PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) TO STATIN TREATMENT IN PATIENTS WITH TYPE-2 DIABETES
|
Renaudin, C
|
|
2005
|
8 |
6 |
p. A157-
1 p.
|
artikel
|
| 272 |
PDB6 REDUCTION IN DIABETES DRUGS USE AND DRUG COSTS IN OBESE PEOPLE TREATED WITH ORLISTAT
|
Rowe, R
|
|
2005
|
8 |
6 |
p. A156-
1 p.
|
artikel
|
| 273 |
PDB43 SHOULD WE LOOK FOR A NEWAPPROACH IN DIABETES MELLITUS (DM) MANAGEMENT? IS IT A COST-EFFECTIVE STRATEGY IN THE POLISH SETTING?
|
Sieradzki, J
|
|
2005
|
8 |
6 |
p. A168-
1 p.
|
artikel
|
| 274 |
PDB35 THE COST OF DIABETES MELLITUS IN SPAIN
|
Rubio-Terrés, C
|
|
2005
|
8 |
6 |
p. A165-
1 p.
|
artikel
|
| 275 |
PDB13 THE ESTIMATION OF POTENTIAL BUDGETARY IMPACT OF INSULIN GLARGINE IN POLISH SETTINGS
|
Kamiñski, B
|
|
2005
|
8 |
6 |
p. A158-
1 p.
|
artikel
|
| 276 |
PDB7 THE METABOLIC EFFECTS OF ORLISTAT AND ROSIGLITAZONE ON INSULIN ACTION IN A GROUP OF CHINESE PATIENTS AFFECTED BYTHE METABOLIC SYNDROME
|
Loh, SC
|
|
2005
|
8 |
6 |
p. A156-
1 p.
|
artikel
|
| 277 |
PDB57 TREATMENT SATISFACTION AND QUALITY OF LIFE WITH AN EARLY INSULINIZATION STRATEGYWITH INSULIN GLARGINE COMPARED TO AN ADJUSTED ORAL THERAPY IN THE MANAGEMENT OF TYPE-2 DIABETES: THE CANADIAN INSIGHT STUDY
|
Houlden, R
|
|
2005
|
8 |
6 |
p. A172-
1 p.
|
artikel
|
| 278 |
PDB62 TREATMENT SATISFACTION IN SUBJECTS WITH TYPE-2 DIABETES RECEIVING INSULIN GLARGINE
|
Davies, M
|
|
2005
|
8 |
6 |
p. A174-
1 p.
|
artikel
|
| 279 |
PDB47 TYPE-2 DIABETES AND GLYCEMIC CONTROL IN GERMANY
|
Yurgin, N
|
|
2005
|
8 |
6 |
p. A169-
1 p.
|
artikel
|
| 280 |
PDB10 TYPE-2 DIABETES IN GERMANY: PREVALENCE AND MEDICATION USE
|
Yurgin, N
|
|
2005
|
8 |
6 |
p. A157-
1 p.
|
artikel
|
| 281 |
PDB52 TYPE-2 DIABETES MODELS THAT DO NOT ACCOUNT FOR MICROVASCULAR DISEASE SCREENING RATESAND IMPORTANT CONCOMITANT MEDICATION USE MAY LEAD TO SUBSTANTIAL MISREPRESENTATION OF THE COST-EFFECTIVENESS OF NEW MEDICATIONS
|
Palmer, AJ
|
|
2005
|
8 |
6 |
p. A171-
1 p.
|
artikel
|
| 282 |
PDB44 USE OF ACETYL-SALICYLIC ACID FOR CARDIOVASCULAR PREVENTION IN PRIMARY CARE PATIENTS WITH DIABETES MELLITUS
|
Sicras, A
|
|
2005
|
8 |
6 |
p. A168-
1 p.
|
artikel
|
| 283 |
PED3 A PROSPECTIVE REAL-LIFE STUDY OF QUALITY OF LIFE IN PATIENTS WITH ACROMEGALY
|
Badia, X
|
|
2005
|
8 |
6 |
p. A117-A118
nvt p.
|
artikel
|
| 284 |
PED2 LONG-TERM QUALITY OF LIFE (QOL) OUTCOMES IN THE TREATMENT OF ADULTS WITH GROWTH HORMONE DEFICIENCY (GHD)—A 5 YEAR STUDY
|
Mattsson, A
|
|
2005
|
8 |
6 |
p. A117-
1 p.
|
artikel
|
| 285 |
PED4 SUSTAINED IMPROVEMENT IN PATIENT-REPORTED OUTCOMES (PRO) AND NORMALIZATION OF HEALTHCARE UTILIZATION (HCU) DURING GROWTH HORMONE (GH) REPLACEMENT THERAPY IN HYPOPITUITARY ADULTS IN THE NETHERLANDS
|
Koltowska-Haggstrom, M
|
|
2005
|
8 |
6 |
p. A118-
1 p.
|
artikel
|
| 286 |
PED1 USING EQ-5DTO DERIVE UTILITIES FORTHE QUALITY OF LIFE-ASSESSMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS (QOL-AGHDA)
|
Koltowska-Haggstrom, M
|
|
2005
|
8 |
6 |
p. A117-
1 p.
|
artikel
|
| 287 |
PEY1 ANXIETY AND DEPRESSION IN WET AGE-RELATED MACULAR DEGENERATION (ARMD)
|
Maurel, F
|
|
2005
|
8 |
6 |
p. A174-
1 p.
|
artikel
|
| 288 |
PEY6 A PUBLIC HEALTH IMPACT MODEL OF ANECORTAVE ACETATE IN WET AGE-RELATED MACULAR DEGENERATION
|
Deschaseaux-Voinet, C
|
|
2005
|
8 |
6 |
p. A176-
1 p.
|
artikel
|
| 289 |
PEY10 COMBIGAN—COST-MINIMIZATION ANALYSIS OF BRIMONIDINE/TIMOLOL FIXED COMBINATION IN THE TREATMENT OF PRIMARY OPEN ANGLE GLAUCOMA
|
Poulsen, PB
|
|
2005
|
8 |
6 |
p. A177-
1 p.
|
artikel
|
| 290 |
PEY5 COMPARING EFFICACY OF PROSTAGLANDIN ANALOGUES FOR CONTROLLING INTRA-OCULAR PRESSURE (IOP): RESULTS OF A META-ANALYSIS
|
Mimaud, V
|
|
2005
|
8 |
6 |
p. A175-A176
nvt p.
|
artikel
|
| 291 |
PEY11 COST-EFFECTIVENESS MODEL FORAGE-RELATED MACULAR DEGENERATION: COMPARING EARLY AND LATE MACUGEN TREATMENT
|
Earnshaw, SR
|
|
2005
|
8 |
6 |
p. A177-
1 p.
|
artikel
|
| 292 |
PEY9 COST-EFFECTIVENESS MODEL FORAGE-RELATED MACULAR DEGENERATION: COMPARING MACUGEN TO VISUDYNE
|
Earnshaw, SR
|
|
2005
|
8 |
6 |
p. A176-A177
nvt p.
|
artikel
|
| 293 |
PEY15 COST OF ENDOPHTHALMITIS: A NATIONWIDE APPROACH
|
Colin, X
|
|
2005
|
8 |
6 |
p. A178-A179
nvt p.
|
artikel
|
| 294 |
PEY13 COSTS AND CONSEQUENCES OF ENDOPHTHALMITIS: RESULTS FROM THE NATIONAL ENDOPHTALMITIS SURVEY
|
Berdeaux, G
|
|
2005
|
8 |
6 |
p. A178-
1 p.
|
artikel
|
| 295 |
PEY22 DEVELOPMENT AND VALIDATION OF A COMPREHENSIVE PAINFUL SYMPTOM CHECKLIST ALLOWING PROVIDING A COMPLETE DESCRIPTION OF PAIN IN OPHTHALMIC DISEASES
|
Arnould, B
|
|
2005
|
8 |
6 |
p. A181-
1 p.
|
artikel
|
| 296 |
PEY4 EVALUATION OF INCREMENTAL EFFICACY OF LATANOPROST-TIMOLOL IN THE TREATMENT OF PRIMARY OPEN-ANGLE GLAUCOMA USING RETROSPECTIVE ANALYSIS OF THE GLASGOW ROYAL INFIRMARY GLAUCOMA DATABASE
|
Montgomery, D
|
|
2005
|
8 |
6 |
p. A175-
1 p.
|
artikel
|
| 297 |
PEY8 EYE ADVERSE EFFECTS ASSOCIATED WITH POLYVINYL ALCOHOL TEAR DROPS AFTER LASER ASSISTED SUBEPITHELIAL KERATECTOMY (LASEK)
|
Flores, C
|
|
2005
|
8 |
6 |
p. A176-
1 p.
|
artikel
|
| 298 |
PEY20 IMPACT OF BEST AND WORST EYE VISUAL ACUITY ON VISION-SPECIFIC HEALTH-RELATED QUALITY OF LIFE AND UTILITY IN PATIENTS SUFFERING FROM AGE-RELATED MACULAR DEGENERATION
|
Maurel, F
|
|
2005
|
8 |
6 |
p. A180-
1 p.
|
artikel
|
| 299 |
PEY14 IMPACT OF VISUAL ACUITY ON MEDICAL AND NON-MEDICAL COSTS IN PATIENTS SUFFERING FROM WET AGE-RELATED MACULAR DEGEN-ERATION IN FRANCE, GERMANY AND ITALY
|
Benhaddi, H
|
|
2005
|
8 |
6 |
p. A178-
1 p.
|
artikel
|
| 300 |
PEY3 INTRA-OCULAR PRESSURE (IOP) CONTROL OF LATANOPROST AND TRAVOPROST MONOTHERAPY IN DAILY PRACTICE
|
Denis, P
|
|
2005
|
8 |
6 |
p. A175-
1 p.
|
artikel
|
| 301 |
PEY19 METHODS FOR A POPULATION-BASED INTERNATIONAL STUDY ON THE BURDEN OF ILLNESS OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
|
Soubrane, G
|
|
2005
|
8 |
6 |
p. A180-
1 p.
|
artikel
|
| 302 |
PEY17 MODELING TREATMENTS FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE RELATED MACULAR DEGENERATION: COST-EFFECTIVENESS METHODS
|
Earnshaw, SR
|
|
2005
|
8 |
6 |
p. A179-
1 p.
|
artikel
|
| 303 |
PEY7 NUMBER OF TREATABLE EYES WITH WET SUB-FOVEAL AGE-RELATED MACULAR DEGENARATION (ARMD) : USE OF DIRECT STANDARDIZATION AND MARKOV MODEL
|
Moore, N
|
|
2005
|
8 |
6 |
p. A176-
1 p.
|
artikel
|
| 304 |
PEY12 PHARMACOECONOMIC ANALYSIS OF LATANOPROST VERSUS DORZOLAMIDE/TIMOLOL IN THE TREATMENT OF OPEN-ANGLE GLAUCOMA IN SPAIN
|
Ortega, P
|
|
2005
|
8 |
6 |
p. A177-A178
nvt p.
|
artikel
|
| 305 |
PEY16 THE PREVALENCE AND COST OF TREATMENT OF PATIENTS TAKING ANTIGLAUCOMA AGENTS FOR GLAUCOMA OR OCULAR HYPERTENSION IN FRANCE
|
De Pouvourville, GA
|
|
2005
|
8 |
6 |
p. A179-
1 p.
|
artikel
|
| 306 |
PEY2 USE OF NEURAL NETWORKS TO PREDICT NIGHT INTRA-OCULAR PRESSURE (IOP) PEAK CONTROL BY PROSTAGLANDIN ANALOGUES
|
Nordmann, JP
|
|
2005
|
8 |
6 |
p. A174-A175
nvt p.
|
artikel
|
| 307 |
PEY18 USING DISCRETE CHOICE EXPERIMENTS TO ESTIMATE QUALITY WEIGHTS WITHIN THE FRAMEWORK OF QALYS: AN APPLICATION TO GLAUCOMA
|
Ryan, M
|
|
2005
|
8 |
6 |
p. A179-A180
nvt p.
|
artikel
|
| 308 |
PEY21 UTILITY ASSESSMENT AMONG PATIENTS WITH DRY EYE DISEASE IN THE UK
|
Buchholz, P
|
|
2005
|
8 |
6 |
p. A180-A181
nvt p.
|
artikel
|
| 309 |
PFM6 CROSS-SURVEY OF FRENCH AND PORTUGUESE GENERAL PRACTITIONERS AWARENESS AND KNOWLEDGE OF FIBROMYALGIA
|
Blotman, F
|
|
2005
|
8 |
6 |
p. A51-A52
nvt p.
|
artikel
|
| 310 |
PFM3 CROSS-SURVEY OF FRENCH AND PORTUGUESE GENERAL PRACTITIONERS GLOBAL MANAGEMENT OF FIBROMYALGIA
|
Blotman, F
|
|
2005
|
8 |
6 |
p. A50-A51
nvt p.
|
artikel
|
| 311 |
PFM5 CROSS-SURVEY OF FRENCH AND PORTUGUESE RHEUMATOLOGISTS GLOBAL MANAGEMENT OF FIBROMYALGIA
|
Blotman, F
|
|
2005
|
8 |
6 |
p. A51-
1 p.
|
artikel
|
| 312 |
PFM4 DIAGNOSIS OF FIBROMYALGIA AND HEALTH CARE RESOURCE USE IN PRIMARY CARE IN THE UK
|
Myon, E
|
|
2005
|
8 |
6 |
p. A51-
1 p.
|
artikel
|
| 313 |
PFM2 FIBROMYALGIA SYNDROME: AN ITALIAN EPIDEMIOLOGICAL SURVEY
|
Zoppi, M
|
|
2005
|
8 |
6 |
p. A50-
1 p.
|
artikel
|
| 314 |
PFM1 FIBROMYALGIA SYNDROME: A PORTUGUESE EPIDEMIOLOGICAL SURVEY
|
Branco, J
|
|
2005
|
8 |
6 |
p. A50-
1 p.
|
artikel
|
| 315 |
PGI17 ARTIFICIAL LIVER SUPPORT SYSTEMS—A MEDICAL AND HEALTH ECONOMIC HTA-REPORT
|
Hessel, FP
|
|
2005
|
8 |
6 |
p. A123-
1 p.
|
artikel
|
| 316 |
PGI22 BURDEN OF ILLNESS IS HIGHEST IN PATIENTS WITH SEVERE PAIN SYMPTOMS
|
Ten Berg, MJ
|
|
2005
|
8 |
6 |
p. A125-
1 p.
|
artikel
|
| 317 |
PGI21 BURDEN OF ILLNESS OF IBS PATIENTS IN THE NETHERLANDS
|
Ten Berg, MJ
|
|
2005
|
8 |
6 |
p. A124-
1 p.
|
artikel
|
| 318 |
PGI1 CLINICAL OUTCOMES OF RABEPRAZOLE IN PATIENTS WITH GASTRO-OESOPHAGEAL REFLUX DISEASE IN REAL-WORLD CLINICAL PRACTICE
|
Haiderali, A
|
|
2005
|
8 |
6 |
p. A118-
1 p.
|
artikel
|
| 319 |
PGI2 COST EFFECTIVENESS AND BUDGET IMPACT OF LAMIVUDINE ANTIVIRAL TREATMENT FOR CHRONIC HEPATITIS TYPE B PATIENTS IN TAIWAN
|
Shau, WY
|
|
2005
|
8 |
6 |
p. A118-A119
nvt p.
|
artikel
|
| 320 |
PGI9 COST-EFFECTIVENESS OF ESOMEPRAZOLE VERSUS GENERIC OMEPRAZOLE IN THE ACUTE TREATMENT OF REFLUX ESOPHAGITIS IN SWEDEN
|
Wahlqvist, P
|
|
2005
|
8 |
6 |
p. A121-
1 p.
|
artikel
|
| 321 |
PGI3 COST-EFFECTIVENESS OF HELICOBACTER PYLORI TESTING FOR PATIENTS WITH PERSISTENT DYSPEPSIA IN THE UK
|
Brown, GL
|
|
2005
|
8 |
6 |
p. A119-
1 p.
|
artikel
|
| 322 |
PGI7 COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) COMPARED TO LAMIVUDINE AS FIRST LINE TREATMENT OF CHRONIC HEPATITIS B (CHB) IN THE UK
|
Veenstra, PL
|
|
2005
|
8 |
6 |
p. A120-
1 p.
|
artikel
|
| 323 |
PGI10 COST EFFECTIVENESS OF PROTON PUMP INHIBITOR TRIPLE THERAPY REGIMENS FOR HELICOBACTER PYLORI ERADICATION IN THE PRIMARY CARE SETTING IN IRELAND
|
Nagle, V
|
|
2005
|
8 |
6 |
p. A121-
1 p.
|
artikel
|
| 324 |
PGI8 ECONOMIC EVALUATION OF ADACOLUMN® APHERESIS FOR THE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE (CD)/ULCERATIVE COLITIS (UC)
|
Persson, U
|
|
2005
|
8 |
6 |
p. A120-A121
nvt p.
|
artikel
|
| 325 |
PGI20 ECONOMIC VALUATION MODELING FOR ASSESSING BIOTECHNOLOGY/PHARMACEUTICAL DEVELOPMENTAL OPPORTUNITIES
|
Shane, LG
|
|
2005
|
8 |
6 |
p. A124-
1 p.
|
artikel
|
| 326 |
PGI6 ESOMEPRAZOLE IS COST-EFFECTIVE COMPARED WITH PANTOPRAZOLE IN THE ACUTE AND MAINTENANCE TREATMENT OF REFLUX ESOPHAGITIS IN FINLAND
|
Wahlqvist, P
|
|
2005
|
8 |
6 |
p. A120-
1 p.
|
artikel
|
| 327 |
PGI23 ESOMEPRAZOLE TREATMENT IN PATIENTS WITH UNINVESTIGATED NON-GERD DYSPEPSIA LEADS TO SIGNIFICANT IMPROVEMENTS IN PRODUCTIVITYWHILE ATWORKAND IN DAILY ACTIVITIES—RESULTS FROMA RANDOMISED, PLACEBO-CONTROLLED CLINICAL STUDY
|
Wahlqvist, P
|
|
2005
|
8 |
6 |
p. A125-
1 p.
|
artikel
|
| 328 |
PGI19 GASTROESOPHAGEAL REFLUX DISEASE (GERD) COST OF CARE: ROLE OF NAÏVE AND RELAPSED SYMPTOMS IN GENERAL PRACTICE
|
Cammarota, S
|
|
2005
|
8 |
6 |
p. A124-
1 p.
|
artikel
|
| 329 |
PGI16 GASTROESOPHAGEAL REFLUX DISEASE (GERD) — PREVALENCE, MANAGEMENT AND COST IN INTERNATIONAL COMPARISON
|
Kilgert, K
|
|
2005
|
8 |
6 |
p. A123-
1 p.
|
artikel
|
| 330 |
PGI11 IBD: INDIRECT COSTS OF ILLNESS AND QUALITY OF LIFE IN GERMANY
|
Stark, R
|
|
2005
|
8 |
6 |
p. A121-
1 p.
|
artikel
|
| 331 |
PGI15 MEDICAL RESOURCE USE AND DIRECT MEDICAL COST OF CHRONIC HEPATITIS C VIRUS INFECTION (HCVI) IN BRAZIL
|
Fonseca, MC
|
|
2005
|
8 |
6 |
p. A122-A123
nvt p.
|
artikel
|
| 332 |
PGI18 META-ANALYSIS OF MULTIPLE TREATMENT COMPARISONS REPORTED AT MULTIPLE FOLLOW-UP TIMES
|
Lu, G
|
|
2005
|
8 |
6 |
p. A123-A124
nvt p.
|
artikel
|
| 333 |
PGI5 THE COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2B (I2KD) PLUS RIBAVIRIN VS. INTERFERON ALFA-2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C (CHC) IN A DEVELOPING COUNTRY—BRAZIL
|
Fonseca, MC
|
|
2005
|
8 |
6 |
p. A119-A120
nvt p.
|
artikel
|
| 334 |
PGI12 THE COSTS OF ACUTE-ON-CHRONIC LIVER FAILURE—A BOTTOM-UP ANALYSIS BASED ON INDIVIDUAL PATIENT DATA
|
Hessel, FP
|
|
2005
|
8 |
6 |
p. A121-A122
nvt p.
|
artikel
|
| 335 |
PGI13 THE IMPACT OF GASTROESOPHAGEAL REFLUX DISEASE ON WORK PRODUCTIVITY: A SYSTEMATIC REVIEW
|
Wahlqvist, P
|
|
2005
|
8 |
6 |
p. A122-
1 p.
|
artikel
|
| 336 |
PGI4 TREATMENT OF CIRRHOSIS OF THE LIVER WITH SILYMARIN, A COST-EFFECTIVENESS ANALYSIS, BASED ON GERMAN DATA
|
Heinen-Kammerer, T
|
|
2005
|
8 |
6 |
p. A119-
1 p.
|
artikel
|
| 337 |
PGI14 WORK ABSENTEEISM IN IRRITABLE BOWEL SYNDROME (IBS): MEASURING DAYSVS HOURS MISSED
|
Reilly, M
|
|
2005
|
8 |
6 |
p. A122-
1 p.
|
artikel
|
| 338 |
PHM6 ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN ADULT PATIENTS WITH HAEMOPHILIA A SWITCHED TO PROPHYLACTIC REPLACEMENT TREATMENT
|
Ravera, S
|
|
2005
|
8 |
6 |
p. A127-
1 p.
|
artikel
|
| 339 |
PHM5 ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HAEMOPHILIA WITH THE NEWLY DEVELOPED HAEMOPHILIA-SPECIFIC INSTRUMENT HAEM-A-QOL
|
Von Mackensen, S
|
|
2005
|
8 |
6 |
p. A127-
1 p.
|
artikel
|
| 340 |
PHM1 COST-EFFECTIVENESS OF REGULAR CONTINUOUS PROPHYLACTIC TREATMENT IN ADULT PATIENTS WITH SEVERE HAEMOPHILIA A
|
Monzini, M
|
|
2005
|
8 |
6 |
p. A125-A126
nvt p.
|
artikel
|
| 341 |
PHM3 COSTS OF HAEMOPHILIA ASSISTANCE IN ROMANIA
|
Mihailov, MD
|
|
2005
|
8 |
6 |
p. A126-
1 p.
|
artikel
|
| 342 |
PHM7 DISEASE STATE AND QUALITY OF LIFE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: A REVIEW OF INSTRUMENTS, DISEASE BURDEN, AND PREDICTIVE FACTORS FOR OUTCOMES
|
Szende, A
|
|
2005
|
8 |
6 |
p. A127-
1 p.
|
artikel
|
| 343 |
PHM9 HOW PATIENTS WITH HAEMOPHILIA ARE SATISFIED WITH THEIR TREATMENT
|
Von Mackensen, S
|
|
2005
|
8 |
6 |
p. A128-
1 p.
|
artikel
|
| 344 |
PHM2 THE COST OF CARE OF HEMOPHILIC PATIENTS WITHOUT INHIBITORS: THE COCHE STUDY
|
Mantovani, LG
|
|
2005
|
8 |
6 |
p. A126-
1 p.
|
artikel
|
| 345 |
PHM8 THE POTENTIAL IMPACT OF CHELATION THERAPY (CT) ON THE QUALITY OF LIFE (QOL) OF PATIENTS WITH IRON OVERLOAD (IO)
|
Abetz, L
|
|
2005
|
8 |
6 |
p. A128-
1 p.
|
artikel
|
| 346 |
PHM4 UK COST COMPARISON OF BUCY2 CONDITIONING IN ALLOGENEIC HSCT: ORAL VERSUS IV BUSULFAN (BUSILVEX®)
|
Groves, LJ
|
|
2005
|
8 |
6 |
p. A126-
1 p.
|
artikel
|
| 347 |
PHP23 A COMPARATIVE ANALYSIS OF THE FINANCING, PRICING AND REIMBURSEMENT SYSTEMS FOR PRESCRIPTION DRUGS IN THE NORDIC COUNTRIES
|
Kristensen, FKO
|
|
2005
|
8 |
6 |
p. A188-
1 p.
|
artikel
|
| 348 |
PHP1 A COMPARISON OF FREQUENTIST AND BAYESIAN STATISTICAL APPROACHES IN COST-BENEFIT ANALYSIS
|
Blizzard, J
|
|
2005
|
8 |
6 |
p. A181-
1 p.
|
artikel
|
| 349 |
PHP26 ADHERENCE INDEX OF PERFORMANCE—A NEW METHOD AND TOOL FOR ONGOING EVALUATION OF MEDICATION ADHERENCE IMPROVEMENT INITIATIVES
|
Day, D
|
|
2005
|
8 |
6 |
p. A188-A189
nvt p.
|
artikel
|
| 350 |
PHP35 AGE AND GENDER IN PHARMACEUTICAL EXPENDITURE: ATOOL FOR RISK CALCULATION
|
Gilabert i Perramon, A
|
|
2005
|
8 |
6 |
p. A191-
1 p.
|
artikel
|
| 351 |
PHP11 AN INTRODUCTION TO HEALTH TOURISM AND MEDICAL TOURISM
|
Carrera, P
|
|
2005
|
8 |
6 |
p. A184-
1 p.
|
artikel
|
| 352 |
PHP45 APPRAISAL OF FIVE NEW OUT-OF-HOURS (OOH) PRIMARY CARE CENTRES IN THE PARISIAN REGION: “MAISONS MÉDICALES DE GARDE (MMG)”
|
Lemasson, H
|
|
2005
|
8 |
6 |
p. A194-
1 p.
|
artikel
|
| 353 |
PHP48 A SURVEY OF PATIENT REPORTED OUTCOME (PRO) CLAIMS IN PHARMACEUTICAL ADVERTISING
|
Yuwaree, V
|
|
2005
|
8 |
6 |
p. A195-
1 p.
|
artikel
|
| 354 |
PHP24 A SYSTEMATIC REVIEW OF THE EUROPEAN PHARMACEUTICAL MARKET AND THE IMPACT OF EUROPEAN UNION REGULATION AND JURISDICTION
|
Van Ginneken, EJ
|
|
2005
|
8 |
6 |
p. A188-
1 p.
|
artikel
|
| 355 |
PHP38 BELIEFS ABOUT MEDICINES AMONG SWEDISH PHARMACY EMPLOYEES
|
Jörgensen, T
|
|
2005
|
8 |
6 |
p. A192-
1 p.
|
artikel
|
| 356 |
PHP31 CHARGES FOR HOSPITAL ADMISSIONS ATTRIBUTABLE TO HEALTH DISPARITIES FOR AFRICAN AMERICAN PATIENTS IN SOUTH CAROLINA DURING 1998-2002
|
Chumney, EC
|
|
2005
|
8 |
6 |
p. A190-
1 p.
|
artikel
|
| 357 |
PHP32 COMBINING PHARMACY AND HOSPITAL DATA IN A RISK ADJUSTMENT MODEL
|
Yuen, EJ
|
|
2005
|
8 |
6 |
p. A190-A191
nvt p.
|
artikel
|
| 358 |
PHP44 COST AVOIDANCE OF CLINICAL PHARMACIST INTERVENTIONS AT A UNIVERSITYTEACHING HOSPITAL
|
Howe, AM
|
|
2005
|
8 |
6 |
p. A194-
1 p.
|
artikel
|
| 359 |
PHP5 COST OF SEVERE BLUNT TRAUMA IN THE UK
|
Porter, K
|
|
2005
|
8 |
6 |
p. A182-
1 p.
|
artikel
|
| 360 |
PHP46 DEFINING COMPLIANCE/ADHERENCE AND PERSISTENCE: ISPOR SPECIAL INTEREST WORKING GROUP
|
Burrell, A
|
|
2005
|
8 |
6 |
p. A194-A195
nvt p.
|
artikel
|
| 361 |
PHP6 DRUG PRICE INDICES 1980-2004 IN FINLAND
|
Hahl, J
|
|
2005
|
8 |
6 |
p. A182-A183
nvt p.
|
artikel
|
| 362 |
PHP4 ECONOMIC COMPARISON OF TWO XENETIX® 300 PRESENTATIONS
|
Castelli, C
|
|
2005
|
8 |
6 |
p. A182-
1 p.
|
artikel
|
| 363 |
PHP28 ECONOMIC EVALUATION OF NEWTECHNOLOGIES IN THE HOSPITAL SETTING: THE EXPERIENCE OFTHEAZIENDA OSPEDALIERA Dl VERONA, ITALY
|
Marini, P
|
|
2005
|
8 |
6 |
p. A189-
1 p.
|
artikel
|
| 364 |
PHP3 ECONOMIC IMPACT OF A DEVICE FOR PREPARING STERILE SOLUTIONS IN THE MT. SINAI HOSPITAL PHARMACY
|
Ellegard, B
|
|
2005
|
8 |
6 |
p. A182-
1 p.
|
artikel
|
| 365 |
PHP22 EFFECTS OF DECENTRALIZED RESPONSIBILITY FOR COSTS OF OUTPATIENT PRESCRIPTION DRUGS ON THE PHARMACEUTICAL COST DEVELOPMENT IN SWEDEN
|
Bergstrom, G
|
|
2005
|
8 |
6 |
p. A187-
1 p.
|
artikel
|
| 366 |
PHP17 EFFECTS OF GENERIC SUBSTITUTION ON THE DEVELOPMENT OF PHARMACEUTICAL EXPENDITURES DURING THE PERIOD JANUARY I 998 TO MAY 2005
|
Andersson, K
|
|
2005
|
8 |
6 |
p. A186-
1 p.
|
artikel
|
| 367 |
PHP34 EFFECTS OF MEDICAL SAVINGS ACCOUNTS ON HEALTH CARE UTILIZATION AND HEALTH EXPENDITURE: EVIDENCE FROM CHINA
|
Yi, Y
|
|
2005
|
8 |
6 |
p. A191-
1 p.
|
artikel
|
| 368 |
PHP16 ESTIMATING THE COST SAVINGS AND RATIONAL USE EFFECTS OF IMPLEMENTING AN ESSENTIAL MEDICINES LIST
|
Hamidi, S
|
|
2005
|
8 |
6 |
p. A185-A186
nvt p.
|
artikel
|
| 369 |
PHP47 EVALUATION OF THE RELATIONSHIP BETWEEN PHARMACEUTICAL PRODUCT PRICE AND HEALTH-RELATED QUALITY OF LIFE USING WHOLESALE ACQUSITION COST AND AVERAGE EFFECT SIZE
|
Murawski, MM
|
|
2005
|
8 |
6 |
p. A195-
1 p.
|
artikel
|
| 370 |
PHP41 EXAMINING THE QUALITY OF HEALTH ECONOMIC ANALYSES SUBMITTED TO THE REIMBURSEMENT AGENCIES IN SWEDEN AND FINLAND—A CROSS COUNTRY COMPARISON
|
Engstrom, A
|
|
2005
|
8 |
6 |
p. A193-
1 p.
|
artikel
|
| 371 |
PHP20 GENERIC DRUG PRICES REMAIN HIGHER IN CANADA THAN IN THE UNITED STATES
|
Palmer, WN
|
|
2005
|
8 |
6 |
p. A187-
1 p.
|
artikel
|
| 372 |
PHP18 GEOGRAPHICAL INFORMATION SYSTEM (GIS) ANALYSIS OF SMALL AREA INEQUALITIES IN DRUG EXPENDITURES IN HUNGARY
|
Boncz, I
|
|
2005
|
8 |
6 |
p. A186-
1 p.
|
artikel
|
| 373 |
PHP43 IMPACT OF PHARMACEUTICAL POLICIES ON PROMOTIONAL TARGETED DRUGS
|
Layton, MR
|
|
2005
|
8 |
6 |
p. A193-A194
nvt p.
|
artikel
|
| 374 |
PHP2 IMPLEMENTATION OF AN EVIDENCE BASED GUIDELINE FOR CLINICAL NUTRITION IN A 500 BED HOSPITAL IN NORTHERN GERMANY: INFLUENCE ON DIRECT COST FOR CLINICAL NUTRITION
|
Steinhausen, K
|
|
2005
|
8 |
6 |
p. A181-
1 p.
|
artikel
|
| 375 |
PHP7 MANAGING ACUTE INJURIES RESULTING FROM MOTORCYCLE ACCIDENTS: EMERGENCY DEPARTMENT AND INPATIENT HOSPITAL RESOURCE USE AND COSTS
|
O'Brien, JA
|
|
2005
|
8 |
6 |
p. A183-
1 p.
|
artikel
|
| 376 |
PHP13 MULTIPLE APPRAISAL OF DRUGS IN THE UK HEALTH CARE SYSTEM
|
Hutton, J
|
|
2005
|
8 |
6 |
p. A184-A185
nvt p.
|
artikel
|
| 377 |
PHP14 OPPS PHARMACY HANDLING COSTS: POLICY IMPLICATIONS
|
Baker, JJ
|
|
2005
|
8 |
6 |
p. A185-
1 p.
|
artikel
|
| 378 |
PHP42 PAYMENT FOR PHARMACY HANDLING COSTS IN THE HOPD: 2006 REIMBURSEMENT IMPLICATIONS
|
Baker, JJ
|
|
2005
|
8 |
6 |
p. A193-
1 p.
|
artikel
|
| 379 |
PHP9 PHARMACEUTICAL CARE IN GREECE: A CITIZEN SATISFACTION SURVEY
|
Geitona, M
|
|
2005
|
8 |
6 |
p. A183-A184
nvt p.
|
artikel
|
| 380 |
PHP21 PHARMACEUTICAL POLICY IN GREECE: RECENT DEVELOPMENTS AND THE ROLE OF PHARMACOECONOMICS
|
Vandoros, C
|
|
2005
|
8 |
6 |
p. A187-
1 p.
|
artikel
|
| 381 |
PHP37 PHARMACOECONOMIC CLAIMS IN PRESCRIPTION DRUG ADVERTISEMENTS IN FINNISH MEDICAL JOURNALS
|
Norjamäki, A
|
|
2005
|
8 |
6 |
p. A192-
1 p.
|
artikel
|
| 382 |
PHP27 PREDICTIVE VALUE OF PHARMACEUTICAL TREATMENT (PT) COST AND LENGTH OF STAY (LOS) ON TOTAL HOSPITAL (TH) COST USING THE MINIMUM BASIC DATA SET (MBDS)
|
Van Wilder, P
|
|
2005
|
8 |
6 |
p. A189-
1 p.
|
artikel
|
| 383 |
PHP30 PRESCRIBING PATTERNS AND ASSOCIATED COSTS OF PSYCHOTROPIC DRUGS IN A MAJOR HEALTH CARE SYSTEM IN SAUDI ARABIA
|
Alsultan, MS
|
|
2005
|
8 |
6 |
p. A190-
1 p.
|
artikel
|
| 384 |
PHP19 PRESCRIPTION DRUGS AND ANNUAL BENEFIT CAPS—DO PATIENTS ANTICIPATE EXCEEDING THE CAP?
|
Hsu, J
|
|
2005
|
8 |
6 |
p. A186-A187
nvt p.
|
artikel
|
| 385 |
PHP12 PRICING POLICIES FOR THE PHARMACEUTICAL MARKET—AN INTERNATIONAL PERSPECTIVE
|
Ilgin, Y
|
|
2005
|
8 |
6 |
p. A184-
1 p.
|
artikel
|
| 386 |
PHP39 PUBLIC FUNDING OF DRUGS FOR ORPHAN DISEASES
|
Hughes, D
|
|
2005
|
8 |
6 |
p. A192-A193
nvt p.
|
artikel
|
| 387 |
PHP29 REIMBURSEMENT OF HIGH-PRICED NEW EMERGING MEDICAL TECHNOLOGIES IN A DRG-BASED HOSPITAL CARE SYSTEM
|
Hessel, FP
|
|
2005
|
8 |
6 |
p. A189-A190
nvt p.
|
artikel
|
| 388 |
PHP8 RESOURCE CONSUMPTION IN PLATELET PRODUCTION FROM THE PERSPECTIVE OF A TRANSFUSION MEDICINE DEPARTMENT IN GERMANY
|
Segerer, C
|
|
2005
|
8 |
6 |
p. A183-
1 p.
|
artikel
|
| 389 |
PHP15 THE CONSUMPTION OF DRUGS FINANCED BYTHE SPANISH NATIONAL HEALTH SYSTEM AND THE IMPACT OF PHARMACOVIGILANT ACTIONS
|
Gaspar, MD
|
|
2005
|
8 |
6 |
p. A185-
1 p.
|
artikel
|
| 390 |
PHP10 THE IMPACT OF MEDICARE MANAGED CARE ON USE OF VA PHARMACY SERVICES
|
Morgan, RO
|
|
2005
|
8 |
6 |
p. A184-
1 p.
|
artikel
|
| 391 |
PHP40 THE IMPACT ON DECISION-MAKING OF CHANGING COST-EFFECTIVENESS OF HEALTH TECHNOLOGIES OVERTIME
|
Pang, F
|
|
2005
|
8 |
6 |
p. A193-
1 p.
|
artikel
|
| 392 |
PHP33 USE OF PHARMACOECONOMICS FOR CREATION OF THE STATE FORMULARY IN UKRAINE
|
Zaliska, O
|
|
2005
|
8 |
6 |
p. A191-
1 p.
|
artikel
|
| 393 |
PHP25 USING AN ITALIAN POPULATION DATABASE TO PROFILE PREVALENCE AND COSTS OF CHRONIC CONDITIONS
|
Yuen, EJ
|
|
2005
|
8 |
6 |
p. A188-
1 p.
|
artikel
|
| 394 |
PIH13 ASSESSING THE PSYCHOMETRIC PROPERTIES OF THE PSYCHOSOCIAL SUBSCALE OF THE MENOPAUSE-SPECIFIC QUALIPAUSE INVENTORY (QPI)WITH ITEM RESPONSE THEORY
|
Kuessner, D
|
|
2005
|
8 |
6 |
p. A55-
1 p.
|
artikel
|
| 395 |
PIH1 COST-EFFECTIVENESS MODEL OF PALIVIZUMAB IN THE NETHERLANDS
|
Nuijten, MJ
|
|
2005
|
8 |
6 |
p. A52-
1 p.
|
artikel
|
| 396 |
PIH10 COST-EFFECTIVENESS STUDY OF ASSISTED REPRODUCTIVE TECHNIQUES IN SPAIN
|
Prieto, L
|
|
2005
|
8 |
6 |
p. A54-
1 p.
|
artikel
|
| 397 |
PIH3 ESTIMATING A PREFERENCE-BASED MEASURE OF SOCIAL PARTICIPATION FROM THE HANDICAP SCALE FOR CHILDREN
|
Van Dommelen, P
|
|
2005
|
8 |
6 |
p. A52-
1 p.
|
artikel
|
| 398 |
PIH6 GRUMPY OLD MEN OR HAPPY YOUNG WOMEN: THE COMPARATIVE HEALTH STATUS OF SWEDEN ANDTHE UK
|
Bingefors, K
|
|
2005
|
8 |
6 |
p. A53-
1 p.
|
artikel
|
| 399 |
PIH8 LIFESTYLE, PHYSICAL ACTIVITY AND EQ-5D HEALTH STATUS IN A OVER 65 YEARS POPULATION
|
Cavrini, G
|
|
2005
|
8 |
6 |
p. A54-
1 p.
|
artikel
|
| 400 |
PIH12 QUALITY OF LIFE AND HEALTH BEHAVIORS OF VENEZUELAN PHARMACY STUDENTS
|
Bastardo, YM
|
|
2005
|
8 |
6 |
p. A55-
1 p.
|
artikel
|
| 401 |
PIH7 QUALITY OF LIFE OF ITALIAN GENERAL POPULATION AGED 40 TO 79 YEARS OLD
|
Mantovani, LG
|
|
2005
|
8 |
6 |
p. A53-A54
nvt p.
|
artikel
|
| 402 |
PIH5 SENIORS' PHARMACEUTICAL EXPENDITURES IN THE CZECH REPUBLIC
|
Davidova, J
|
|
2005
|
8 |
6 |
p. A53-
1 p.
|
artikel
|
| 403 |
PIH2 THE COST OF PREMATURITY: TWO NEONATAL INTENSIVE CARE UNITS (NICUS) FROM UNIVERSITY HOSPITALS OF ATHENS
|
Hatzikou, M
|
|
2005
|
8 |
6 |
p. A52-
1 p.
|
artikel
|
| 404 |
PIH4 WHAT METHODS OF ASSESSMENT AND MANAGEMENT OF ELDERLY PEOPLE ARE COST EFFECTIVE
|
Davies, LM
|
|
2005
|
8 |
6 |
p. A52-A53
nvt p.
|
artikel
|
| 405 |
PIH11 WORKAND HEALTH CONDITIONS DURING PREGNANCY IN WOMEN OF THE MEXICAN SOCIAL SECURITY INSTITUTE
|
Torres-Arreola, LDP
|
|
2005
|
8 |
6 |
p. A55-
1 p.
|
artikel
|
| 406 |
PIN9 A COST UTILITY ANALYSIS OF PEGINTERFERON ALFA-2A (40 KD) VERSUS PEGINTERFERON ALFA-2B (I2KD) FOR THE TREATMENT OF CHRONIC HEPATITIS C (CHC) IN THE UK
|
Latimer, NR
|
|
2005
|
8 |
6 |
p. A58-
1 p.
|
artikel
|
| 407 |
PIN24 ADDING A QUADRIVALENT (6, I I, 16 & 18 TYPES) HUMAN PAPILLOMAVIRUS VACCINE TO THE EXISTING UK CERVICAL SCREENING PROGRAMME IS POTENTIALLY COST-EFFECTIVE
|
Shalini, Kulasingam
|
|
2005
|
8 |
6 |
p. A63-
1 p.
|
artikel
|
| 408 |
PIN10 ANTIMICROBIAL TREATMENT OF ACUTE OTITIS MEDIA AND ITS PHARMACOECONOMIC ANALYSIS IN SLOVAKIA
|
Banasova, K
|
|
2005
|
8 |
6 |
p. A58-
1 p.
|
artikel
|
| 409 |
PIN11 A RETROSPECTIVE EVALUATION OF THE MANAGEMENT AND OUTCOME IN HOSPITALIZED PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA IN AN INNER-CITY HOSPITAL
|
Sakalis, E
|
|
2005
|
8 |
6 |
p. A59-
1 p.
|
artikel
|
| 410 |
PIN12 ASSESSEMENT OF THE EFFECT OF DROTRECOGIN ALPHA (ACTIVATED)TREATMENT OF SEVERE SEPSIS ON BLEEDING EVENTS WITH COUNT MODELS
|
Payet, S
|
|
2005
|
8 |
6 |
p. A59-
1 p.
|
artikel
|
| 411 |
PIN1 ASSESSING THE EXTERNAL VALIDITY OF DROTRECOGIN ALFA (ACTIVATED) CLINICAL TRIALS IN AN OBSERVATIONAL STUDY USING PROPENSITY SCORE MATCHING TO REDUCE RECRUITMENT BIAS
|
Riou França, L
|
|
2005
|
8 |
6 |
p. A55-A56
nvt p.
|
artikel
|
| 412 |
PIN4 COST-EFFECTIVENESS ANALYSIS OF ALTERNATIVE ANTIMICROBIAL TREATMENTS FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP)
|
Martin, M
|
|
2005
|
8 |
6 |
p. A56-A57
nvt p.
|
artikel
|
| 413 |
PIN3 COST-EFFECTIVENESS ANALYSIS OF COMBINED THERAPY WITH PEGINTERFERONALFA2A (40KD) (PEGASYS®) AND RIBAVIRIN (COPEGUS®) IN PATIENTS WITH CHRONIC C HEPATITIS (CHC)AND PERSISTENTLY NORMAL ALT LEVELS (PNALT)
|
Rubio Terres, C
|
|
2005
|
8 |
6 |
p. A56-
1 p.
|
artikel
|
| 414 |
PIN17 COST-EFFECTIVENESS ANALYSIS OF ENFUVIRTIDE ADDED TO AN OPTIMISED THERAPYVS. AN OPTIMISED THERAPY ALONE IN PATIENTS WITH H.I.V/AIDS
|
Serrano, D
|
|
2005
|
8 |
6 |
p. A60-A61
nvt p.
|
artikel
|
| 415 |
PIN23 COST-EFFECTIVENESS MODEL OF PALIVIZUMAB IN THE UK
|
Nuijten, MJ
|
|
2005
|
8 |
6 |
p. A62-
1 p.
|
artikel
|
| 416 |
PIN26 COST-EFFECTIVENESS OF PREVENTING OF RECURRENT UPPER RESPIRATORYTRACT INFECTIONS WITH NONSPECIFIC IMMUNOSTIMULATING BACTERIAL EXTRACT
|
Zaniolo, O
|
|
2005
|
8 |
6 |
p. A63-
1 p.
|
artikel
|
| 417 |
PIN27 COST-MINIMIZATION ANALYSIS OF VORICONAZOLE AND LIPOSOMALAMPHOTERICIN B FOR THE TREATMENT OF INVASIVE CANDIDA AND ASPERGILLOSIS INFECTIONS IN SPAIN
|
Aguado, JM
|
|
2005
|
8 |
6 |
p. A63-A64
nvt p.
|
artikel
|
| 418 |
PIN22 COST-UTILITY ANALYSIS OF A HYPOTHETICAL VACCINATION PROGRAM AMONG THE CURRENTLY TARGETED POPULATION IN THE NETHERLANDS IN CASE OF AN INFLUENZA PANDEMIC
|
Meijboom, M
|
|
2005
|
8 |
6 |
p. A62-
1 p.
|
artikel
|
| 419 |
PIN18 DETERMINANTS OF HEALTH CARE COSTS IN AMBULATORY PATIENTS LIVING WITH HIV/AIDS
|
Lopez-Bastida, J
|
|
2005
|
8 |
6 |
p. A61-
1 p.
|
artikel
|
| 420 |
PIN5 DYNAMIC MODELLING FOR ESTIMATING THE COST-EFFECTIVENESS OF A CHLAMYDIA TRACHOMATIS SCREENING PROGRAM
|
De Vries, R
|
|
2005
|
8 |
6 |
p. A57-
1 p.
|
artikel
|
| 421 |
PIN2 ECONOMIC IMPLICATION OF HEPATITIS B VIRAL (HBV) LOAD REDUCTION FOR ENTEVAVIR IN HEPATITIS B E ANTIGEN-POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS
|
Yuan, Y
|
|
2005
|
8 |
6 |
p. A56-
1 p.
|
artikel
|
| 422 |
PIN29 ESTIMATED ANNUAL NHS COSTS OF HUMAN PAPILLOMAVIRUS (HPV) RELATED DISEASES IN THE UK
|
Theodoratou, D
|
|
2005
|
8 |
6 |
p. A64-
1 p.
|
artikel
|
| 423 |
PIN14 IMPACT ON QUALITY OF LIFE OF HEALTH STATES INDUCED BY CHRONIC HEPATITIS B INFECTION: ESTIMATES FROM INFECTED AMERICANS
|
Levy, A
|
|
2005
|
8 |
6 |
p. A59-A60
nvt p.
|
artikel
|
| 424 |
PIN15 IMPACT ON QUALITY OF LIFE OF HEALTH STATES INDUCED BY CHRONIC HEPATITIS B INFECTION: ESTIMATES FROM UNINFECTEDAND INFECTED PERSONS IN THE UK
|
Ossa, DF
|
|
2005
|
8 |
6 |
p. A60-
1 p.
|
artikel
|
| 425 |
PIN30 INCIDENCE, PREVALENCE AND COSTS OF TREATING GENITAL WARTS IN THE PRE-HPVVACCINE ERA IN GERMANY, 2005
|
Gieseking, F
|
|
2005
|
8 |
6 |
p. A64-A65
nvt p.
|
artikel
|
| 426 |
PIN19 INCORPORATING COMPLIANCE RATES INTO THE COST OF TREATING HIV/AIDS IN TWO AFRICAN COUNTRIES
|
Becker, RV
|
|
2005
|
8 |
6 |
p. A61-
1 p.
|
artikel
|
| 427 |
PIN8 INCREASED MANAGEMENT NEEDS AND CARE COSTS FOR NURSING HOME RESIDENTS WITH CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA
|
O'Brien, JA
|
|
2005
|
8 |
6 |
p. A58-
1 p.
|
artikel
|
| 428 |
PIN6 INFECTIONS CAUSED BY RESISTANT CANDIDA SPECIES: COST-MINIMIZATION ANALISYS OF ANTIFUNGALTHERAPY IN BRAZIL
|
Guerra, AL
|
|
2005
|
8 |
6 |
p. A57-
1 p.
|
artikel
|
| 429 |
PIN16 MEDICAL COSTS ASSOCIATED WITH NON-ADHERENCE TO ANTIRETROVIRAL THERAPY IN HIV-POSITIVE PATIENTS
|
Merito, M
|
|
2005
|
8 |
6 |
p. A60-
1 p.
|
artikel
|
| 430 |
PIN25 PRELIMINARY COST-EFFECTIVENESS ANALYSIS OF A POTENTIAL PROPHYLACTIC STHAPHYLOCOCCUS AUREUS VACCINE (STAPHVAX) IN HEMODIALYSIS PATIENTS IN GERMANY
|
Staginnus, U
|
|
2005
|
8 |
6 |
p. A63-
1 p.
|
artikel
|
| 431 |
PIN28 RESOURCE USE AND COSTS ASSOCIATED WITH THE MANAGEMENT OF PAP III, PAP MID AND PAP IV IN THE PRE-HPVVACCINE ERA IN GERMANY
|
Petry, KU
|
|
2005
|
8 |
6 |
p. A64-
1 p.
|
artikel
|
| 432 |
PIN21 SELF ASSESSED HEALTH-RELATED QUALITY OF LIFE AMONG HIV PATIENT IN UK
|
Shafie, AA
|
|
2005
|
8 |
6 |
p. A62-
1 p.
|
artikel
|
| 433 |
PIN20 STUDYVALIDATION OF QUALITY OF LIFE QUESTIONNAIRE MINI-HIV
|
Badia, X
|
|
2005
|
8 |
6 |
p. A61-A62
nvt p.
|
artikel
|
| 434 |
PIN13 SYSTEMATIC REVIEW ON THE SHARE OF ANTIBIOTIC THERAPY COST IN RELATION OVERALL DIRECTTREAMENT COSTS OF MOST FREQUENT NOSOCOMIAL AND COMMUNITY ACQUIRED INFECTIONS IN ADULTS
|
Dietrich, ES
|
|
2005
|
8 |
6 |
p. A59-
1 p.
|
artikel
|
| 435 |
PMC6 AFFORDABLE BOOTSTRAPS? EVALUATING FREEWARE OPTIONS FORANALYZING INCREMENTAL COST EFFECTIVENESS DATA
|
McGhan, W
|
|
2005
|
8 |
6 |
p. A66-A67
nvt p.
|
artikel
|
| 436 |
PMC10 A METHODOLOGICAL APPROACH TO ASSESS COST DATA IN THE CONTEXT OF A DECISION ANALYTIC MODEL TO EVALUATE THE COST-EFFECTIVENESS OF THE TREATMENT OF THE METABOLIC SYNDROME
|
Aidelsburger, P
|
|
2005
|
8 |
6 |
p. A68-
1 p.
|
artikel
|
| 437 |
PMC25 ANALYSIS OF QUALITY OF LIFE DATA FROM DIFFERENT UTILITY INSTRUMENTS—AN EXAMPLE USING IMPUTATION
|
Fitzgerald, P
|
|
2005
|
8 |
6 |
p. A72-
1 p.
|
artikel
|
| 438 |
PMC5 A STANDARD SET OF UNIT COSTS FOR GERMANY
|
Schweikert, B
|
|
2005
|
8 |
6 |
p. A66-
1 p.
|
artikel
|
| 439 |
PMC11 DEVELOPMENT AND VALIDATION OF A CLAIMS-BASED RISK ASSESSMENT MODEL TO PREDICT PHARMACY EXPENDITURES IN A U.S. MEDICAID POPULATION
|
Cantrell, CR
|
|
2005
|
8 |
6 |
p. A68-
1 p.
|
artikel
|
| 440 |
PMC26 DEVELOPMENT AND VALIDATION OF A DUTCH VERSION OF THE LONDON HANDICAP SCALE
|
Groothuis-Oudshoorn, CG
|
|
2005
|
8 |
6 |
p. A72-
1 p.
|
artikel
|
| 441 |
PMC1 DEVELOPMENT OF A NEW QUESTIONNAIRE TO MEASURE SATISFACTION WITH TREATMENT WITH MEDICINES (SATMED-Q)
|
Ruíz, M
|
|
2005
|
8 |
6 |
p. A65-
1 p.
|
artikel
|
| 442 |
PMC15 DIRECT AND INDIRECT COSTS AND EFFECTS IN COST-EFFECTIVENESS ANALYSIS OF PREVENTION: A DYNAMIC MODELLING ANALYSIS
|
Van Baal, P
|
|
2005
|
8 |
6 |
p. A69-
1 p.
|
artikel
|
| 443 |
PMC23 ECONOMIC EVALUATION OF MEDICAL DEVICES IN FRANCE: A CHALLENGE FOR HEALTH ECONOMISTS
|
Späth, HM
|
|
2005
|
8 |
6 |
p. A71-A72
nvt p.
|
artikel
|
| 444 |
PMC13 ECONOMIC IMPACT OF HOSPITAL MALNUTRITION
|
Ethgen, O
|
|
2005
|
8 |
6 |
p. A68-A69
nvt p.
|
artikel
|
| 445 |
PMC8 ESTIMATING COSTS AT THE FAMILY LEVEL
|
Boudreau, DM
|
|
2005
|
8 |
6 |
p. A67-
1 p.
|
artikel
|
| 446 |
PMC21 EVALUATING THE DIFFERENCE BETWEEN AVERAGE WHOLESALE PRICE AND WHOLESALE ACQUISITION COST FOR PHARMACEUTICALS IN THE UNITED STATES
|
Malone, DC
|
|
2005
|
8 |
6 |
p. A71-
1 p.
|
artikel
|
| 447 |
PMC19 HOW LONG AGO …?: ASSESSING PATIENT ADHERENCE TO SPECIFIED QUESTIONNAIRE RECALL PERIODS
|
Coyne, KS
|
|
2005
|
8 |
6 |
p. A70-
1 p.
|
artikel
|
| 448 |
PMC20 INDIRECT COMPARISON (OR COMMON-COMPARATOR) METHODS FOR META-ANALYSIS OF SUMMARY DATA
|
Fitzgerald, P
|
|
2005
|
8 |
6 |
p. A70-A71
nvt p.
|
artikel
|
| 449 |
PMC3 INTERNATIONAL VARIATION IN CLINICAL INJURY INCIDENCE: REAL OR ARTIFICIAL DIFFERENCES?
|
Polinder, S
|
|
2005
|
8 |
6 |
p. A65-A66
nvt p.
|
artikel
|
| 450 |
PMC28 ITEM RESPONSE BIAS IN INSTRUMENTAL ACTIVITY DAILY LIVING SCALE IN ASIAN OLDER ADULTS
|
Niti, M
|
|
2005
|
8 |
6 |
p. A73-
1 p.
|
artikel
|
| 451 |
PMC12 PHARMACOECONOMIC ASPECTS OF THE ADMINISTRATIVE REFORMS IN PHARMACEUTICAL SECTORS OF REPUBLIC HEALTH DEPARTMENTS IN MONTENEGRO
|
Tomic, Z
|
|
2005
|
8 |
6 |
p. A68-
1 p.
|
artikel
|
| 452 |
PMC14 POPULATION KNOWLEDGE: AN APPROACH TO CLASSIFY A GENERAL POPULATION ACCORDING TO LIFESTYLE, HEALTH BEHAVIOUR AND ATTITUDE
|
Auray, JP
|
|
2005
|
8 |
6 |
p. A69-
1 p.
|
artikel
|
| 453 |
PMC18 PSYCHOMETRIC PROPERTIES OF A TOUCH SCREEN COMPUTER-BASED VERSION OF THE SF-36
|
Ramachandran, S
|
|
2005
|
8 |
6 |
p. A70-
1 p.
|
artikel
|
| 454 |
PMC17 RASCH ANALYSIS OF THE FATIGUE IMPACT SCALE
|
Meads, DM
|
|
2005
|
8 |
6 |
p. A70-
1 p.
|
artikel
|
| 455 |
PMC22 RELATIVE WEIGHTS ASSIGNED TO PHARMACY PROCEDURES: OPPS METHODS DESIGN AND CONCEPTS
|
Baker, JJ
|
|
2005
|
8 |
6 |
p. A71-
1 p.
|
artikel
|
| 456 |
PMC2 REVIEW OF THE ACTIVITIES OF THE ISOQOL TRANSLATION AND CULTURAL ADAPTATION (TCA) SPECIAL INTEREST GROUP (SIG)
|
Acquadro, C
|
|
2005
|
8 |
6 |
p. A65-
1 p.
|
artikel
|
| 457 |
PMC4 THE CONTRIBUTION OF PREVENTION AND MEDICAL CARE TO POPULATION HEALTH
|
Meerding, WJ
|
|
2005
|
8 |
6 |
p. A66-
1 p.
|
artikel
|
| 458 |
PMC27 THE DEVELOPMENT OF A TREATMENT SATISFACTION QUESTIONNAIRE FOR IRON OVERLOAD (IO) PATIENTS ON CHELATION THERAPY (CT)
|
Abetz, L
|
|
2005
|
8 |
6 |
p. A72-A73
nvt p.
|
artikel
|
| 459 |
PMC9 THE OPTIMAL COST-EFFECTIVENESS RATIO THRESHOLD IN CASE OF CO-MORBIDITIES
|
Jakubczyk, MK
|
|
2005
|
8 |
6 |
p. A67-
1 p.
|
artikel
|
| 460 |
PMC16 THE US NATIONAL VIOLENT DEATH REPORTING SYSTEM (NVDRS) AS A MODEL OF A NATIONAL PUBLIC HEALTH REGISTRY
|
Crosby, A
|
|
2005
|
8 |
6 |
p. A69-
1 p.
|
artikel
|
| 461 |
PMC24 USE OF PHARMACOECONOMICS/HEALTH ECONOMIC TOOL (PE/HE) IN LOCAL HEALTH CARE DECISION MAKING (DM)
|
Soto, H
|
|
2005
|
8 |
6 |
p. A72-
1 p.
|
artikel
|
| 462 |
PMD3 A COST EFFECTIVENESS MODEL FOR THE EVALUATION OF TOTAL HIP ARTHROPLASTY (THA) AND TOTAL KNEE ARTHROPLASTY (TKA) IN SWEDEN
|
Borgstrom, F
|
|
2005
|
8 |
6 |
p. A74-
1 p.
|
artikel
|
| 463 |
PMD1 COST ANALYSIS OF MANAGEMENT STRATEGIES FOR CLOSED AND OPEN GRADE ITIBIAL SHAFT FRACTURES
|
Busse, JW
|
|
2005
|
8 |
6 |
p. A73-
1 p.
|
artikel
|
| 464 |
PMD2 COST-EFFECTIVENESS ANALYSIS OF ACLASTA IN PAGET'S DISEASE OF BONE IN BELGIUM
|
Lecomte, P
|
|
2005
|
8 |
6 |
p. A73-A74
nvt p.
|
artikel
|
| 465 |
PMH38 A DISCRETE EVENT SIMULATION (DES) MODEL TO DESCRIBE SCHIZOPHRENIA
|
Heeg, B
|
|
2005
|
8 |
6 |
p. A207-
1 p.
|
artikel
|
| 466 |
PMH10 A MODELLED ECONOMIC EVALUATION COMPARING ATOMOXETINEWITH CURRENT THERAPIES FOR THE TREATMENT OF CHILDREN WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN THE NETHERLANDS
|
Laing, A
|
|
2005
|
8 |
6 |
p. A198-
1 p.
|
artikel
|
| 467 |
PMH5 A MODELLED ECONOMIC EVALUATION OF ATOMOXETINE (STRATTERA) FOR THE TREATMENT OF THREE PATIENT GROUPS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER
|
Tilden, D
|
|
2005
|
8 |
6 |
p. A197-
1 p.
|
artikel
|
| 468 |
PMH35 ARE INDIRECT COSTS MEASUREMENTS RELEVANT INA SCHIZOPHRENIC PATIENTS POPULATION? AN OVERVIEW OF A LONGITUDINAL STUDY IN FRANCE
|
Primus, C
|
|
2005
|
8 |
6 |
p. A206-
1 p.
|
artikel
|
| 469 |
PMH39 ARE QALYS SUITABLE FOR SCHIZOPHRENIA TRIALS?
|
Mangalore, R
|
|
2005
|
8 |
6 |
p. A207-A208
nvt p.
|
artikel
|
| 470 |
PMH13 ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS: SF-6D UTILITIES FROM SF-36 SCORES IN A RANDOMISED TRIAL OF ATOMOXETINE
|
Laing, A
|
|
2005
|
8 |
6 |
p. A199-
1 p.
|
artikel
|
| 471 |
PMH4 ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS: MENTAL HEALTH AND PHYSICAL CO-MORBIDITY IN NORDBADEN/GERMANY
|
Schlander, M
|
|
2005
|
8 |
6 |
p. A196-A197
nvt p.
|
artikel
|
| 472 |
PMH3 ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GROWN-UPS: ADMINISTRATIVE DATA ON CO-EXISTING CONDITIONS
|
Schlander, M
|
|
2005
|
8 |
6 |
p. A196-
1 p.
|
artikel
|
| 473 |
PMH36 CASE STUDY OF PATTERN MIXTURE APPROACH FOR COMBINING COMPLETION RATESAND EFFICACY FOR CLINCALLY MEANINGFULL OUTCOMES IN SCHIZOPHRENIA DRUG TRIALS
|
Rabinowitz, J
|
|
2005
|
8 |
6 |
p. A206-A207
nvt p.
|
artikel
|
| 474 |
PMH19 CHANGES IN NOVEL ANTIPSYCHOTIC USE IN ELDERLY INPATIENTS
|
Coley, KC
|
|
2005
|
8 |
6 |
p. A201-
1 p.
|
artikel
|
| 475 |
PMH43 CLINICAL COMPARISON OF SSRIS AND SNRIS IN MAJOR DEPRESSIVE DISORDER: A META-ANALYSIS
|
Machado, M
|
|
2005
|
8 |
6 |
p. A209-
1 p.
|
artikel
|
| 476 |
PMH42 COMPARISON OF SSRI AND SNRI TREATMENT FOR DEPRESSION IN PRIMARY CARE: A NATURALISTIC STUDY
|
Machado, M
|
|
2005
|
8 |
6 |
p. A208-A209
nvt p.
|
artikel
|
| 477 |
PMH46 COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN GERMANY
|
Kulp, W
|
|
2005
|
8 |
6 |
p. A210-
1 p.
|
artikel
|
| 478 |
PMH28 COST-EFFECTIVENESS ANALYSIS OF ZIPRASIDONE VERSUS NO TREATMENT FOR SCHIZOPHRENIA RELAPSE PREVENTION
|
Azanza, JR
|
|
2005
|
8 |
6 |
p. A204-
1 p.
|
artikel
|
| 479 |
PMH45 COST EFFECTIVENESS OF DULOXETINE COMPARED WITH VENLAFAXINE-XR IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
|
Van Baardewijk, M
|
|
2005
|
8 |
6 |
p. A209-A210
nvt p.
|
artikel
|
| 480 |
PMH1 COST EFFECTIVENESS OF ESCITALOPRAM IN THE TREATMENT OF GENERALIZED ANXIETY DISORDER (GAD)
|
Walker, JH
|
|
2005
|
8 |
6 |
p. A195-A196
nvt p.
|
artikel
|
| 481 |
PMH47 COST OF AFFECTIVE DISORDERS IN EUROPE
|
Andlin-Sobocki, P
|
|
2005
|
8 |
6 |
p. A210-
1 p.
|
artikel
|
| 482 |
PMH50 DEVELOPMENT OF A COMPREHENSIVE EMOTIONAL, SOMATIC AND PAINFUL PHYSICAL SYMPTOMS CHECKLIST IN DEPRESSION IN FIVE EUROPEAN COUNTRIES
|
Arnould, B
|
|
2005
|
8 |
6 |
p. A211-
1 p.
|
artikel
|
| 483 |
PMH29 DRUG UTILIZATION PATTERNS AND COSTS AND TOTAL COSTS OF SCHIZOPHRENIA TREATMENT IN AN INSURED POPULATION
|
Wilson, L
|
|
2005
|
8 |
6 |
p. A204-A205
nvt p.
|
artikel
|
| 484 |
PMH44 DULOXETINE AND VENLAFAXINE-XR IN THE TREATMENT OF MDD: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS
|
Vis, PM
|
|
2005
|
8 |
6 |
p. A209-
1 p.
|
artikel
|
| 485 |
PMH14 DUTCH ADAPTION OF THE COST-EFFECTIVENESS OF QUETIAPINE IN COMBINATION THERAPY IN THE MANAGEMENT OF ACUTE MANIA IN BIPOLAR I DISORDER
|
Klok, RM
|
|
2005
|
8 |
6 |
p. A199-A200
nvt p.
|
artikel
|
| 486 |
PMH25 EFFECTIVENESS AND TOLERABILITY OUTCOMES OF RISPERIDONE LONG-ACTING INJECTION COMPARED TO CONVENTIONAL DEPOT ANTIPSYCHOTICS IN A LARGE CANADIAN PSYCHIATRIC HOSPITAL
|
Snaterse, MH
|
|
2005
|
8 |
6 |
p. A203-
1 p.
|
artikel
|
| 487 |
PMH16 EFFECT OF BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD) ON COST OF CARE IN THE CANADIAN OUTCOMES STUDY IN DEMENTIA
|
Herrmann, N
|
|
2005
|
8 |
6 |
p. A200-
1 p.
|
artikel
|
| 488 |
PMH30 FACTORS AFFECTING COST OF SCHIZOPHRENIA TREATMENT WITH ATYPICAL ANTIPSYCHOTIC AGENTS
|
Law, W
|
|
2005
|
8 |
6 |
p. A205-
1 p.
|
artikel
|
| 489 |
PMH33 FACTORS INFLUENCING ZIPRASIDONE PRESCRIBED DOSES AMONG MEDICAID PATIENTS WITH SCHIZOPHRENIA
|
Mullins, CD
|
|
2005
|
8 |
6 |
p. A206-
1 p.
|
artikel
|
| 490 |
PMH15 GALANTAMINE REDUCES CAREGIVER BURDEN: RESULTS FROM A NATURALISTIC STUDY
|
Nguyen, E
|
|
2005
|
8 |
6 |
p. A200-
1 p.
|
artikel
|
| 491 |
PMH24 GEO OBSERVATIONAL STUDY: 24 MONTHS CHARACTERISTICS OF SOCIOECONOMIC AND CLINICAL STATUS IN SCHIZOPHRENIA PATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY
|
Eichmann, F
|
|
2005
|
8 |
6 |
p. A203-
1 p.
|
artikel
|
| 492 |
PMH17 HEALTH RELATED QUALITY OF LIFE (HRQOL) AND BURDEN OF FAMILY CAREGIVERS OF DIALYSIS PATIENTS
|
Alvarez-Ude, F
|
|
2005
|
8 |
6 |
p. A200-A201
nvt p.
|
artikel
|
| 493 |
PMH22 HOSPITALIZATION AND MEDICATION USE IN SCHIZOPHRENIA PATIENTS RECEIVING RISPERIDONE LONG-ACTING INJECTABLE OR ORAL ATYPICAL ANTIPSYCHOTIC MEDICATION
|
Chue, P
|
|
2005
|
8 |
6 |
p. A202-
1 p.
|
artikel
|
| 494 |
PMH23 IMPACT OF RISPERIDONE LONG-ACTING INJECTABLE ON HOSPITALIZATION AND MEDICATION USE IN PATIENTS WITH SCHIZOPHRENIA
|
Beauclair, L
|
|
2005
|
8 |
6 |
p. A202-A203
nvt p.
|
artikel
|
| 495 |
PMH40 LONG-TERM MAINTENANCE OF INITIAL HEALTH RELATED QUALITY OF LIFE (HRQL) IMPROVEMENTS GAINED THROUGH ANTIPSYCHOTIC TREATMENT: 24-MONTH RESULTS FROM THE SCHIZOPHRENIA HEALTH OUTCOMES (SOHO) STUDY
|
Alonso, J
|
|
2005
|
8 |
6 |
p. A208-
1 p.
|
artikel
|
| 496 |
PMH34 LONG-TERM TREATMENT OF SCHIZOPHRENIA FOR RELAPSE PREVENTION (LASER): 6-MONTH OUTCOMES IN PATIENTS STARTED ON RISPERIDONE LONG-ACTING INJECTABLE IN GERMANY—DATA FROM THE E-STAR DATABASE
|
Naber, D
|
|
2005
|
8 |
6 |
p. A206-
1 p.
|
artikel
|
| 497 |
PMH27 12-MONTH COST-EFFECTIVENESS ANALYSIS OF ORAL ANTIPSYCHOTIC TREATMENTS IN PATIENTS WITH SCHIZOPHRENIA IN THE PAN-EUROPEAN SOHO (SCHIZOPHRENIA OUTPATIENT HEALTH OUTCOMES) STUDY
|
Knapp, M
|
|
2005
|
8 |
6 |
p. A204-
1 p.
|
artikel
|
| 498 |
PMH31 12 MONTH COST-UTILITY ANALYSIS OF ORAL ANTIPSYCHOTIC TREATMENTS IN PATIENTS WITH SCHIZOPHRENIA IN THE PAN-EUROPEAN SOHO (SCHIZOPHRENIA OUTPATIENT HEALTH OUTCOMES) STUDY
|
Knapp, M
|
|
2005
|
8 |
6 |
p. A205-
1 p.
|
artikel
|
| 499 |
PMH32 NEUROLEPTIC TREATMENT OF SCHIZOPHRENIA IN AMBULATORY CARE IN GERMANY
|
Gericke, CA
|
|
2005
|
8 |
6 |
p. A205-A206
nvt p.
|
artikel
|
| 500 |
PMH48 QUALITY OF LIFE IN MAJOR DEPRESSION: RESULTS OF THE MC3 TRIAL
|
Mantovani, LG
|
|
2005
|
8 |
6 |
p. A210-
1 p.
|
artikel
|
| 501 |
PMH49 QUALITY OF LIFE IN MAJOR DEPRESSION: RESULTS OF THE MC4 TRIAL
|
Mantovani, LG
|
|
2005
|
8 |
6 |
p. A211-
1 p.
|
artikel
|
| 502 |
PMH20 RELATION BETWEEN SYMPTOMS IN SCHIZOPHRENIA AND RISK OF HARM TO SELF AND OTHERS
|
Heeg, B
|
|
2005
|
8 |
6 |
p. A201-A202
nvt p.
|
artikel
|
| 503 |
PMH41 REMISSION CRITERIA FOR DEPRESSION WHEN USING SHORT VERSIONS OF THE HAMILTON DEPRESSION RATING SCALE (HDRS)
|
Ballesteros, J
|
|
2005
|
8 |
6 |
p. A208-
1 p.
|
artikel
|
| 504 |
PMH9 STIMULANT MEDICATION TREATMENT OF ATTENTION-DEFICIT/ HYPERACTIVITY DISORDER IS ASSOCIATED WITH DECREASED EMERGENCY DEPARTMENT COSTS AND UTILIZATION: POPULATION-BASED STUDY
|
Katusic, SK
|
|
2005
|
8 |
6 |
p. A198-
1 p.
|
artikel
|
| 505 |
PMH7 THE BAD STUDY: SOCIAL AND ECONOMIC BURDEN OF ATTENTION DEFICIT AND HYPERACTIVITY DISORDER (ADHD) IN ITALY
|
Lopatriello, S
|
|
2005
|
8 |
6 |
p. A197-A198
nvt p.
|
artikel
|
| 506 |
PMH37 THE ECONOMIC BURDEN OF SCHIZOPHRENIA IN THE UNITED STATES IN 2002
|
Wu, EQ
|
|
2005
|
8 |
6 |
p. A207-
1 p.
|
artikel
|
| 507 |
PMH8 THE HEATLH-RELATED QUALITY OF LIFE OF CHILDREN SUFFERING FROM ADHD AND THE COSTS TO SOCIETY
|
Hakkaart, L
|
|
2005
|
8 |
6 |
p. A198-
1 p.
|
artikel
|
| 508 |
PMH12 THE NORDBADEN PROJECT FOR HEALTH CARE UTILIZATION RESEARCH IN GERMANY
|
Schlander, M
|
|
2005
|
8 |
6 |
p. A199-
1 p.
|
artikel
|
| 509 |
PMH18 TRANSLATION, GREEK ADAPTATION AND STANDARDIZATION OF THE VERONA SERVICE SATISFACTION SCALE (VSSS-54): AN INSTRUMENT PATIENTS' SATISFACTION WITH MENTAL HEALTH SERVICES
|
Bletsa, D
|
|
2005
|
8 |
6 |
p. A201-
1 p.
|
artikel
|
| 510 |
PMH6 TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD): ARE U.S. COST-EFFECTIVENESS FINDINGS BASED UPON THE MTA STUDY RELEVANTTO MENTAL HEALTH CARE POLICY MAKERS IN GERMANY?
|
Schiander, M
|
|
2005
|
8 |
6 |
p. A197-
1 p.
|
artikel
|
| 511 |
PMH21 TREATMENT PERSISTENCE: A COMPARISON AMONG PATIENTS WITH SCHIZOPHRENIA WHO WERE INITIATED ON ATYPICAL ANTIPSYCHOTIC AGENTS
|
Ren, XS
|
|
2005
|
8 |
6 |
p. A202-
1 p.
|
artikel
|
| 512 |
PMH26 USING CLAIMS DATA TO ESTIMATE THE ANNUAL PREVALENCE OF SCHIZOPHRENIA IN THE UNITED STATES, 2002
|
Wu, EO
|
|
2005
|
8 |
6 |
p. A203-A204
nvt p.
|
artikel
|
| 513 |
PNL17 A COST-UTILITY MODEL COMPARING AZILECT® (RASAGILINE) WITH STANDARD CARE AND ENTACAPONE IN THE TREATMENT OF PARKINSONIAN PATIENTS WITH MOTOR FLUCTUATIONS UNDER LEVODOPA IN FINLAND
|
Hudry, J
|
|
2005
|
8 |
6 |
p. A133-
1 p.
|
artikel
|
| 514 |
PNL5 A PROSPECTIVE STUDY ON THE IMPACT OF A CHILD'S EPILEPSY ON THEIR QUALITY OF LIFE AND THEIR FAMILY
|
Deiratany, S
|
|
2005
|
8 |
6 |
p. A129-A130
nvt p.
|
artikel
|
| 515 |
PNL12 A RETROSPECTIVE STUDY OF DRUG TREATMENT PATTERNS AMONGST UK PRIMARY CARE PATIENTS WITH RESTLESS LEGS SYNDROME (RLS) BETWEEN I ST APRIL 2004 AND 3 I ST MARCH 2005
|
Das Gupta, R
|
|
2005
|
8 |
6 |
p. A131-A132
nvt p.
|
artikel
|
| 516 |
PNL11 A REVIEW OF THE ECONOMIC EVIDENCE FOR BOTULINUM TOXINS IN SPASTICITY ASSOCIATED WITH STROKE AND CEREBRAL PALSY
|
Richard, LJ
|
|
2005
|
8 |
6 |
p. A131-
1 p.
|
artikel
|
| 517 |
PNL2 COST-EFFECTIVENESS OF ADDING MEMANTINE TREATMENT TO PATIENTS RECEIVING STABILISED DOSES OF DONEPEZIL IN THE UK
|
Guilhaume, C
|
|
2005
|
8 |
6 |
p. A128-A129
nvt p.
|
artikel
|
| 518 |
PNL9 COST-EFFECTIVENESS OF ALTERNATIVE POLIO IMMUNIZATION POLICIES IN SOUTH AFRICA
|
Griffiths, UK
|
|
2005
|
8 |
6 |
p. A131-
1 p.
|
artikel
|
| 519 |
PNL8 COST-EFFECTIVENESS OF BETAHISTINE VS CINNARIZINE FOR VERTIGO
|
Avksentieva, M
|
|
2005
|
8 |
6 |
p. A130-A131
nvt p.
|
artikel
|
| 520 |
PNL18 COST-EFFECTIVENESS OF CONTINUOUS DUODENAL DELIVERY OF LEVODOPA (DUODOPA®) IN PATIENTS WITH SEVERE PARKINSON'S DISEASE
|
Kristiansen, IS
|
|
2005
|
8 |
6 |
p. A133-A134
nvt p.
|
artikel
|
| 521 |
PNL20 DISEASE SEVERITY AND HEALTH CARE COSTS OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN PORTUGAL
|
Mateus, C
|
|
2005
|
8 |
6 |
p. A134-
1 p.
|
artikel
|
| 522 |
PNL1 EXTERNAL VALIDATION OF THE PROBABILISTIC MARKOV MODEL ESTIMATING THE COST EFFECTIVENESS OF MEMANTINE VERSUS STANDARD CARE IN ALZHEIMER DISEASE FROM A UK PERSPECTIVE
|
Guilhaume, C
|
|
2005
|
8 |
6 |
p. A128-
1 p.
|
artikel
|
| 523 |
PNL13 IMPLANTABLE SYSTEMS PERFORMANCE REGISTRY (ISPR) A MEDICAL DEVICE AND PATIENT REGISTRY
|
Stoker, V
|
|
2005
|
8 |
6 |
p. A132-
1 p.
|
artikel
|
| 524 |
PNL7 IS THE TREATMENT OF ACUTE MIGRAINE WITH TRIPTANS EFFICIENT FROM A SOCIETAL PERSPECTIVE?
|
Gracia-Naya, M
|
|
2005
|
8 |
6 |
p. A130-
1 p.
|
artikel
|
| 525 |
PNL19 META-ANALYSIS OF CASE SERIES TO PROVIDE INPUTS FOR A DISCRETE EVENT SIMULATION OF DEEP BRAIN STIMULATION FOR THE TREATMENT OF PARKINSON'S DISEASE
|
Caro, JJ
|
|
2005
|
8 |
6 |
p. A134-
1 p.
|
artikel
|
| 526 |
PNL15 PREFERENCE FOR RECONSTRUCTIVE INTERVENTIONS OF THE UPPER EXTREMITIES IN TETRAPLEGIA: THE IMPACT OF TREATMENT CHARACTERISTICS
|
IJzerman, MJ
|
|
2005
|
8 |
6 |
p. A132-A133
nvt p.
|
artikel
|
| 527 |
PNL3 RETROSPECTIVE COMPARATIVE ANALYSIS OF ANTIDEMENTIA MEDICATION PERSISTENCE PATTERNS AT 3 YEARS IN SPANISH ALZHEIMER DISEASE PATIENTS TREATED WITH DONEPEZIL, RIVASTIGMINE, GALANTAMINE AND MEMANTINE
|
Sicras, A
|
|
2005
|
8 |
6 |
p. A129-
1 p.
|
artikel
|
| 528 |
PNL21 THE COST OF MULTIPLE SCLEROSIS (MS) IN EUROPE
|
Berg, J
|
|
2005
|
8 |
6 |
p. A134-
1 p.
|
artikel
|
| 529 |
PNL10 THE COSTS OF INFORMAL CARE IN NEUROLOGICAL DISORDERS IN SPAIN
|
Oliva, J
|
|
2005
|
8 |
6 |
p. A131-
1 p.
|
artikel
|
| 530 |
PNL16 THE ECONOMIC BURDEN OF PARKINSONISM IN ITALY
|
Colombo, GL
|
|
2005
|
8 |
6 |
p. A133-
1 p.
|
artikel
|
| 531 |
PNL6 THE EPIDEMIOLOGY AND MANAGEMENT OF MIGRAINE IN THE UK
|
Ouilici, S
|
|
2005
|
8 |
6 |
p. A130-
1 p.
|
artikel
|
| 532 |
PNL4 THE SOCIAL AND ECONOMIC BURDEN OF PAEDIATRIC EPILEPSY IN IRELAND: A PROSPECTIVE STUDY
|
McGinn, M
|
|
2005
|
8 |
6 |
p. A129-
1 p.
|
artikel
|
| 533 |
PNL22 THE SYMPTOMATIC, FUNCTIONAL AND QUALITY OF LIFE IMPACT OF MULTIPLE SCLEROSIS. REPORT ON A QUALITATIVE INVESTIGATION OF THE PATIENTS' PERSPECTIVE
|
Doward, LC
|
|
2005
|
8 |
6 |
p. A135-
1 p.
|
artikel
|
| 534 |
PNL14 USE OF THE SELF-ADMINISTERED NEUROPATHY TOTAL SYMPTOM SCORE—6 (NTSS-6 SA) IN AN INTERNATIONAL STUDY
|
Mear, I
|
|
2005
|
8 |
6 |
p. A132-
1 p.
|
artikel
|
| 535 |
POB5 AN ANALYSIS OF THE IMPACT OF BARIATRIC SURGERY ON HEALTH OUTCOMES AND PHARMACOLOGICAL TREATMENT AMONG OBESE PATIENTS
|
Ledoux, S
|
|
2005
|
8 |
6 |
p. A75-
1 p.
|
artikel
|
| 536 |
POB4 COST-OF-ILLNESS ANALYSIS OF JUVENILE OBESITY AND OF CO-MORBIDITYTYPE 2 DIABETES MELLITUS (T2DM) IN GERMANY
|
Wolfenstetter, SB
|
|
2005
|
8 |
6 |
p. A75-
1 p.
|
artikel
|
| 537 |
POB7 COSTS AND HEALTH CARE CONSUMPTIONS IN THE ABDOMINALLY OBESE POPULATION
|
Radigue, C
|
|
2005
|
8 |
6 |
p. A76-
1 p.
|
artikel
|
| 538 |
POB9 EVALUATION OF THE ASSOCIATION BETWEEN BODY MASS INDEX, WAIST CIRCUMFERENCE AND HEALTH-RELATED UTILITY (EQ5D)
|
Woehl, A
|
|
2005
|
8 |
6 |
p. A76-A77
nvt p.
|
artikel
|
| 539 |
POB6 MODIFICATION OF LIFE STYLE AND OBESITY MANAGEMENT IN PRIMARY CARE
|
Luque, MJ
|
|
2005
|
8 |
6 |
p. A75-A76
nvt p.
|
artikel
|
| 540 |
POB2 PREVALENCE TRENDS IN OVERWEIGHT AND OBESITY AND WEIGHT CONTROL PRACTICES AMONG ADULTS IN THE US
|
Suh, DC
|
|
2005
|
8 |
6 |
p. A74-
1 p.
|
artikel
|
| 541 |
POB3 THE ECONOMIC BURDEN OF ADULT OBESITY, WITH SPECIAL REFERENCE TO DRUG CONSUMPTION: ESTIMATES FROM THE KORA STUDY REGION
|
John, J
|
|
2005
|
8 |
6 |
p. A75-
1 p.
|
artikel
|
| 542 |
POB1 TRENDS OF DIABETES MELLITUS PREVALENCE AND TREATMENT PATTERNS ASSOCIATED WITH OBESITY IN THE US
|
Barone, JA
|
|
2005
|
8 |
6 |
p. A74-
1 p.
|
artikel
|
| 543 |
POB10 VALIDATION OF A PATIENT-REPORTED OUTCOMES QUESTIONNAIRE FOR ASSESSING POSITIVE WELL-BEING ASSOCIATED WITH BEHAVIORAL CHANGES
|
Mesrobian, X
|
|
2005
|
8 |
6 |
p. A77-
1 p.
|
artikel
|
| 544 |
POB8 VALIDITY OF DATA COLLECTED FROM AN INTERNET-BASED COHORT STUDY
|
Coste, F
|
|
2005
|
8 |
6 |
p. A76-
1 p.
|
artikel
|
| 545 |
PO3 CLASSIFYING AND PREDICTING ANTIPSYCHOTIC ADHERENCE AMONG SCHIZOPHRENIA OUTPATIENTS IN EUROPE: A LATENT CLASS ANALYSIS
|
Croudace, TJ
|
|
2005
|
8 |
6 |
p. A8-
1 p.
|
artikel
|
| 546 |
PO2 DEVELOPMENT AND VALIDATION OF A QUESTIONNAIRE TO EVALUATE SEVERITY OF SYMPTOMS IN PATIENTS WITH IBS-C AND IBS-A
|
Pare, P
|
|
2005
|
8 |
6 |
p. A8-
1 p.
|
artikel
|
| 547 |
PO4 ESTIMATING QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS ORTOXICITY USING A MULTIVARIATE FAILURE TIME REGRESSION MODEL
|
Wang, J
|
|
2005
|
8 |
6 |
p. A8-A9
nvt p.
|
artikel
|
| 548 |
POS11 AN INTERNATIONAL COMPARISON OF THE IMPACT OF DOSING FREQUENCY ON COMPLIANCE AND PERSISTENCE WITH BISPHOSPHONATE THERAPY, AMONG POST-MENOPAUSAL WOMEN IN THE US, UK AND GERMANY
|
Cramer, JA
|
|
2005
|
8 |
6 |
p. A138-
1 p.
|
artikel
|
| 549 |
POS2 CLINICAL EFFICACY AND SAFETY OF BALLOON KYPHOPLASTY FOR THE TREATMENT OF VERTEBRAL COMPRESSION FRACTURES: A SYSTEMATIC REVIEW OF THE LITERATURE
|
Taylor, RS
|
|
2005
|
8 |
6 |
p. A135-A136
nvt p.
|
artikel
|
| 550 |
POS8 CONTENT VALIDATION OF OSTEOPOROSIS TREATMENT PREFERENCE QUESTIONNAIRE
|
Flood, E
|
|
2005
|
8 |
6 |
p. A137-
1 p.
|
artikel
|
| 551 |
POS4 COST-EFFECTIVENESS OF PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS WITH ALENDRONATE ORALFACALCIDOL.THE STOP-STUDY: A RANDOMIZED PLACEBO-CONTROLLED TRIAL
|
De Nijs, R
|
|
2005
|
8 |
6 |
p. A136-
1 p.
|
artikel
|
| 552 |
POS14 ELICITING AND QUANTIFYING PATIENT PREFERENCES FOR DOSING FREQUENCY
|
Walker, M
|
|
2005
|
8 |
6 |
p. A139-
1 p.
|
artikel
|
| 553 |
POS7 EVALUATION OF DISTRIBUTION OF HIP REPLACEMENT IN HUNGARY ACCORDING TO GEOGRAPHICAL REGIONS AND AGE GROUPS
|
Sebestyen, A
|
|
2005
|
8 |
6 |
p. A137-
1 p.
|
artikel
|
| 554 |
POS9 EXTENDING THE BURDEN OF DISEASE PROTOCOL: DERIVING DISABILITY WEIGHTS FOR RISK FACTOR DISEASES—THE CASE FOR OSTEOPOROSIS
|
Janssen, M
|
|
2005
|
8 |
6 |
p. A138-
1 p.
|
artikel
|
| 555 |
POS12 HEALTH-RELATED QUALITY OF LIFE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AND AN INADEQUATE RESPONSE TO ANTI-OSTEOPOROSIS MEDICATION: BASELINE RESULTS OF THE FRENCH COHORT FROM THE OBSERVATIONAL STUDY OF SEVERE OSTEOPOROSIS (OSSO)
|
Fardellone, P
|
|
2005
|
8 |
6 |
p. A139-
1 p.
|
artikel
|
| 556 |
POS6 IMPACT OF BISPHOSPHONATES ON OSTEOPOROTIC FRACTURES, PATIENT QUALITY OF LIFE AND TREATMENT COSTS:THE CASE OF GERMANY
|
Kruse, HP
|
|
2005
|
8 |
6 |
p. A137-
1 p.
|
artikel
|
| 557 |
POS10 PERSISTENCE OF DRUG TREATMENT WITH ALENDRONATE AND RISEDRONATE IN PRIMARY CARE PATIENTS
|
Moehrke, W
|
|
2005
|
8 |
6 |
p. A138-
1 p.
|
artikel
|
| 558 |
POS3 RISK FOR OSTEOPOROTIC FRACTURES IS REDUCED IN PERSISTENT BISPHOSPHONATE USERS
|
Goettsch, WG
|
|
2005
|
8 |
6 |
p. A136-
1 p.
|
artikel
|
| 559 |
POS1 SYSTEMATIC REVIEW OF IBANDRONATE FOR POSTMENOPAUSAL OSTEOPOROSIS
|
Schnitzer, TJ
|
|
2005
|
8 |
6 |
p. A135-
1 p.
|
artikel
|
| 560 |
POS5 THE COST-EFFECTIVENESS OF RISENDRONATE COMPARED TO ALENDRONATE IN POST-MENOPAUSAL WOMEN WITH ESTABLISHED OSTEOPOROSIS: A POLISH ANALYSIS
|
Orlewska, E
|
|
2005
|
8 |
6 |
p. A136-
1 p.
|
artikel
|
| 561 |
POS13 UNDERSTANDING AND ASSESSING TIBIA FRACTURE ON QUALITY OF LIFE; CONCEPTUAL MODELAND NEW DISEASE SPECIFIC HR-QOL MEASURE
|
Brod, M
|
|
2005
|
8 |
6 |
p. A139-
1 p.
|
artikel
|
| 562 |
PO1 TRAJECTORIES OF EQ-5D QUALITY OF LIFE UTILITY SCORES FOR 10,000 SCHIZOPHRENIA OUTPATIENTS OVER 2 YEARS: A REPORT FROM THE SOHO STUDY
|
Hammond, GC
|
|
2005
|
8 |
6 |
p. A7-A8
nvt p.
|
artikel
|
| 563 |
PPN5 A MODEL-BASED COST-UTILITY ANALYSIS OF LYRICA™(PREGABALIN) VERSUS CURRENT PHARMACEUTICAL MANAGEMENT OF PERIPHERAL NEUROPATHIC PAIN
|
Annemans, L
|
|
2005
|
8 |
6 |
p. A141-
1 p.
|
artikel
|
| 564 |
PPN6 A UK PHARMACOECONOMIC MODEL OF PARENTERAL PARECOXIB VERSUS OPIOID ANALGESIA FOLLOWING MAJOR SURGERY
|
Miller, JD
|
|
2005
|
8 |
6 |
p. A141-
1 p.
|
artikel
|
| 565 |
PPN3 BURDEN OF ILLNESS OF PATIENTS WITH NEUROPATHIC PAIN IN PRIMARY CARE IN THE UK
|
Makinson, GT
|
|
2005
|
8 |
6 |
p. A140-
1 p.
|
artikel
|
| 566 |
PPN1 COGNITIVE FUNCTION IMPAIRMENT IN PATIENTS WITH NEUROPATHIC PAIN
|
Povedano, M
|
|
2005
|
8 |
6 |
p. A140-
1 p.
|
artikel
|
| 567 |
PPN7 COST-EFFECTIVENESS ANALYSIS OF THE COMBINATION TRAMADOL PLUS PARACETAMOL VERSUS CODEINE PLUS PARACETAMOL FOR POSTOPERATIVE PAIN THERAPY IN THE NETHERLANDS
|
Nuijten, MJ
|
|
2005
|
8 |
6 |
p. A141-A142
nvt p.
|
artikel
|
| 568 |
PPN4 DIFFERENTIAL COSTS OF NEUROPHATIC PAIN (NEP) MEDICAL MANAGEMENT ACCORDING TO AETIOLOGY: RESULTS OF THE REC STUDY
|
Rodríguez, M
|
|
2005
|
8 |
6 |
p. A140-A141
nvt p.
|
artikel
|
| 569 |
PPN9 HEALTH STATUS AS MEASURED BY PATIENT UTILITY DETERMINATION AMONG PATIENTS WITH PAIN: RESULTS FROM A CROSS-SECTIONAL SURVEY
|
Pérez, C
|
|
2005
|
8 |
6 |
p. A142-
1 p.
|
artikel
|
| 570 |
PPN10 PSYCHOMETRIC PROPERTIES OF THE MOS-SLEEP SCALE IN NEUROPATHIC PAIN (NEP) SYNDROMES
|
Rejas, J
|
|
2005
|
8 |
6 |
p. A142-A143
nvt p.
|
artikel
|
| 571 |
PPN2 THE COST-EFFECTIVENESS OF STRONG, CONTROLLED-RELEASE OPIOIDS FOR THE TREATMENT OF CHRONIC NON-MALIGNANT PAIN: A PROBABILISTIC DECISION-MODEL
|
Hawkins, N
|
|
2005
|
8 |
6 |
p. A140-
1 p.
|
artikel
|
| 572 |
PPN8 THE MOS-SHORT-FORM-12 (SF-12) AS A MEASURE OF HEALTH-RELATED QUALITY OF LIFE IN NEUROPATHIC PAIN (NEP) PATIENTS: RELIABILITY, CONCURRENT AND DISCRIMINANT VALIDITY
|
Rejas, J
|
|
2005
|
8 |
6 |
p. A142-
1 p.
|
artikel
|
| 573 |
PR3 BIPOLAR PATIENTS' STATED THERAPY PREFERENCES AND LIKELY ADHERENCE
|
Johnson, FR
|
|
2005
|
8 |
6 |
p. A19-
1 p.
|
artikel
|
| 574 |
PR1 EVALUATION OF PREFERENCES IN GENITAL HERPES TREATMENT USING A DISCRETE CHOICE EXPERIMENT
|
Scalone, L
|
|
2005
|
8 |
6 |
p. A18-
1 p.
|
artikel
|
| 575 |
PR4 PATIENT PREFERENCE AND WILLINGNESS-TO-PAY FOR ANTICOAGULANT TREATMENT OPTIONS IN PATIENTS RECEIVING ORAL ANTICOAGULANT TREATMENT (OAT): A CONJOINT ANALYSIS EXERCISE
|
Monzini, M
|
|
2005
|
8 |
6 |
p. A19-
1 p.
|
artikel
|
| 576 |
PR2 PERCEIVED UTILITY OF HEALTH STATES INDUCED BY CHRONIC HEPATITIS B: ESTIMATES FROM UNINFECTED PERSONS IN CANADA
|
Levy, A
|
|
2005
|
8 |
6 |
p. A18-A19
nvt p.
|
artikel
|
| 577 |
PRS16 CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A COMPARISON OF ESTIMATES OF HEALTH-RELATED UTILITY (EQ5D) FROM SF36 DATA ALONE, THE SF36 PLUS LUNG FUNCTION DATA, AND THE SF36 PLUS THE ST. GEORGE'S RESPIRATORY QUESTIONNAIRE PLUS LUNG FUNCTION DATA
|
Savani, V
|
|
2005
|
8 |
6 |
p. A216-
1 p.
|
artikel
|
| 578 |
PRS1 CLINICAL AND TREATMENT FACTORS INFLUENCING THE OUTCOME OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS: LESSONS FOR FURTHER CLINICAL AND OUTCOMES RESEARCH
|
Sagnier, PP
|
|
2005
|
8 |
6 |
p. A211-
1 p.
|
artikel
|
| 579 |
PRS3 COST ANALYSIS OF FOURTREATMENT STRATEGIES IN THE MANAGEMENT OF MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE: AN APPLICATION ON NON-PARAMETRIC BOOTSTRAP
|
Fattore, G
|
|
2005
|
8 |
6 |
p. A212-
1 p.
|
artikel
|
| 580 |
PRS13 COST ANALYSIS OF HEALTH CARE RESOURCE UTILIZATION DURING TREATMENT FOR RESPIRATORY TRACK INFECTIONS (RTIS) WITH TELITHROMYCIN OR CLARITHROMYCIN OR AMOXICILLIN/CLAVULANIC ACID IN GREECE
|
Angeli, A
|
|
2005
|
8 |
6 |
p. A215-
1 p.
|
artikel
|
| 581 |
PRS7 COST-EFFECTIVENESS OF FENSPIRIDE IN ADULTS WITH CHRONIC BRONCHITIS EXACERBATIONS IN POLAND
|
Pirozynski, M
|
|
2005
|
8 |
6 |
p. A213-
1 p.
|
artikel
|
| 582 |
PRS8 COST-EFFECTIVENESS OF FLUTICASONE PROPIONATE NASAL DROPS VERSUS SURGICAL TREATMENT FOR NASAL POLYPOSIS IN POLAND
|
Golicki, D
|
|
2005
|
8 |
6 |
p. A213-A214
nvt p.
|
artikel
|
| 583 |
PRS9 COST OF COMMUNITY ACQUIRED PNEUMONIA (CAP) TREATMENT WITH KETEK (TELITHROMYCIN) VS CLARITHROMYCIN FROM PUBLIC PAYER PERSPECTIVE IN POLAND
|
Kawalec, P
|
|
2005
|
8 |
6 |
p. A214-
1 p.
|
artikel
|
| 584 |
PRS18 DOES QUALITY OF LIFE OF COPD PATIENTS AS MEASURED BY THE GENERIC EQ-5D DIFFERENTIATE BETWEEN COPD SEVERITY STAGES?
|
Rutten-van Molken, MP
|
|
2005
|
8 |
6 |
p. A216-A217
nvt p.
|
artikel
|
| 585 |
PRS6 ECONOMIC EVALUATION OF TIOTROPIUM AND SALMETEROL IN THE TREATMENT OF COPD IN GREECE
|
Maniadakis, N
|
|
2005
|
8 |
6 |
p. A213-
1 p.
|
artikel
|
| 586 |
PRS14 HEALTH CARE RESOURCES UTILIZATION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ACCORDING TO THEIR SEVERITY IN SPAIN
|
De Lucas, P
|
|
2005
|
8 |
6 |
p. A215-
1 p.
|
artikel
|
| 587 |
PRS19 IMPACT OF DYSPNOEA ON DAILY ACTIVITIES IN COPD PATIENTS—DEVELOPMENT AND TESTING OF A NEW QUESTIONNAIRE FOR CLINICAL PRACTICE AND CLINICAL TRIALS
|
Arnould, B
|
|
2005
|
8 |
6 |
p. A217-
1 p.
|
artikel
|
| 588 |
PRS4 INHALED CORTICOSTEROIDS AND BROCHODILATORS FOR SEVERE AND VERY SEVERE COPD PATIENTS: COST-EFFECTIVENESS AND HEALTH CARE BUDGET IMPACT IN ITALY
|
Pradelli, L
|
|
2005
|
8 |
6 |
p. A212-
1 p.
|
artikel
|
| 589 |
PRS11 MANAGEMENT OF COPD IN BELGIUM: A REAL LIFE COST OF ILLNESS STUDY
|
Caekelbergh, K
|
|
2005
|
8 |
6 |
p. A214-
1 p.
|
artikel
|
| 590 |
PRS15 OUTCOMES, RESOURCE CONSUMPTION AND COSTS OF INTENSIVE CARE PATIENTS HOSPITALIZED WITH ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN THE USA AND CANADA
|
Eichmann, F
|
|
2005
|
8 |
6 |
p. A215-A216
nvt p.
|
artikel
|
| 591 |
PRS20 PATIENT REPORTED IMPACT OF COUGH AND SPUTUM IN CHRONIC (OBSTRUCTIVE) BRONCHITIS—SIMULTANEOUS DEVELOPMENT OF THE SELF-ADMINISTERED CASA-Q
|
Mesrobian, X
|
|
2005
|
8 |
6 |
p. A217-
1 p.
|
artikel
|
| 592 |
PRS21 PATIENT SATISFACTION WITH TREATMENT FOR COPD
|
Leiva, F
|
|
2005
|
8 |
6 |
p. A217-A218
nvt p.
|
artikel
|
| 593 |
PRS5 PHARMACOECONOMIC EVALUATION OFTIOTROPIUM IN THE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SPAIN
|
De Lucas, P
|
|
2005
|
8 |
6 |
p. A212-A213
nvt p.
|
artikel
|
| 594 |
PRS2 PRESCRIPTION PATTERNS IN COPD PATIENTS IN A GERMAN SICKNESS FUND POPULATION
|
Gothe, H
|
|
2005
|
8 |
6 |
p. A212-
1 p.
|
artikel
|
| 595 |
PRS10 PROJECTING THE FUTURE COSTS OF ASTHMA AND COPD IN THE NETHERLANDS
|
Hoogendoorn, M
|
|
2005
|
8 |
6 |
p. A214-
1 p.
|
artikel
|
| 596 |
PRS17 QUALITY OF LIFE IN COPD: HOW CAN WE MEASURE IT?
|
Leiva, F
|
|
2005
|
8 |
6 |
p. A216-
1 p.
|
artikel
|
| 597 |
PRS12 THE BURDEN OF LUNG DISEASE (BOLD) ECONOMIC MODEL
|
Sullivan, S
|
|
2005
|
8 |
6 |
p. A214-A215
nvt p.
|
artikel
|
| 598 |
PSN25 ADULTS WITH ATOPIC DERMATITIS: QUALITY OF LIFE IMPACT
|
Taieb, C
|
|
2005
|
8 |
6 |
p. A150-
1 p.
|
artikel
|
| 599 |
PSN24 ATOPIC DERMATITIS: A CONJOINT ANALYSIS PILOT STUDY
|
Monzini, M
|
|
2005
|
8 |
6 |
p. A150-
1 p.
|
artikel
|
| 600 |
PSN18 ATOPIC DERMATITIS: IMPACT ON SEXUALITY
|
Taieb, C
|
|
2005
|
8 |
6 |
p. A148-
1 p.
|
artikel
|
| 601 |
PSN14 CHANGES IN FUNCTIONAL ABILITY AS MEASURED BY DLQI IS CONSISTENT WITH CLINICAL RESPONSE IN MODERATE TO SEVERE PLAQUE PSORIASIS PATIENTS TREATED WITH ADALIMUMAB
|
Melilli, LE
|
|
2005
|
8 |
6 |
p. A147-
1 p.
|
artikel
|
| 602 |
PSN2 COST-EFFECTIVENESS ANALYSIS: ALDARA™ (IMIQUIMOD) CREAM, 5% IN THE TREATMENT OF SUPERFICIAL BASAL CELL CARCINOMA IN NORWAY
|
Sverre, JM
|
|
2005
|
8 |
6 |
p. A143-
1 p.
|
artikel
|
| 603 |
PSN4 COST-EFFECTIVENESS MODEL OFALDARA™ (IMIQUIMOD) CREAM, 5% IN SUPERFICIAL BASAL CELL CARCINOMA IN THE NETHERLANDS
|
De Cock, E
|
|
2005
|
8 |
6 |
p. A144-
1 p.
|
artikel
|
| 604 |
PSN6 COST-EFFECTIVENESS OF BRIVUDINE COMPARED TO ACICLOVIR FOR THE TREATMENT OF HERPES ZOSTER IN GERMANY
|
Kaltwasser, MT
|
|
2005
|
8 |
6 |
p. A144-
1 p.
|
artikel
|
| 605 |
PSN3 ECONOMIC EVALUATION OF PIMECROLIMUS, A NEW TREATMENT OF CHILDREN WITH ATOPIC DERMATITIS IN HUNGARY
|
Kósa, J
|
|
2005
|
8 |
6 |
p. A143-A144
nvt p.
|
artikel
|
| 606 |
PSN7 EPIDEMIOLOGY AND MANAGEMENT OF EXTERNAL GENITAL WARTS (EGW) IN FRANCE
|
Vainchtock, A
|
|
2005
|
8 |
6 |
p. A144-A145
nvt p.
|
artikel
|
| 607 |
PSN8 EXAMINATION OF ADHERENCE TO PHARMACOTHERAPY TREATMENT GUIDELINES IN PATIENTS WITH PSORIASIS IN THE UNITED STATES
|
Kulkarni, A
|
|
2005
|
8 |
6 |
p. A145-
1 p.
|
artikel
|
| 608 |
PSN23 FACTORS INFLUENCING QUALITY OF LIFE IN ATOPIC DERMATITIS
|
Hampson, NE
|
|
2005
|
8 |
6 |
p. A149-
1 p.
|
artikel
|
| 609 |
PSN21 IMPACT OF CORTICOSTEROID-SPARING EFFECT OF AN EMOLLIENT MILK ON FAMILY'S QUALITY OF LIFE OF INFANTS AFFECTED BYATOPIC DERMATITIS
|
Myon, E
|
|
2005
|
8 |
6 |
p. A149-
1 p.
|
artikel
|
| 610 |
PSN12 NAIL PSORIASIS: ELABORATION OF A SCALE FOR FUNCTIONAL DISCOMFORT
|
Taieb, C
|
|
2005
|
8 |
6 |
p. A146-
1 p.
|
artikel
|
| 611 |
PSN16 NAIL PSORIASIS: IMPACT ON QUALITY OF LIFE
|
Taieb, C
|
|
2005
|
8 |
6 |
p. A147-
1 p.
|
artikel
|
| 612 |
PSN9 PATTERNS OF TOPICAL ACNE PRESCRIPTION MEDICATION USE: ANALYSIS OF A LARGE-SCALE RETROSPECTIVE CLAIMS DATABASE
|
Hankin, C
|
|
2005
|
8 |
6 |
p. A145-
1 p.
|
artikel
|
| 613 |
PSN11 PREDICTORS OF HEALTH CARE OUTCOMES AND COSTS RELATED TO MEDICATION USE IN PATIENTS WITH ACNE IN THE UNITED STATES
|
Balkrishnan, R
|
|
2005
|
8 |
6 |
p. A146-
1 p.
|
artikel
|
| 614 |
PSN15 QUALITY OF LIFE IMPROVEMENT AS MEASURED BY EQ-5D IS CONSISTENT WITH CLINICAL RESPONSE IN MODERATE TO SEVERE PLAQUE PSORIASIS PATIENTS TREATED WITH ADALIMUMAB
|
Melilli, LE
|
|
2005
|
8 |
6 |
p. A147-
1 p.
|
artikel
|
| 615 |
PSN19 QUALITY OF LIFE OF PAEDIATRIC PATIENTS WITH ATOPIC ECZEMAANDTHEIR FAMILIES
|
Scalone, L
|
|
2005
|
8 |
6 |
p. A148-
1 p.
|
artikel
|
| 616 |
PSN13 REFINEMENT AND REDUCTION OF THE IMPACT OF PSORIASIS QUESTIONNAIRE: CLASSICAL TEST THEORY VS RASCH ANALYSIS
|
Nijsten, T
|
|
2005
|
8 |
6 |
p. A146-A147
nvt p.
|
artikel
|
| 617 |
PSN22 SENSITIVE SKIN: IMPACT ON QUALITY OF LIFE
|
Misery, L
|
|
2005
|
8 |
6 |
p. A149-
1 p.
|
artikel
|
| 618 |
PSN10 THE RISE OF THE GENERIC DRUG MARKET: IMPLICATIONS FOR THE TREATMENT OF SKIN DISEASES
|
Bhosle, M
|
|
2005
|
8 |
6 |
p. A145-A146
nvt p.
|
artikel
|
| 619 |
PSN1 USING THE GENERAL PRACTICE RESEARCH DATABASE TO ESTIMATE THE INCIDENCE, PREVALENCE AND MANAGEMENT OF HYPERHIDROSIS IN THE UK
|
Brown, B
|
|
2005
|
8 |
6 |
p. A143-
1 p.
|
artikel
|
| 620 |
PSN20 VALIDATION OF THE ITALIAN VERSION OF THE DERMATOLOGY LIFE QUALITY INDEX
|
Baranzoni, N
|
|
2005
|
8 |
6 |
p. A148-A149
nvt p.
|
artikel
|
| 621 |
PSN17 VALIDATION OF THE ITALIAN VERSION OF THE INFANTS' DERMATITIS QUALITY OF LIFE & FAMILY DERMATITIS INDEXES
|
Baranzoni, N
|
|
2005
|
8 |
6 |
p. A147-A148
nvt p.
|
artikel
|
| 622 |
PST3 CLOPIDOGREL VERSUS ASPIRIN IN HIGH-RISK PATIENTS WITH RECENT ISCHEMIC STROKE ORTRANSIENT ISCHEMIC ATTACK: COST-EFFECTIVENESS ANALYSIS IN ITALY
|
Rudelli, G
|
|
2005
|
8 |
6 |
p. A151-
1 p.
|
artikel
|
| 623 |
PST5 COST AND OUTCOMES AFTER FIRST STOKE HOSPITAL ADMISSION: A LONGITUDINAL STUDY USING ADMINISTRATIVE DATABASES
|
Morsanutto, A
|
|
2005
|
8 |
6 |
p. A151-A152
nvt p.
|
artikel
|
| 624 |
PST4 COST-CONSEQUENCE ANALYSIS FOR THE HANDMASTER IN THE NETHERLANDS
|
Nuijten, MJ
|
|
2005
|
8 |
6 |
p. A151-
1 p.
|
artikel
|
| 625 |
PST2 COST-EFFECTIVENESS OF LOSARTAN IN PATIENTS WITH HYPERTENSION AND LVH: AN ECONOMIC EVALUATION FOR THE NETHERLANDS BASED ON THE LIFE-STUDY
|
Boersma, C
|
|
2005
|
8 |
6 |
p. A150-A151
nvt p.
|
artikel
|
| 626 |
PST7 DO PATIENTS WITH ATRIAL FIBRILLATION RECEIVE APPROPRIATE STROKE PREVENTION THERAPY IN PRACTICE?
|
Liovas, AM
|
|
2005
|
8 |
6 |
p. A152-
1 p.
|
artikel
|
| 627 |
PST13 EFFECTIVENESS OF AN EARLY REHABILITATION STRATEGY WITH HOME FOLLOW-UP FOR PATIENTS WITH ISCHEMIC VASCULAR CEREBRAL DISEASE IN MEXICO
|
Torres-Arreola, LDP
|
|
2005
|
8 |
6 |
p. A154-
1 p.
|
artikel
|
| 628 |
PST6 FACTORS RELATED TO LONGER HOSPITAL STAY AFTER FIRST-EVER ISCHEMIC STROKE
|
Tseng, MC
|
|
2005
|
8 |
6 |
p. A152-
1 p.
|
artikel
|
| 629 |
PST9 MANDARIN VERSION OF STROKE IMPACT SCALE: ADAPTATION AND VALIDATION
|
Chang, KC
|
|
2005
|
8 |
6 |
p. A152-A153
nvt p.
|
artikel
|
| 630 |
PST1 PREDICTORS OF STROKE RISK ASSOCIATED WITH ATRIAL FIBRILLATION: RESULTS FROM A LARGE COMMERCIALLY INSURED US POPULATION
|
Ollendorf, D
|
|
2005
|
8 |
6 |
p. A150-
1 p.
|
artikel
|
| 631 |
PST10 THE METHODOLOGY BEHIND A PROSPECTIVE, OBSERVATIONAL STUDY OF THE ECONOMIC BURDEN OF ISCHEMIC STROKE
|
Seung, SJ
|
|
2005
|
8 |
6 |
p. A153-
1 p.
|
artikel
|
| 632 |
PST11 THE USE OF MULTI-CRITERIA DECISION METHODS IN HEALTH CARE. DOES METHOD USED INFLUENCE OUTCOME?
|
Van Til, JA
|
|
2005
|
8 |
6 |
p. A153-
1 p.
|
artikel
|
| 633 |
PST12 THE USE OF MULTI-CRITERIA DECISION METHODS IN HEALTH CARE.WHICH METHOD IS MOST SUITABLE FOR HEALTHY AND COGNITIVELY IMPAIRED POPULATION?
|
Van Til, JA
|
|
2005
|
8 |
6 |
p. A153-A154
nvt p.
|
artikel
|
| 634 |
PST8 WARFARIN PATIENT SEGMENTS: GENERAL PRACTITIONERS VERSUS SPECIALISTS
|
Liovas, AM
|
|
2005
|
8 |
6 |
p. A152-
1 p.
|
artikel
|
| 635 |
PSU8 APPLICATION OF (PRO)SPECTIVE STUDY OF PATIENT SATISFACTION (PS) TO MONITOR QUALITY AND TO SUPPORT MANAGEMENT OF HEALTH CARE PROVIDER—AN EXAMPLE OF MEETING ISO 9001:2000 REQUIREMENTS BY THE CARDIOSURGICAL UNIT IN POLAND.
|
Koltowski, LN
|
|
2005
|
8 |
6 |
p. A220-
1 p.
|
artikel
|
| 636 |
PSU2 COST-EFFECTIVENESS OF TWO REGIMENS OF TOTAL INTRAVENOUS ANESTHESIA USING INFUSION PUMP IN MEXICO
|
Carlos, FDJ
|
|
2005
|
8 |
6 |
p. A218-
1 p.
|
artikel
|
| 637 |
PSU6 DIFFERENCES IN BLOOD TRANSFUSION COSTS BY HIP AND KNEE REPLACEMENT AND REVISION SURGERY SUBTYPES
|
Joshi, AV
|
|
2005
|
8 |
6 |
p. A219-A220
nvt p.
|
artikel
|
| 638 |
PSU5 FACTORS ASSOCIATED WITH BLOOD TRANSFUSION COSTS DURING AND FOLLOWING SPINAL SURGERY IN THE UNITED STATES
|
Wang, PF
|
|
2005
|
8 |
6 |
p. A219-
1 p.
|
artikel
|
| 639 |
PSU7 “TECHNO-MARKERS” FOR THE ASSESSMENT OF HEALTH TECHNOLOGY UTILIZATION
|
Ostfeld, I
|
|
2005
|
8 |
6 |
p. A220-
1 p.
|
artikel
|
| 640 |
PSU3 THE COST OF ANTIBIOTIC THERAPY IN PATIENTS UNDERGOING COLORECTAL SURGERY
|
Borin, F
|
|
2005
|
8 |
6 |
p. A218-A219
nvt p.
|
artikel
|
| 641 |
PSU1 THE SOCIETAL COST OF AUTOLOGOUS, ALLOGENEIC AND PERIOPERATIVE RBC TRANSFUSION—THE CASE OF SWEDEN
|
Persson, U
|
|
2005
|
8 |
6 |
p. A218-
1 p.
|
artikel
|
| 642 |
PSU4 TOTAL INSURANCE COST OF TREATMENT OF HIP FRACTURES ACCORDING TO THE LOAD STABILITY OF DIFFERENT SURGICAL METHODS
|
Sebestyen, A
|
|
2005
|
8 |
6 |
p. A219-
1 p.
|
artikel
|
| 643 |
PUK12 ASSESSING THE EFFICIENCY OF INTERSTIM® IN FECAL INCONTINENCE (Fl) IN THE SPANISH SETTING. A COST-EFFECTIVENESS SIMULATION MODEL
|
Brosa, M
|
|
2005
|
8 |
6 |
p. A81-
1 p.
|
artikel
|
| 644 |
PUK20 BENIGN PROSTATE HYPERPLASIA: MUST BOTHERSOMENESS OF SYMPTOMS BE PRIVILEGED?
|
Perrin, P
|
|
2005
|
8 |
6 |
p. A83-
1 p.
|
artikel
|
| 645 |
PUK30 BENIGN PROSTATE HYPERPLASIA: RELATION BETWEEN IPSS, SPI AND QUALITY OF LIFE IPSS ITEM SCORES
|
Perrin, P
|
|
2005
|
8 |
6 |
p. A86-
1 p.
|
artikel
|
| 646 |
PUK17 BENIGN PROSTATIC HYPERPLASIA: CROSS EVALUATION OF THE GP-PATIENT IPSS
|
Perrin, P
|
|
2005
|
8 |
6 |
p. A82-
1 p.
|
artikel
|
| 647 |
PUK16 BPH AND IPSS SCORES EVALUATED AFTER 6 MONTHS ACCORDING TO THE TYPE OF DISEASE MANAGEMENT
|
Marionneau, N
|
|
2005
|
8 |
6 |
p. A82-
1 p.
|
artikel
|
| 648 |
PUK24 BPH: CONSEQUENCES ON THE SPOUSE'S & PATIENT'S SEXUALITY
|
Perrin, P
|
|
2005
|
8 |
6 |
p. A84-
1 p.
|
artikel
|
| 649 |
PUK4 BUDGET IMPACT ANALYSIS OF MIMPARAAMONG DIALYSIS PATIENTS IN BELGIUM USING A MARKOV SIMULATION MODEL
|
Roze, S
|
|
2005
|
8 |
6 |
p. A78-
1 p.
|
artikel
|
| 650 |
PUK3 CLINICAL IMPACT OF NONCOMPLIANCE AFTER RENAL TRANSPLANTATION
|
Babarykin, D
|
|
2005
|
8 |
6 |
p. A78-
1 p.
|
artikel
|
| 651 |
PUK11 COST ANALYSIS OF RENAL REPLACEMENT THERAPIES IN LATVIA
|
Babarykin, D
|
|
2005
|
8 |
6 |
p. A80-A81
nvt p.
|
artikel
|
| 652 |
PUK10 COST-EFFECTIVENESS OF MIMPARAAMONG DIALYSIS PATIENTS IN BELGIUM USING A MARKOV SIMULATION MODEL
|
Roze, S
|
|
2005
|
8 |
6 |
p. A80-
1 p.
|
artikel
|
| 653 |
PUK9 COST-EFFECTIVENESS OF PARICALCITOL IN THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM: THE EXPERIENCE IN ITALY
|
Chiroli, S
|
|
2005
|
8 |
6 |
p. A80-
1 p.
|
artikel
|
| 654 |
PUK8 COST-EFFECTIVENESS OF SCREENING FOR ALBUMINURIA AND SUBSEQUENT TREATMENT WITH AN ACE-INHIBITOR; A PHARMACO-ECONOMIC ANALYSIS
|
Atthobari, J
|
|
2005
|
8 |
6 |
p. A79-A80
nvt p.
|
artikel
|
| 655 |
PUK13 COST-MINIMISATION-ANALYSIS ON THE TREATMENT OF URINARY INCONTINENCE WITH TROSPIUM CHLORIDE IN COMPARISON WITH OXYBUTYNIN IN GERMANY
|
Heinen-Kammerer, T
|
|
2005
|
8 |
6 |
p. A81-
1 p.
|
artikel
|
| 656 |
PUK14 COST OF ILLNESS OF FEMALE LOWER URINARYTRACT SYMPTOMS (LUTS)
|
Prezioso, D
|
|
2005
|
8 |
6 |
p. A81-
1 p.
|
artikel
|
| 657 |
PUK7 DELIVERING TREATMENT EFFECTIVENESS: COSTS AND PERSISTENCE OF TOLTERODINE IN THE MANAGEMENT OF OAB IN FIVE EUROPEAN COUNTRIES
|
Reeves, P
|
|
2005
|
8 |
6 |
p. A79-
1 p.
|
artikel
|
| 658 |
PUK31 DEVELOPMENT AND PILOT TESTING OF A NEW SCALE SPECIFICALLY MEASURING THE IMPACT OF STRESS URINARY INCONTINENCE (SUI) ON COMMON PHYSICAL ACTIVITIES OF DAILY LIFE
|
Arnould, B
|
|
2005
|
8 |
6 |
p. A86-
1 p.
|
artikel
|
| 659 |
PUK33 DEVELOPMENT AND TESTING OF A COMPOSITE SCALE TO ASSESS THERAPEUTIC RESPONSE IN STRESS URINARY INCONTINENCE
|
Arnould, B
|
|
2005
|
8 |
6 |
p. A87-
1 p.
|
artikel
|
| 660 |
PUK29 DEVELOPMENT AND VALIDATION OF A COMPREHENSIVE SYMPTOM CHECKLIST IN URINARY INCONTINENCE
|
Arnould, B
|
|
2005
|
8 |
6 |
p. A86-
1 p.
|
artikel
|
| 661 |
PUK5 ECONOMIC EVALUATION OF EVEROLIMUS WITH REDUCED-DOSE CYCLOSPORINE IN DE NOVO RENAL TRANSPLANT RECIPIENTS IN HUNGARY
|
Kósa, J
|
|
2005
|
8 |
6 |
p. A78-A79
nvt p.
|
artikel
|
| 662 |
PUK6 ECONOMIC IMPACT OF EXTENDED-RELEASE TOLTERODINE VERSUS IMMEDIATE-AND EXTENDED-RELEASE OXYBUTYNIN AMONG COMMERCIALLY-INSURED PERSONS WITH OVERACTIVE BLADDER
|
Ollendorf, D
|
|
2005
|
8 |
6 |
p. A79-
1 p.
|
artikel
|
| 663 |
PUK18 ESTIMATION AND ANALYSIS OF DIRECT MEDICAL COST OF SECONDARY HYPERPARATHYROIDISM (SHPT) IN DIALYSIS PATIENTS
|
Rosillon, D
|
|
2005
|
8 |
6 |
p. A82-
1 p.
|
artikel
|
| 664 |
PUK34 EVALUATION OF TWO TENSION FREE VAGINAL TAPES WITH URODYNAMICS AND ICIQ-UI SF QUESTIONNAIRE
|
Rebollo, P
|
|
2005
|
8 |
6 |
p. A87-
1 p.
|
artikel
|
| 665 |
PUK19 EXPLORING NEUROGENIC DETRUSOR OVERACTIVITY WITHIN AN OVERACTIVE BLADDER POPULATION
|
Bridge, S
|
|
2005
|
8 |
6 |
p. A82-A83
nvt p.
|
artikel
|
| 666 |
PUK21 INDUCED BOTHERSOMENESS IN THE ANALYSIS OF THE IPSS QUESTIONNAIRE
|
Marionneau, N
|
|
2005
|
8 |
6 |
p. A83-
1 p.
|
artikel
|
| 667 |
PUK28 LONG-TERM DARIFENACIN TREATMENT FOR OVERACTIVE BLADDER: QUALITY OF LIFE OUTCOMES FROM A 2-YEAR, OPEN-LABEL EXTENSION STUDY
|
Young, J
|
|
2005
|
8 |
6 |
p. A85-A86
nvt p.
|
artikel
|
| 668 |
PUK22 PATIENT SATISFACTION: INTERNATIONAL DEVELOPMENT, TRANSLATABILITY ASSESSMENT AND LINGUISTIC VALIDATION OF THE OAB-S, AN OVERACTIVE BLADDER TREATMENT SATISFACTION QUESTIONNAIRE
|
Conway, K
|
|
2005
|
8 |
6 |
p. A83-A84
nvt p.
|
artikel
|
| 669 |
PUK36 PATIENT SATISFACTION: PSYCHOMETRIC VALIDATION OF THE OAB-S, AN OVERACTIVE BLADDER TREATMENT SATISFACTION QUESTIONNAIRE.
|
Piault, EC
|
|
2005
|
8 |
6 |
p. A88-
1 p.
|
artikel
|
| 670 |
PUK27 PSYCHOMETRIC VALIDATION OF THE UK ENGLISH INCONTINENCE-SPECIFIC QUALITY OF LIFE MEAURE (I-QOL)
|
Bushneil, DM
|
|
2005
|
8 |
6 |
p. A85-
1 p.
|
artikel
|
| 671 |
PUK25 SPANISH RESEARCH NETWORK ON TRANSPLANTATION: THE SPANISH VERSION OF THE END-STAGE RENAL DISEASE SYMPTOM CHECK-LIST, A USEFUL TOOL FOR EVALUATE THE PERCEIVED HEALTH STATUS OF RENAL TRANSPLANT BEARERS
|
Rebollo, P
|
|
2005
|
8 |
6 |
p. A84-A85
nvt p.
|
artikel
|
| 672 |
PUK26 THE IMPACT OF THE OVERACTIVE BLADDER ON QUALITY OF LIFE (SF36) AND UTILITY (EQ5D)
|
Poole, C
|
|
2005
|
8 |
6 |
p. A85-
1 p.
|
artikel
|
| 673 |
PUK1 THE TIMELY CONSTRUCTION OF AN ARTERIOVENOUS FISTULAE: A KEY FACTOR IN REDUCING MORBIDITY AND MORTALITY AND IMPROVING ECONOMIC EFFECTIVENESS
|
Ortega, T
|
|
2005
|
8 |
6 |
p. A77-
1 p.
|
artikel
|
| 674 |
PUK23 VALIDATION OF A QUALITY OF LIFE QUESTIONNAIRE (KING'S HEALTH QUESTIONNAIRE) IN BRAZILIAN WOMEN WITH URINARY INCONTINENCE
|
Fonseca, MC
|
|
2005
|
8 |
6 |
p. A84-
1 p.
|
artikel
|
| 675 |
PUK32 VALIDATION OF THE INTERNATIONAL PROSTATE SYMPTOMS SCORE IN ITALIAN WOMEN WITH LUTS.THE FLOW STUDY
|
Zattoni, F
|
|
2005
|
8 |
6 |
p. A87-
1 p.
|
artikel
|
| 676 |
PUK35 VALIDATION OF THE SYMPTOM FREQUENCY AND BOTHERSOMENESS SCALE FOR STRESS URINARY INCONTINENCE (SFB-SUI) IN A BRITISH POPULATION
|
Bushneil, DM
|
|
2005
|
8 |
6 |
p. A88-
1 p.
|
artikel
|
| 677 |
QL6 ADALIMUMAB REDUCES FATIGUE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS)—6-MONTH RESULTS OF A CANADIAN AS STUDY
|
Luo, MP
|
|
2005
|
8 |
6 |
p. A13-
1 p.
|
artikel
|
| 678 |
QL5 CLINICAL RESPONSES TO TREATMENT AND CHANGES IN THE DERMATOLOGY LIFE QUALITY INDEX (DLQI) IN MODERATE TO SEVERE PLAQUE PSORIASIS PATIENTS TREATED WITH ADALIMUMAB
|
Shikiar, R
|
|
2005
|
8 |
6 |
p. A13-
1 p.
|
artikel
|
| 679 |
QL1 DETERMINING THE MINIMALLY IMPORTANT DIFFERENCE OF THE OVERACTIVE BLADDER QUESTIONNAIRE (OAB-Q)
|
Coyne, KS
|
|
2005
|
8 |
6 |
p. A9-
1 p.
|
artikel
|
| 680 |
QL3 “FAMIDIAL STUDY”: ANALYSIS OF THE DIFFERENCES BETWEEN DIALYSIS PATIENTS AND THEIR CAREGIVERS (FAMILY CARERS, NURSES AND DOCTORS) ON DIALYSIS PATIENTS' HRQOL, AND OF THE FAMILY CARERS' HRQOL AND BURDEN
|
Alvarez-ude, F
|
|
2005
|
8 |
6 |
p. A9-A10
nvt p.
|
artikel
|
| 681 |
QL7 IMPACT OF LUTS ON QUALITY OF LIFE IN ITALIAN WOMEN
|
Prezioso, D
|
|
2005
|
8 |
6 |
p. A13-A14
nvt p.
|
artikel
|
| 682 |
QL8 QUALITY OF LIFE IN HEMOPHILIC PATIENTS WITHOUT INHIBITORS: THE COCHE STUDY
|
Scalone, L
|
|
2005
|
8 |
6 |
p. A14-
1 p.
|
artikel
|
| 683 |
QL2 TESTING THE CROSS-WALK: SALVAGING CANCER SPECIFIC MEASURES FOR USE IN ECONOMIC EVALUATION
|
Wilson, TR
|
|
2005
|
8 |
6 |
p. A9-
1 p.
|
artikel
|
| 684 |
QL4 VARIABILITY IN QOL QUESTIONNAIRES AND THE HANDLING OF MISSING DATA IN PATIENTS WITH NON-SMALL CELL LUNG CANCER TREATED WITH CHEMOTHERAPY
|
Johnson, LL
|
|
2005
|
8 |
6 |
p. A10-
1 p.
|
artikel
|
| 685 |
UB3 A COMPARISON OF THE EQ-5D AND THE SF-6D IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
|
Brown, MC
|
|
2005
|
8 |
6 |
p. A4-
1 p.
|
artikel
|
| 686 |
UB4 DETERMINANTS OF HEALTH STATE UTILITY IN PATIENTS WITH PSORIATIC ARTHRITIS
|
Anis, AH
|
|
2005
|
8 |
6 |
p. A4-A5
nvt p.
|
artikel
|
| 687 |
UB1 MAPPING FROM DISEASE SPECIFIC MEASURES TO UTILITY: ALGORITHMS FOR ESTIMATING EQ-5D AND SF-6D VALUES FROM THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE IN PATIENTS WITH CROHN'S DISEASE
|
Buxton, M
|
|
2005
|
8 |
6 |
p. A3-A4
nvt p.
|
artikel
|
| 688 |
UB2 QUANTIFYING THE RELATIONSHIP BETWEEN DISEASE SEVERITY, UTILITY AND HEALTH CARE RESOURCE USE IN CROHN'S DISEASE
|
Weston, AR
|
|
2005
|
8 |
6 |
p. A4-
1 p.
|
artikel
|
| 689 |
UH4 CHARACTERISTICS RELATED TO PRODUCTIVITY LOSS IN PATIENTS WITH OVERACTIVE BLADDER: RESULTS FROM THE MATRIX STUDY
|
Pizzi, LT
|
|
2005
|
8 |
6 |
p. A6-
1 p.
|
artikel
|
| 690 |
UH1 COST AND QUALITY OF LIFE OF HEMOPHILIA: COMPARISON BETWEEN PATIENTS WITH AND PATIENTS WITHOUT INHIBITORS
|
Scalone, L
|
|
2005
|
8 |
6 |
p. A5-
1 p.
|
artikel
|
| 691 |
UH2 COST DRIVERS IN MULTIPLE MYELOMA TREATMENT—A 2 YEAR ANALYSIS FROM A MULTICOUNTRY RETROPROJECTED CHART REVIEW
|
Moeremans, K
|
|
2005
|
8 |
6 |
p. A5-
1 p.
|
artikel
|
| 692 |
UH3 OVERACTIVE BLADDER IN MALES: A GROWING HEALTH AND ECONOMIC BURDEN
|
Reeves, P
|
|
2005
|
8 |
6 |
p. A5-A6
nvt p.
|
artikel
|
Tijdschrift beschrijving